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Chapter 1
Introduction
1.1. Membrane anchored proteins
1.1.1. Membranes
To the origin of life certainly contributed the spontaneous self association of am-
phiphilic lipid molecules, that formed a physical boundary permitting the segregation
of specific chemical reactions. Simple organisms have evolved to increasingly complex
prokaryotes and eukaryotes. About 2,5 billions of years ago, eukaryote life appeared,
concomitantly with an increase of oxygen in the composition of atmosphere. Eukaryote
cells acquired the ability of sub-segregating chemical reactions in their different organelles.
Membranes of eukaryote cells and organelles are mainly composed of glycerophospholipids,
sphingolipids and cholesterol (which appearance also corresponds with the increase in at-
mospheric oxygen). An extremely wide variety of lipids composes these families and is
present in membranes (more than 100 different lipids for bacteria but more than 1000 for
eukaryotes). The lipid composition of membranes is highly variable in different organ-
isms, but also in different cells of an organism, and in different organelles in a cell. In
addition to phospholipids, membranes contain carbohydrates, and also a huge amount of
proteins (depending on the membrane type, it can vary from 20 % up to 75 %) (Sonnino
and Prinetti, 2009). Membrane asymmetry results from the difference in composition of
lipids, carbohydrates and proteins in the inner and outer leaflets. Lipid polymorphism
makes lipids able to accommodate for the presence of proteins (by “filling the holes”) (Si-
mons and Sampaio, 2011) and is also source of membrane plasticity. Cell and organelles
11
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surfaces are not flat, two-dimensional entities, but adopt a wide variety of shapes (local
concave or convex deformations). Membranes are maintained in a fluid state, enabling
lateral diffusion of the embedded molecules (both lipids and proteins) (Sonnino and
Prinetti, 2013).
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protein
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cytoskeleton
Non-raft-associated 
transmembrane protein
Cytoplasmic protein
Transmembrane protein GPI-anchored protein Lipid
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Figure 1 | The plasma membrane. The plasma membrane is composed of lipids and 
proteins that are associated through non-covalent interactions. The lipid bilayer  Figure 1.1: The plasma membrane is composed of lipids, proteins and carbohydrates that
are associated through non-covalent interactions. The illustration accounts for membrane
asymmetry, for the presence of lipid rafts and that of protein-lipid shells. Figure from
Viola and Gupta (2007).
Nevertheless, nanodomains enriched in sphingolipids, cholesterol, and specific lipids
(such as phosphoinositides) or proteins (often possessing long saturated carbon chains)
have been observed in the recent years by different techniques (AFM, fluorescence mi-
croscopy) as transient lateral clusters with reduced disorder (McIntosh, 2007). These
“liquid-ordered phase” domains dynamically assemble and disassemble among the “liquid
disordered phase” environment. These so-called lipid rafts constitute an additional two-
dimensional segregation of chemical reactions, since they have the capacity of including
or excluding biomolecules: rafts are entities of physical and chemical specificity (Sonnino
and Prinetti, 2013). Lipid rafts are described as signaling nanoplatforms, from which
signal transduction can be initiated by complex protein-protein interactions. Yet, the
lipid raft theory probably does not fully describe the membrane complexity; the amount
of membrane proteins is still often underestimated, and membranes should be viewed as
lipid-protein composites instead of entities in which proteins are diluted in a lipid sol-
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vent (Ken Jacobson et al., 2007). In addition, interactions of the membrane constituents
with the cytoskeleton probably play an important role in membrane segregation. Addi-
tional theories are emerging, such as the “shell model”. It accounts for the observation of
non-raft clustering phenomena. In this model, shelled proteins recruit specific lipids and
exist alone or in nanoclusters. This hypothesis supports the observation of “known” raft
proteins that are diffusing at different speeds, and in particular at a rate compatible with
that of monomers (Ken Jacobson et al., 2007). One of the hypothesis linking rafts and
signalization describes small lipid rafts and/or protein shells as inactive entities, until they
merge into larger active rafts, placing the proteins in a new and specific environment, from
which protein signaling can start, protected from outside competing reactions (for instance
kinases protected from the role of phosphatases) (Simons and Toomre, 2000) (Ken Ja-
cobson et al., 2007). A schematic view of a membrane is represented in Figure 1.1 (Viola
and Gupta, 2007).
Figure 1.2 contains most of the configurations found for proteins residing at the cell
membrane environment; integral membranes proteins and anchored proteins.
Figure 1.2: Types of attachment for proteins residing at the cell membrane. Figure
from Makoto Asashima et al. (2010)
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Among them, lipid anchored proteins constitute a peculiar family, by acting as soluble
protein with a two-dimensional restricted movement. Protein modified by the addition
of one or several acyl chains acquire an amphiphilic character, which affects in a subtle
manner their transport, location and function in the cell, through the interplay of hy-
drophobic and electrostatic forces. More than 1000 proteins undergo covalent attachment
of a lipophilic group (Resh, 2013), in the form of fatty acid, isoprenoid, sterol, phos-
pholipid and GPI anchor. Only a few fatty acids have been selected during evolution
as candidates for such modification. The primary role of protein acylation is to target
these molecules to membranes. Nevertheless, acylated proteins acquire unique features in
protein-lipid and protein-protein interactions.
1.1.2. Lipid Modifications
Figure 1.3 illustrates some of the lipid chains involved in protein modifications (Resh,
2006). Proteins may undergo many kinds of modification, but we will focus in three main
lipidation mechanisms, namely myristoylation, palmitoylation and farnesylation.
N
H
O
S
O
S
S
Myristate
Palmitate
Farnesyl
Geranylgeranyl
Modifying Group Chemical Structure
Figure 1.3: Myristoyl, Palmitoyl and Farnesyl
are three common lipids co- or post-translationaly
added to proteins.
Myristoylation is a co-translational
modification occurring at the N-
terminal glycine on the nascent
polypeptide, after removal of the ini-
tiator methionine residue (Kasaharaa
et al., 2007) (Sandilands et al., 2004)
(Martin et al., 2011). The reaction is
catalyzed by N-Myristoyl Transferase
(NMT) and results in the covalent at-
tachment of the myristoyl chain at the
N-terminal side of the protein. Myris-
toylation is a very stable modification
and only rare cases of demyristoyla-
tion have been reported (the Myris-
toylated Alanine-rich C Kinase Substrate (MARCKS) protein being one of the cases
observed (Brauna et al., 2000) (Resh, 1996)). The amino-terminal glycine residue is ab-
solutely required for myristoylation – substitution of this residue to any other abrogates
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myristoylation (Martin et al., 2011). But an additional "consensus peptide" is needed
for protein recognition by NMT, typically consisting in a Met-Gly-X-X-X-Ser/Thr se-
quence. Despite of the low abundance of myristic acid in cells, about 1% (Resh, 1996),
this modification is very specific; myristoyl constitutes the shortest lipid motif capable of
stably (but not irreversibly) anchoring proteins to membranes (Peitzsch and McLaugh-
lin, 1993) (Resh, 1996). Although myristate is irreversibly bound to proteins it allows
the acylated protein to reversibly sample membranes because of its weak hydrophobic
nature (Martin et al., 2011). A common regulation mechanism of reversible binding
to membranes occurs in proteins having a hydrophobic pocket in which the acyl chain
can burry. If myristoyl is hidden in the pocket, the protein is cytoplasmic. When a
triggering signal is received and the chain is released from the pocket, binding of the
protein to membrane is allowed. This is called the myristoyl switch. The transition
can be induced by different mechanisms (Resh, 1999): ligand-dependent conformational
change (Ames et al., 1996), electrostatic switch (McLaughlin and Aderem, 1995), pro-
teolitic switch (Hermida-Matsumoto and Resh, 1999), and entropic switch (Tang et al.,
2004). Myristic acid possesses the minimum chain length able to trigger micelle formation
– at non physiological high protein concentration (Pool and Thompson, 1998) – and is in-
volved in protein protein interactions (Taniguchia, 1999). An example is the transition of
the Matrix-Associated (MA) viral protein, through a myristoyl-switch mechanism, from
a monomeric cytoplasmic state to a membrane bound trimer configuration (Resh, 2004).
Although the mechanism remains unclear, myristoylated proteins are often preferentially
targeted to the plasma membrane (Resh, 1999). They can be found both within or out of
rafts, which can affect their activity (Seong et al., 2009). Myristoyl is generally added in
its saturated form, but alternative chains have been found (Bereta and Palczewski, 2011),
namely C14:1 or C14:2, which can influence the localization of the protein (Liang et al.,
2001).
Palmitoylation consists in S-acylation of a 16 or 18 carbon chain, usually palmitoyl, in
which the acyl chain is reversibly attached to cysteine residues of a proteins (there is no
other known sequence requirements). It is a post-translational modification that requires
first membrane targeting, since the enzyme catalyzing the reaction is a membrane protein,
Palmitoyl AcylTransferase (PAT) (Bijlmakers and Marsh, 2003). Palmitoylation serves
primarily as a strong lipid anchor, which makes the substrate specificity for palmitic
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not as strict as for myristoyl (Liang et al., 2001). Since it acts as a second membrane
anchoring point, palmitoylation confers a stable protein anchoring to membrane, but
in a reversible way, through palmitoylation and depalmitoylation cycles (via palmitoyl
protein thioestherases (PTE) mechanisms) (Drisdel et al., 2006) (Goodwin et al., 2005).
Palmitoylation also plays a role in membrane targeting and usually directs proteins to
lipid rafts (Mumby, 1997). A class of palmitoylated proteins, transmembrane proteins,
are also directed to lipid rafts by palmitoylation (Resh, 1999).
Prenylation is a posttranslational reaction that occurs in the cytosol. A 15-carbon
(farnesyl) or 20-carbon (geranylgeranyl) isoprenoid is linked through a thioether bond to
one or more cysteine residues at or near the C terminus of the protein. Many prenylated
proteins contain a C-terminal “CAAX box” (Cysaliphatic- aliphatic-X). The X amino
acid determines whether the cysteine within the CAAX box is farnesylated by farnesyl-
transferase or geranylgeranylated by geranylgeranyltransferase I. The three C-terminal
amino acids (AAX) are then cleaved, and the C-terminal prenylated cysteine residue is
carboxymethylated in the endoplasmic reticulum (Sorek et al., 2009). Like myristoyl,
farnesyl is not enough to stably anchor a protein to the membrane, but geranylgeranyl is
longer and provides a much stronger binding (Resh, 2013).
1.1.3. Two-signal membrane anchoring
Often, such proteins are modified by more than one lipid chain, which modulates in a
cooperative manner its binding to membranes (Resh, 1999). Many cases of myristoylated
protein that are subsequently palmitoylated have been found (Resh, 1996). Dual myris-
toylation and palmitoylation greatly enhances the protein affinity towards membranes.
Indeed, the binding energy corresponding to myristoyl insertion is very low, with an ap-
parent affinity of 10–4 M–1 and additional palmitoylation increases this affinity with a
10-fold (Taniguchia, 1999) (Resh, 1996). The half-life of a membrane bound myristoy-
lated peptide is in the order of minutes in comparison to hours for palmitoylated or dually
acylated peptides (Martin et al., 2011).
In some instances, the second membrane binding signal is not a lipid chain, but a
highly positively charged peptide in the protein sequence, that we will call Positively
Charged Domain, PCD (Tao et al., 2006). A PCD can interact with the negatively
charged acidic lipids and stabilize in a cooperative way the protein attachment. On their
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own, neither the acyl chain not the basic peptide would bind lipids with strong affinity,
but the cooperative action is more than additive, and the resulting total affinity is greatly
enhanced (Ladokhin and White, 2001). Location of the PCD can vary within the protein
sequence; c-Src possesses a PCD just after the myristoyl tail (Sigal et al., 1994), while the
PCD of MARCKS is located further away from the N-terminal (Arbuzova et al., 1997). A
farnesyl tail can also be found instead of myristoyl: K-Ras4B is farnesylated and contains
a PCD (Resh, 2013). PCD binding to membranes can be electrostatically modulated, in
particular by phosphorylation of amino acids in the proximity of the PCD sequence. Ser-
ine will become negatively charged under phosphorylation, which will diminish the overall
charge around the PCD (Tournaviti et al., 2009) and consequently the electrostatic inter-
action. Variation of the lipid composition can also modulate such electrostatic interaction,
since the presence of negative charges and their distribution can be tuned by the types
of lipids present in the interacting membrane area. In some proteins, modulation of the
electrostatic interaction is the triggering signal involved in the myristoyl switch (called
in this case the myristoyl electrostatic switch). As an example, phosphorylation events
in the PCD of MARCKS release the peptide from the membrane and lower the protein
affinity towards the membrane. In the released soluble form of MARCKS, the acyl chain
hides back in its hydrophobic pocket (Arbuzova et al., 1998).
Other dual-signal mechanisms exist, for instance H-Ras and N-Ras are prenylated and
palmitoylated (Weise et al., 2013). Some α-subunits of G protein possess a hydropho-
bic peptide interacting with lipids, and are also palmitoylated (Veit et al., 1994). This
demonstrates that myristoylation is not essential for palmitoylation (Resh, 1996); mem-
brane association rather than myristoylation is important for palmitoylation (Degtyarev
et al., 1994).
Figure 1.4 (Resh, 1999) summarizes the main configurations of dual-signal lipid binding
involving a myristoyl group.
More than two interactions are also found among lipidated proteins. Table 1.1 lists
examples of such proteins. A myristoylated protein comprising a PCD may also be stabi-
lized once bound to membranes by the hydrophobic interaction of another domain in the
amino acid chain; the MARCKS protein contains 5 phenylalanine residues inserting in
the lipid bilayer (Arbuzova et al., 1997) upon membrane association. Additional binding
to a membrane protein may also occur (Liu et al., 2014). Thus the role of the myristoyl
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can be quite diverse according to the other coexisting binding motifs. In some cases, the
specificity of the acyl chain is crucial for protein function; replacing the myristoyl of Arf6
by a prenyl group directly hampers its function (Boutin, 1997). In other cases, it is less
clear, and protein function can even seem unaltered in the absence of the acyl chain; no
striking effect was observed in absence of the myristoyl tail of calcineurin (Kennedy et al.,
1996). The role of the acyl chain might be more subtle; the effect of the lack of myristoy-
lation is more subtle for c-Src than for Lck proteins (Abraham and Veillette, 1990), both
belonging to the Src family tyrosine kinase.
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Figure 1.4: Dual Signal Configuration enabling
strong binding of Myristoylated proteins to mem-
branes. Figure from Resh (1999)
Another role of the dual signal
mechanism is related to protein local-
ization, in which the palmitoyl chain
often plays a crucial role. Localization
can occur via at least two phenomena.
First, kinetic trapping can occur when
a protein undergoes palmitoylation, in
which the localization of LAT will de-
termine that of the protein, since the
addition of the palmitic acid produces
an almost reversible binding of the
protein to the membrane (Cabrera-
Vera et al., 2003). Second, the degree of saturation of the acyl chain may localize the
protein in a more local way. As previously mentioned, saturated carbon chains bind pref-
erentially to lipid rafts, so the presence of a palmitoyl usually targets proteins there (Resh,
2006). Addition of a cysteine at position 3 of the c-Src sequence (which is normally not
palmitoylated and not specifically directed to rafts) induces c-Src palmitoylation and raft
targeting (Alland et al., 1994). Fine tuning of the myristoyl saturation state may also
occur: it has been demonstrated that incorporation of an unsaturated myristoyl chain
to Fyn (normally targeted to raft via myristoylation and palmytoylation) displaces the
protein from lipid rafts (Liang et al., 2001).
In the case of the dual myristoyl-PCD signal, specific targeting can also be achieved
because of the presence of the charges. The plasma membrane is indeed more negatively
charged than the other membranes in the cell, possibly attracting effectively the PCDs of
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myristoylated proteins. Presence of specific lipids (phosphoinositides) also plays a role in
the targeting of PCD-containing proteins to the plasma membrane (Heo et al., 2006). An
interesting remark is the similarity of polybasic sequences with that of nuclear localization,
suggesting a possible role in which the lipid chain may impede nuclear localization (Li
et al., 2014).
Apart from the PCD, other protein domains may have lipid specificity: the Visinin-
Like Protein (VILIP) has enhanced affinity for phosphatidylinositol-4-phosphates, which
can specifically direct the protein to the correct location (Wang et al., 2014). Arf1
can interact specifically with both a membrane protein and phosphatidylinositol 4,5-
bisphosphate (Liu et al., 2014).
Table 1.1: Examples of lipidated proteins; the second lipid-anchoring signal is indicated
Protein Signal 1 Signal 2 Signal 3
c-Src Myristate PCD
SFKs Myristate Palmitate
PKA Myristate PCD
Gαi subunits Myristate Palmitate
Gαq subunit Palmitate Palmitate
Arf1 Myristate Palmitate PI45P
MARCKS Myristate PCD alpha helix
Gravin Myristate PCD alpha helix
Rhodopsin Farnesyl PCD
H-Ras Farnesyl Palmitate
H-Ras Farnesyl Palmitate
K-Ras4B Farnesyl PCD
RhoGTPase Geranylgeranyl
Hedgehog Palmitate Cholesterol
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1.2. Disorder in myristoylated proteins
1.2.1. Intrinsically Disordered Proteins
The paradigm linking the three-dimensional structure of proteins with their function
has been reshaped in the recent years. All these domains that usually correspond to a
lack of electron density in the protein structure derived from X-ray crystallography raised
increasing interest in the recent years. It is now well accepted that many functional
proteins or domains lack a three dimensional structure. They are called Intrinsically
Disordered Proteins or Domains, IDPs or IDDs – among all the name they have been
attributed. They are biologically active but do not have a well defined equilibrium struc-
ture and form an heterogeneous ensemble of conformations, resulting from a relatively
flat free energy surface (Dunker and Obradovic, 2014). These highly dynamics structures
interconvert on a number of time scales. By assuming that the lack of structure must
be encoded in the sequence, the characteristics of “coded disorder” have been studied.
There is a clear balance between hydrophobicity and charges: IDPs usually contain many
charged residues and have a very high net charge, with a relatively low hydrophobic-
ity (Uversky et al., 2000); they contain disorder promoting residues (A and G) and also
have a low sequence complexity (Radivojac, 2007). In a Charged-Hydropathy plot, IDPs
occupy a quite confined region, while well-structured domains stand in another, more
dispersed, area (Habchi et al., 2014). Identification of the properties of IDPs enabled to
develop predictive algorithms based on protein sequences. These predictions point out
the underestimated abundance of IDPs in the proteome. In fact, the number of discov-
ered functional IDPs is still increasing very fast. Some algorithms forecast that 25 % of
proteins in Swiss-Prot have predicted IDDs longer than 40 consecutive residues, and that
at least 11 % of the residues among the proteome are likely to be disordered (Radivojac,
2007). Higher IDP abundance is found in eukaryotes, certainly because of the gain of
regulation they provide in the cell function. IDPs are evolutionary persistent (Dunker
and Obradovic, 2014), which means that disorder is conserved. But they are also subject
to fast evolution: domains that were gained during evolution by the extension of exist-
ing exons contain the highest degree of disordered regions (Lee et al., 2014). They are
involved in a wide variety of functions which have been classified in many different ways.
IDPs often have an important role within signal control pathways. Because of their
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high plasticity, their activity must be under tight control (Uversky et al., 2014). For
instance some IDDs probably adopt a “misfolded conformation”, in which intramolecular
interactions with adjacent folded domains prevent non native interactions (Habchi et al.,
2014). Their deregulation can lead to dramatic consequences and is often related to
serious diseases such as cancers (Uversky et al., 2014). Thus, IDPs are also seen as
potential new drug targets (Dunker et al., 2008). For instance, allosteric modulation of
Bcr-Abl involving the myristate binding site of Abl can be used to design drug targeted to
this domain and directly influence the enzymatic activity of the oncogene protein (Zhang
et al., 2010).
Figure 1.5: Different “configurations” of IDDs: disordered, premolten, molten globule and
folded domain. Figure from Dunker et al. (2008).
The lack of 3D-structure is often needed for protein function, but the “disordered
state” is not as random as it was initially thought. Among the different IDPs, and even
within a same IDP, compactness can vary significantly. Different states corresponding to
the degree of disorder have been described, from totally disordered to premolten, molten
globule and folded domain, as illustrated in Figure 1.5 (Dunker et al., 2008). The net
charge is usually related to the compactness (Habchi et al., 2014), but as said, IDPs
can interchange between different states. These properties confer them the possibility of
interacting with a multitude of partners. IDPs can bind their ligands with both specificity
CHAPTER 1. INTRODUCTION 22
and low affinity, leading to specific interactions that can be easily dispersed, which is an
important feature for regulation (Dunker and Obradovic, 2001).
Some small regions contain a higher degree of compactness (Radivojac, 2007), indica-
tive for short-structure binding motifs, which are the ones that can undergo unfolded to
folded transitions. These transitions can be triggered by passive factors (e.g. variations in
the pH, the temperature, the redox conditions, or response to light) or active factors (e.g.
membrane induced changes, ligand binding, protein-protein interactions). These common
functional modules within IDPs are composed of short stretches of adjacent amino acids,
known as short linear motifs (SLiMs). Depending on the partner proteins that recognize
them, these sites can facilitate a diverse set of functions including targeting a protein to
a specific subcellular location, determining its modification state, controlling its stability,
and regulating its context-dependent activity (Van Roey et al., 2014). Highly flexible
domains containing SLiMs have an important role in allosteric regulations and autoinhi-
bition processes (Tompa, 2014). Probably due to their exposed character, they are also
often subject to degradation and PTMs (Jakob et al., 2014); one common PTM is phos-
phorylation which takes place very often in disordered regions (Iakoucheva and other,
2004). More than 300 different PTMs exist, through which the targeted protein will gain
new functions. As we saw, myristoylation induces in many cases membrane binding; fre-
quently, myristoylated proteins undergo other PTMs (phosphorylation, palmitoylation)
that provide them with additional regulation capabilities.
1.2.2. Myristoylation and disorder
Myristoylation usually happens cotranslationally before protein folding, thus it is
tempting to classify the N-terminal NMT recognition peptide as a SLiM. This peptide
sometimes does not participate in the 3D-structure of the protein, or can even be part of
a longer N-terminal disordered region. In fact, N-terminal disordered domains are found
in many myristoylated proteins, and the total abundance of such proteins may be higher
than we think. Combination of disorder and myristoylation increases the possibility of
fine tuning protein functions at the membrane interface, often together with other PTMs.
We will look into more detail into the gain of function provided to a protein possessing
an N-terminal myristoylated disordered domain.
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Facilitate membrane binding N-terminal disordered segments can enhance mem-
brane binding. Indeed, steric hindrance has been found to decrease the binding partition-
ing of a protein lacking a flexible N-terminal (for instance in bovine pancreatic trypsin
inhibitor derived with a myristoyl chain) when compared with proteins featured with a
flexible peptide segment (such as c-Src or MARCKS) (Pool and Thompson, 1998).
Favor PTMs
– Myristoylated proteins acquire a membrane binding capacity which in turn per-
mits S-acylation (Resh, 1999), often catalyzed by a membrane-embedded palmitoyl-
transferase. This second PTM is probably favored in case of an exposed cysteine
among a disordered region. The subsequent membrane binding regulation by palmi-
toylation / depalmitoylation cycles may be facilitated at this disordered region.
Among the not so many examples of dually myristoylated and palmitoylated pro-
teins stand almost all members of the Src family kinase, some α-subunits of G
proteins, some AKAPs proteins like AKAP15 (Gray et al., 1998), and eNOS. The
first two have a N-terminal intrinsically disordered region (Ingley, 2008) (Cabrera-
Vera et al., 2003), AKAP15 also is probably disordered at its N-terminus (Few et al.,
2007).
– The myristoylated proteins possessing a PCD are plenty, and membrane binding is
very often modulated by phosphorylation; addition of phosphate groups decreases
the peptide charge and therefore its binding to membranes (Tournaviti et al., 2009).
One can think that phosphorylation is facilitated if PCDs are disordered and more
accessible. Among proteins possessing a PCD, many are regulated by an electro-
static switch triggered through phosphorylation events, probably facilitated by an
easier access to disordered segments, like in the case of MARCKS (McLaughlin and
Aderem, 1995).
Favor protein protein interactions The HIV-Matrix protein also possesses a myris-
toyl switch, and it has been shown that is can form trimers upon membrane binding. The
N-terminal residues involved in the myristoyl switch appears to be critical determinants of
the myr(in)/myr(out) equilibrium and have higher than average intrinsic conformational
mobility (Tang et al., 2004). In this example, protein-protein interactions are favored by
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the flexibility of the N-terminal region capable of adopting diverse conformations (Resh,
2004)
Favor protein ligand interactions Modulation of membrane binding can also be
achieved by a ligand binding mechanism. MARCKS and AKAP12 (gravin) have several
PCDs at their N-terminal disordered domain. These domains are also capable of binding
Calmodulin/Ca2+. By this mechanism, the protein is released from the membrane since
the electrostatic interaction from the PCDs to the membrane is diminished (Malbon
et al., 2004) (Tao et al., 2006). By interacting with several partners (lipid or ligand),
the IDD favors membrane binding modulation. Some myristoylated proteins also shows
specific interactions with lipids (for instance PI(45)P2 which is a lipid often involved
in signaling pathways), like the HIV-matrix protein, which also regulates the myristoyl-
switch mechanism (Saad et al., 2006). Once again, a disordered segment is capable of
interacting with multiple partners.
Play a role in protein targeting PCDs often have a disordered character, and their
electrostatic interactions with acidic lipids may be quite unspecific; a myristoylated pro-
tein possessing a PCD may have the capacity of spanning unspecifically the membrane
until finding a proper localization – e.g. getting palmitoylated by a palmytoyl acyl trans-
ferase (Li et al., 2014).
IDPs are subjected to degradation It has been found that MARCKS can be cleaved
between amino acids 6 and 7 in certain extracts, and that this cleavage is myristoylation-
dependent (Brauna et al., 2000). The disordered character of the N-terminal probably
facilitates this cleavage – that could hypothetically be a possible mechanism to detach
myristoylated proteins from membranes.
Disorder to order: alpha helix formation Myristoyl is capable of stabilizing an
intrinsically disordered N-terminal domain to an alpha helix. In the case of Protein Kinase
A (PKA), the first amino acids of the protein are disordered in absence of the myristoyl
chain, and myristoylation promotes helix formation, which in turn promotes membrane
binding. Nevertheless, this helix can be destabilized under phosphorylation of serine 10,
increasing its disordered state, and probably decreasing the membrane affinity (Tholey
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et al., 2001). Fine tuning of membrane binding is achieved through the plasticity of the
disordered domain. In the case of Nef, the unfolding to folding transition seems to happen
when encountering the membrane. After myristoyl insertion and electrostatic attraction,
formation of an alpha helix occurs and subsequently inserts into the bilayer, magnifying
membrane binding (Gerlach et al., 2010).
Allostery at the interface c-Abl has a structure very close to that of c-Src kinase,
but possesses a myristoyl switch features; non-myristoylated forms of c-Abl have much
higher activity levels. The myristoylated disordered domain is directly involved in the
myristoyl switch, which in turn is related to kinase activation (Hantschel et al., 2003). This
example shows the crucial role of the flexible linker undergoing conformational changes
and involved in intramolecular interactions, which ultimately results in kinase activation
or inactivation.
Table 1.2 lists several myristoylated proteins among which the disordered regions are
pointed out.
Myristoylation only occurs in eukaryote organisms. Two myristoylated proteins were
identified in 1982, PKA and calcineurin. The subsequent discovery of more than 100 fatty
acid modified proteins occurred rapidly (Resh, 1996) (Taniguchia, 1999). The extent of
the “myristoylome” is still under study, since the techniques to assess protein myristoy-
lation in-vivo are not straightforward (but under improvement (Traverso et al., 2013)).
As previously described, specific combinations of amino acids have been identified for
N-myristoylation of the candidate protein. Removal of initiator methionine is a common
modification of proteins, occurring in up to 80 % of total proteins. The reaction is cat-
alyzed by methionine aminopeptidase and is even more efficient when the amino acid
residue following the initiator methionine is a glycine residue, yet only selected proteins
are myristoylated due to the selectivity of NMT. Several myristoylation prediction models
have been developed (Martin et al., 2011); the 17 N-terminal residues following the initial
methionine were actually demonstrated to be required for the prediction of the myristoyla-
tion status of the protein. There are several exceptions to the basic rules, for instance the
Fyn anchor (Maurer-Stroh et al., 2002b). Another type of myristoylation, which occurs
posttranslationally, is known to happen as a result of caspase cleavage during cell apopto-
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Table 1.2: List of some myristoylated proteins; the second lipid-anchoring signal is indi-
cated; the presence of a short or a long disordered region at the N-terminal is also pointed
out
Protein Lipid 1 Signal 2 Comment N-terminal
Protein kinases and phosphatases
c-Src Myristate PCD Disordered
SFKs Myristate Palmitate Disordered
c-Abl Myristate PCD Hydrophobic Cleft Disordered
PKA Myristate PCD/α helix Hydrophobic Cleft Short disordered
AKAP15 Myristate Palmitate
AKAP12 (gravin) Myristate PCD Disordered
Calcineurin B Myristate PCD
Guanidine nucleotide binding proteins
Gαi1 subunit Myristate PCD Disordered
Gαi subunits Myristate Palmitate Short Disordered
Arf1 Myristate Palmitate PI45P
Arf6 Myristate PCD
Calcium binding proteins
Recoverin Myristate PCD Hydrophobic Cleft
Neurocalcin Myristate PI45P Hydrophobic Cleft
VILIP Myristate PI4P Hydrophobic Cleft
Membrane bound structural proteins
MARCKS Myristate PCD/α helix Disordered
Viral proteins
MA Myristate Short disordered
Nef Myristate Disordered
Miscellaneous
eNOS Myristate Palmitate
BASP Myristate PCD/α helix Disordered
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sis. This pool could significantly increase the total abundance of myristoylated proteins.
As said, myristoyl is a rare fatty acid in cells (Boutin, 1997), but myristoylated proteins
constitute 0,5 to 2 % of the proteome in human (Traverso et al., 2013) (or 0.5 to 3 % of the
mammalian and plant proteomes (Martin et al., 2011)), and it might be larger (Traverso
et al., 2013). Appearance of PTMs (and in particular myristoylation) and of IDPs are
features brought by evolution in higher order organisms, and they are present in proteins
playing crucial roles in signaling cascades. Here we showed that by acting in synergy,
they provide important gain of function to proteins and improve their regulation mecha-
nisms. Though they are difficult to detect and study, computational predictions nowadays
highlight their underestimated abundance (Boisson et al., 2003) (Uverskya, 2011) and im-
portance. Consequently, the abundance of myristoylated IDDs could be more important
than is currently thought and have critical functions in signaling pathways.
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1.3. c-Src and the Src family
1.3.1. c-Src family
The Src tyrosine kinase family (SFK) takes his name from its leading member, the
c-Src protein, and is composed of at least 9 other members: Blk, Fgr, Frk, Fyn, Hck,
Lck , Lyn, Yes and Yrk. Some members are ubiquitously expressed, like c-Src, and some
are found in specific cells (Thomas and Brugge, 1997). SKFs are enzymes catalyzing the
phosphorylation of a tyrosine, readily transferring a phosphate group from ATP to the
hydroxyl group of tyrosine residues of their substrate (Parsons and Parsons, 2004). Ty-
rosine phosphorylation is considered to be one of the key steps in signal transduction and
regulation of enzymatic activity. SFKs are indeed involved in many signaling pathways
and their deregulation, in particular that of c-Src, affects cell migration, proliferation and
survival (Parsons and Parsons, 2004) (Thomas and Brugge, 1997). Redundancy has been
observed in many instances among the family, but c-Src is one of the members having a
broad range of functions. c-Src it self was the first discovered oncogene and takes its name
from Sarcoma. Peyton Rous observed in 1911 that a virus was capable of inducing tumors
in chicken. Src viral counterpart v-Src was identified in the viral genome in the 1970s. Its
capacity of transforming cells and inducing tumors made it the first discovered viral onco-
gene. Subsequently, the human form of the gene was evidenced to be a proto-oncogene
that has a key signaling function in cells, and is potentially oncogenic only upon dereg-
ulated activity (Steven Martin, 2001). As a cytoplasmic membrane anchored protein,
c-Src has a critical role in mediating signal transduction via interactions with multiple
proteins and protein complexes (Kim et al., 2009). Depending on its cellular localization,
c-Src phosphorylates different substrates in the cytosol or at the inner face of the plasma
membrane, at cell-matrix or cell-cell adhesions. These signaling complexes initiate path-
ways that regulate protein synthesis, gene expression, cytoskeletal assembly and many
other aspects of cell function such as adhesion, invasion, motility or survival (Thomas
and Brugge, 1997) (Yeatman, 2004) (Kefalas et al., 1995). Its activity is under tight con-
trol (Sen and Johnson, 2010) via phosphorylation/dephosphorylation cycles (Roskoski,
2005), and acts as a cancer promoter when deregulated (Irby, 2000). Overexpression of
the c-Src protein and an increase in its specific activity have been observed in numerous
cancer types (in colorectal cancer, several other gastrointestinal malignancies, as well as in
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breast, ovarian and lung cancers); increased c-Src kinase activity is often associated with
advanced-stage tumors that readily metastasize and is thought to have an important role
in the increased metastatic potential of these tumors. Therefore, it is since many years
an important therapeutic target (Kim et al., 2009).
c-Src was the fifth protein in which incorporation of a N-terminal myristoyl was dis-
covered (in 1984) (Buss and Sefton, 1985). All the SFK members actually possess a
myristoyl chain (Kefalas et al., 1995), except Frk, and are usually also palmitoylated.
They are lipid anchored kinases acting at the membrane interface. c-Src does not use
S-acylation, but its membrane association is enhanced by the presence of a PCD (Buser
et al., 1994). Table 1.3 shows the consensus sequences of the SFK members, enabling
myristoylation and/or palmitoylation of their N-terminal domain (Resh, 1999).
Table 1.3: Sequence alignment of the N-terminal domains of the SFK members. Myris-
toylation occurs at glycine 2 while palmitoylation at cysteine 3 when present.
SFK Amino acid sequence
Src M G S N K S K P K D P S Q R R R
Yes M G C I K S K E D K G P A M K Y
Fyn M G C V Q C K D K E A T L K T E
Lyn M G C I K S K R K D N L N D D E
Lck M G C V C S S N P E D D W M E N
Hck M G C M K S K F L Q V G G N T G
Fgr M G C V C F K K L E P V A T A K
Yrk M G C V H C K E K I S G K G Q G
Blk M G L L S S K R Q V S E K G K G
The association of c-Src with the plasma membrane is considered as an essential feature
for its function. In absence of myristoylation, v-Src is not able to transform cells (Kamps
et al., 1985), and c-Src stability and kinase activity is also affected (Patwardhan and
Resh, 2010). The N-terminal domain of all SFKs is intrinsically disordered and consti-
tutes a poorly conserved region among the family; therefore, it was named the Unique
Domain (Ingley, 2008).
c-Src is composed of 536 amino acids (Maffei, 2014). Its first X-ray structure was
obtained in 1997 (Sicheri and Kuriyan, 1997). The structures determined by x-ray lack
the Unique Domain because of its disordered character. Apart for the N-terminal region,
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Figure 1.6: Structure and activation of c-Src protein. Figure from Yeatman (2004).
SFKs share a similar structure conserved among the members. Three Src Homology
domains are connected to the Unique Domain, namely the SH3, the SH2 and the SH1
(or kinase) domains. The SH2 and SH1 are connected by another partially disordered
loop, containing a proline rich motif. After the SH1 domain follows a C-terminal tail.
These kinases have a mechanism for autoinhibition and activation driven by two key
tyrosine residues, one negative-regulatory in the C-tail (Y527), and the other positive-
regulatory in the so-called A-loop of the SH1 domain (Y416). Mutation of Y527 results in
constitutive activation of c-Src, therefore loss of Y527 phosphorylation leads to activation
of c-Src catalytic activity. v-Src lacks the C-terminal regulatory tail, which makes it always
activated in the viral form (Thomas and Brugge, 1997). When phosphorylated, the kinase
is locked in an inactive form through two intramolecular interactions: the SH2 domains
binds the phosphorylated tyrosine Y527 while the SH3 domain binds the proline motif of
the region connecting the SH2 and SH1. Upon dephosphorylation, the kinase adopts an
open conformation and becomes kinetically active (Yeatman, 2004). Autophosphorylation
of Y416 results in an additional activation step in which the enzyme reaches maximal
activity. The activation mechanism is illustrated in Figure 1.6 (Yeatman, 2004).
Y527 is phosphorylated by the cytoplasmic tyrosine kinase Csk (Irby, 2000), thereby
inactivating c-Src. Among the ligands capable of regulating c-Src activity stand the phos-
phatases and the receptor tyrosine kinases (RTKs). The mechanism of c-Src autoinhibition
and activation relies on intramolecular interactions between the different domains, but the
latter also participate in protein-protein interactions, thus playing an additional role in
CHAPTER 1. INTRODUCTION 31
the regulation of the enzyme. SH3 domains bind short contiguous amino acid sequences
rich in proline residues and its ligands contain a core consensus sequence of P-X-X-P.
SH2 domains bind to short contiguous amino acid sequences containing phosphotyrosine.
The SH2 and SH3 domains play a central role in regulating c-Src catalytic activity. In
addition to intramolecular interactions, the SH3 domain is important for intermolecular
interactions, that regulate c-Src catalytic activity, localization, and recruitment of sub-
strates (Ingley, 2008), the SH2 for regulation of the localization of c-Src or its binding
proteins (Thomas and Brugge, 1997).
In vivo, c-Src molecules are present mainly in a inactive dormant form; in about 90-
95 % of c-Src proteins,Y527 is phosphorylated in basal conditions (Roskoski, 2005). If
c-Src is not phosphorylated at Y416, its activity is low (Superti-Furga, 1995). Autophos-
phorylation increases the catalytic activity and modifies substrate specificity (Sun et al.,
2002). Mutation of Y413 (equivalent to Y416 in c-Src) diminishes the transforming po-
tential of v-Src (Thomas and Brugge, 1997) and Y416 is constitutively phosphorylated in
activated oncogenic c-Src mutants. Autophosphorylation has also been found to override
the negative regulation process in some instances (Ingley, 2008). At high concentration
and activation levels, v-Src diplays a high transformation potential. The requirement
for a trans-autophosphorylation of the A-loop for full activation suggests that SFKs are
activated in clusters of at least two identical or related molecules, that may implicate
adaptor molecules having a crucial regulatory role in this process (Ingley, 2008). Very
tight regulation of c-Src is needed to avoid aberrant kinase activity.
Myristoylation targets c-Src proteins to membranes, which dramatically affects its cel-
lular localization (Buss et al., 1986) (Pellman et al., 1985). In one study, non myristoy-
lated c-Src has been found in the cytoplasm but also in the nucleus, which suggests that a
possible role for myristoylation might be to prevent unregulated nuclear transport of pro-
teins (David-Pfeuty et al., 1993). This phenomenon could be explained by the presence of
a PCD sequence of c-Src (that may resemble a nuclear targeting domain (Li et al., 2014)),
or by that of FG repeats in the Unique Lipid Binding Region – also found to promote nu-
clear localization in Hough et al. (2015). It is not clear whether non myristoylated forms
of c-Src can exist in cells – David-Pfeuty et al. (1993) specify that they have been exper-
imentally observed in some studies (Buss and Sefton, 1985). Several studies established
that v-Src in its wild type form was present at both the plasma membrane (Courtneidge,
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1980) and the perinuclear region of transformed cells (Kim et al., 2009). v-Src was found
to be inactive in the perinuclear region, but it was in the active state at the cell periph-
ery (Welham and Wyke, 1988). This activity-localization relationship was also observed
for c-Src: studies on the subcellular localization of c-Src revealed that it was associated
with the plasma, perinuclear, and endosomal membranes. The inactive form of c-Src
has juxtanuclear localization (Yeatman, 2004). The actin cytoskeleton is needed for cat-
alytic activation (Sandilands et al., 2004): upon activation by phosphorylation, c-Src SH3
domain associates with actin filaments, which then drives the translocation of c-Src to
cell-cell and cell-matrix adhesion sites, where c-Src can interact with plasma membrane-
bound molecular partners (Sen and Johnson, 2010). It is not really known how the kinase
is spatially regulated. Endosomal trafficking is involved in the delivery of c-Src to the
plasma membrane, and also in the recycling and degradation pathways (Sandilands and
Frame, 2008). A soluble pool of c-Src proteins has also been observed (Buss et al., 1994)
(David-Pfeuty et al., 1993) (Donepudi and Resh, 2008). Unlike the other members of the
SFK, c-Src does not possess a palmitoyl chain, which is known to target proteins to rafts.
c-Src is found to be localized in both raft and non-raft regions, with a different activity
at the different compartments (Seong et al., 2009). In addition, c-Src can localize to late
endosomes / lysosomes, which is specific to non palmitoylated SFKs, and is involved in
lysosome distribution. An altered distribution of this distribution is often found in cancer
cells (Kasahara et al., 2008).
1.3.2. The Unique and SH3 Domains of c-Src
Figure 1.7 displays the domain structure and sequence of the first N-terminal domains
of c-Src, namely the SH4 and Unique disordered domains (USrc), and the SH3 folded
domain. Figure 1.8-A is a scheme of c-Src bound to membranes, and Figure 1.8-B shows
the scheme of the domains we will focus on during this work, namely the Myristoylated
Unique and SH3 domains.
As already mentioned, c-Src does not undergo S-acetylation but possesses a PCD,
called the SH4 domain, situated just after the glycine 2 residue. The SH4 domain of c-Src
is enriched in three lysines and three arginine among its first 17 amino acids. c-Src binding
to membranes via the myristoylated SH4 domain (MyrSH4) is one of the most studied
case of cooperative binding between a myristoyl group and a PCD (Sigal et al., 1994).
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SH4 Unique Domain SH3 SH2 SH1
ULBR RT loop
nSrc loop
Myr-GSNKSKPKDASQRRRSLEPAENVHGAGGGAFPASQTPSKPASADGHRGPS
AAFAPAAA EPKLFGGFNSSDTVTSPQRAGPLAGGVTTFVALYDYESRTETDLSFK
KGERLQIVNNTGDWWLAHSLSTGQTGYIPSNYVAPSDSIQAEE
Figure 1.7: Domain structure and amino acid sequence of the SH4, Unique and SH3 do-
mains of c-Src. The main functional domains (ULBR, RT and nSrc loops) are highlighted.
Binding to lipid vesicles (made of charged or neutral lipids) of variants of MyrSH4 showed
that the electrostatic interactions increased the peptide partition to membranes in a non-
additive manner (Buser et al., 1994). The partition coefficient derived were compatible
with that of c-Src alone (Murray et al., 1998), confirming the essential role of MyrSH4
in c-Src anchoring to membranes. The three arginines seem to have a dominant role in
the electrostatic interaction processes – as seen in NMR experiments of USrc binding to
charged bicelles (Pérez et al., 2013). Myristoyl chain insertion has been studied by solid
state NMR and showed that the acyl chain insertion depth varied according to the lipid
composition; the depth was influenced by the degree of saturation, the chain length and
the charge of the lipids (Scheidt and Huster, 2009). In the molecular model computed for
MyrSH4 binding to a bilayer, the SH4 domain does not penetrate the bilayer but stands
on top of it through electrostatic interactions (Murray et al., 1997) (Murray et al., 1998).
Experimentally, non myristoylated SH4 binding to a lipid monolayer was not found to
insert into it (Sigal et al., 1994). MyrSH4 can be phosphorylated in S17 (Amata et al.,
2013), which decreases the total charge of the SH4 domain and therefore the binding of
SH4 to charged lipids (Pérez et al., 2013).
Going towards the C-terminal, after the SH4 domain comes the Unique Domain, and
both constitute the intrinsically disordered N-terminal domain of c-Src. This unfolded
domain possesses the general characteristics of IDDs, (for instance it has a high isoelectric
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point), with some peculiarities: it contains more aromatic residues than a usual IDD.
Within its sequence, a partially ordered region has been found (Bernadó et al., 2008), that
was also shown to have lipid binding capabilities. For this reason, it was called the Unique
Lipid Binding Region (ULBR) (Pérez et al., 2013). This secondary, or weak, interaction
towards lipids is postulated not to play a role in c-Src anchoring, but in fine tuning of
c-Src interactions with membranes and possibly kinase activity regulation. The Unique
and SH4 domains are non conserved among the Src family, and thought to provide unique
functions to each member Ingley (2008). Though it has raised low interest until now, a
few studies highlight its biological importance. Swapping the N-terminal region, including
the Unique domain, between c-Src and c-Yes, results in functional exchange (Hoey et al.,
2000) (Summy, 2003). Additional phosphorylations to S17 have been found in the Unique
Domain, close to the ULBR, at S69 and S75 (Amata et al., 2013), which also abolishes the
interaction of ULBR with membranes (Pérez et al., 2013). Other phosphorylation events
at serine and threonine residues have been observed in the Unique Domain (Ralston and
Bishop, 1985), for instance at S12, T34 and S72, and have been shown to modulate the
activity of c-Src (Pan et al., 2011) (Joung et al., 1995) (Gould and Hunter, 1988) (Amata
et al., 2014). Mutations in the ULBR of full length c-Src resulted in strong phenotypes in
model organisms (Pérez et al., 2013) as well as colorectal cancer cell lines (Maffei, 2014),
suggesting that fine tuning of membrane interactions is an important functional element
in c-Src regulation. As a consequence, the membrane environment probably plays an
important role for c-Src regulation.
After the Unique Domain comes the small folded SH3 Domain. It consists of a beta-
sandwich formed by five beta-strands connected by three loops (the RT, nSrc, and distal
loops) and a short 310-helix. The SH3 also contains lipid binding regions, in particular in
the RT loop, and also in the nSrc loop (Pérez et al., 2013). Binding of a polyproline on
the other side of the SH3 allosterically hampers the RT loop to bind lipids (Amata et al.,
2013).
In-vitro studies on the non-myristoylated form of USH3 revealed intramolecular inter-
actions between the SH3 and the Unique domains, highlighting the role of intramolecular
interactions at the N-terminal of c-Src. Indeed, these interactions take place in regions
already involved in lipid binding. The ULBR has been found to interact with the RT loop.
Another interaction between the n-Src loop and the SH4 domain has been observed, and
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Figure 1.8: A) Scheme of c-Src bound to membranes B) Scheme of the myristoylated
Unique + SH3 domain of c-Src bound to membranes. Additional electrostatic interaction
occurs at the PCD SH4.
revealed that the Unique Domain possibly adopts a restricted conformation through in-
tramolecular interactions. External ligands are also capable of competing with the same
sites (for instance ligands containing a polyproline-like motif) (Maffei et al., 2015). Fig-
ure 1.9 represents the different intramolecular interactions taking place in the Unique and
SH3 domains of c-Src.
SH4 Unique Domain SH3 SH2 SH1
Primary Lipid Binding Region
Secondary Lipid Binding region
Intramolecular interactions
Figure 1.9: Scheme of USH3 intramolecular interactions, as well as its interactions with
lipids
c-Src constitutes a striking example of an unfolded domain with high functional ver-
satility. It remains disordered, yet is conformationally restricted, interacts with multiple
partners with low affinity and acts in synergy with other PTMs such as phosphorylation,
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and all this at the membrane boundary via its myristoyl anchoring. This current knowl-
edge sheds light on the existence of the rich repertoire of regulatory interactions at the
N-terminal domain of c-Src and highlights the functional role of the disordered N-terminal
of c-Src. As said earlier, the Unique and SH3 Domains can influence c-Src function, and
are thought to add a regulation layer in c-Src activation mechanism, specific to the protein
because of its unique sequence. A detailed understanding of the regulation mechanism
would allow this domain to constitute a novel drug target.
However, the in-vitro studies that have been carried out on the N-terminal region of
Src in order to characterize its detailed mechanism at the lipid bilayer interface either
lack the Unique Domain or the myristoyl chain. A study of the myristoylated Unique and
SH3 domains would constitute a better approximation of the natural form of c-Src.
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1.4. Lipid membrane models and Protein-Membranes
interactions
To study the binding of proteins or peptides to membrane, there is a need to mimic
biological membranes in order to conduct biophysical assays. As discussed earlier, mem-
branes are highly complex environments, made of a high number of different lipids and
proteins. They are neither flat nor symmetric and even have lateral inhomogeneities (lipid
rafts). Fully understanding the mechanisms underlying the wide variety of membrane
function is a huge research field, and more research is needed before artificial membranes
can perform the full range of roles required of them: reproducing asymmetry, specialized
patches and membrane curvatures are still current challenges (Ken Jacobson et al., 2007).
Nevertheless, very simple membrane models can provide very valuable information on the
interaction of proteins to lipid layers of certain compositions.
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Figure 1.10: Classes of the most common lipid-composing membranes
Glycerophospholipids are the main components of membranes and are responsible for
its architecture. They are composed of two hydrophobic carbons chains linked to a polar
head, as illustrated in Figure 1.10.
The chain can vary in length and saturation, and the head can be of distinct composi-
tion. Phosphatidylcholine is the most abundant phospholipid and is zwitterionic. Smaller
amounts of negatively (phosphatidylglycerol, phosphatidic acid, phosphatidylserine) or
positively (phosphatydilethanolamine) charged are found, in quantities depending on the
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membrane location in the organism. Different types of phosphoinositides, considered as
signaling lipids with specific functions, are found in very small amounts, especially in
rafts. Rafts are also enriched in sphingolipids and cholesterol.
Bilayer formation is a consequence of the dominance of glycerophospholipids in the
membrane composition. A bilayer formed of a single lipid can be either in the gel phase
or in the liquid phase, depending on the temperature. The temperature at which the
transition from the gel to the liquid phase occurs is called the melting temperature (Tm).
This temperature depends a lot on the carbon chain length and saturation, and to some
extent on the head.
Temperature and 
pressure are constant
Li is the phase rich in
component i
Figure 1.11: Phase diagram for a bilayer
composed of three lipids, showing in which
phase it is according to lipid composition i,
at constant temperature and pressure
Three classical chain lengths are very
useful in the common experimental condi-
tions used. Unsaturated C18-chains ensure
that at 4 ◦C or more, the bilayer is always
in a fluid state (for instance DOPC has a
Tm of –17 ◦C). Saturated C14-chains are
in the gel phase below room temperature,
and are fluid above (for instance DMPC,
with a Tm of 23 ◦C). Saturated C16-chains
have a high transition temperature, thus
are in the gel phase already at room tem-
perature (DPPC has a Tm of 41 ◦C).
According to the needs, the proper
lipids can be chosen to obtain a gel or fluid
phase in the experimental conditions. In-
deed, in the fluid phase, lipids and proteins will diffuse laterally, but this diffusion will be
significantly slowed down in the gel phase. Often, a lipid mixture is used, and the lipids
can be chosen with matching Tm (for instance DMPC and DMPG), or not (to induce
phase separation for instance). Cholesterol is also often added as an important compo-
nent of the phase behavior of the membrane, by having the property of creating “liquid
order phases”, which are fluid but less disordered than liquid phases lacking cholesterol
(“liquid disordered phases”). The phase state of the bilayer from a complex mixture is
represented in a phase diagram (as in Figure 1.11, in which the composition of each lipid
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influences the bilayer phase state.
Table 1.4: Transition temperature of the most common phospholipids (source from Avanti
Polar Lipids webpage)
Phosphatidylcholine Phosphatidylglycerol
12:0 PC (DLPC) -2 12:0 PG (DLPG) -3
13:0 PC 14 14:0 PG (DMPG) 23
14:0 PC (DMPC) 23 16:0 PG (DPPG) 41
15:0 PC 35 18:0 PG (DSPG) 55
16:0 PC (DPPC) 41 18:1 PG (DOPG) -18
17:0 PC 50 16:0-18:1 PG (POPG) -2
18:0 PC (DSPC) 55 Phosphatidylserine
19:0 PC 62 14:0 PS (DMPS) 35
20:0 PC 66 16:0 PS (DPPS) 54
21:0 PC 71 18:0 PS (DSPS) 68
22:0 PC 75 18:1 PS (DOPS) -11
23:0 PC 79.5 16:0-18:1 PS (POPS) 14
24:0 PC 80.3 Phosphatidic Acid
16:1 PC -36 12:0 PA (DLPA) 31
18:1c9 PC (DOPC) -17 14:0 PA (DMPA) 52
18:1t9 PC 12 16:0 PA (DPPA) 65
18:1c6 PC 1 18:0 PA (DSPA) 75
22:1c13 PC 13 18:1 PA (DOPA) -4
18:2 PC -57 16:0-18:1 PA (POPA) 28
18:3 PC -60 Phosphatidylethanolamine
20:4 PC -69 12:0 PE (DLPE) 29
14:0-16:0 PC 35 14:0 PE (DMPE) 50
14:0-18:0 PC 40 16:0 PE (DPPE) 63
16:0-14:0 PC 27 18:0 PE (DSPE) 74
16:0-18:0 PC 49 20:0 PE 83
16:0-18:1 PC (POPC) -2 18:1c9 PE (DOPE) -16
16:0-22:6 PC -27 18:1t9 PE 38
18:0-14:0 PC 30 18:2 PE -40
18:0-16:0 PC 44 16:0-18:1 PE (POPE) 25
18:0-18:1 PC 6
18:0-18:1 PC 6
18:1-16:0 PC -9
18:1-18:0 PC 9
A wide range of techniques are available to screen and analyze protein-lipid layer
interactions (Cooper, 2004); many of them imply measurements at equilibrium which
renders information on the partitioning of the protein towards the lipid. The concept of
partitioning is preferred to that of affinity since the interactions usually do not have a
specific stoichiometry (Leo et al., 1971). Some techniques also enables to study the kinetics
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of the interaction (the velocity at which the protein associate to or dissociate from the lipid
layer), as well as its penetration capacity into the layer. Other techniques allow for peptide
secondary structure and orientation study at the lipid layer. The factors influencing
partitioning, kinetics and penetration can be studied by changing the composition of the
lipid layer, as well as its pressure, its curvatures, etc.
Figure 1.12 shows the main membrane mimics in solution, that will be described in
the following section.
The simplest mimic consists in a large multilamellar vesicle (MLVs) spontaneously
formed upon rehydration of a lipid film (Akashi et al., 1996). The process must be per-
formed above the transition temperature of the lipids in order to obtain a fluid phase. The
composition of the enclosed aqueous phase matches that of the phase medium. However, if
the external medium is replaced, the composition of the internal phase is unchanged. This
can be used, for example, to prepare vesicles loaded with sucrose to increase their density
and facilitate phase separation upon centrifugation. MLVs have a large diameter, are very
heterogeneous in size (from 1 to 10μm) and are multilamellar. Upon centrifugation of the
MLVs with the protein, a lipid sedimentation assay can be performed to determine the
partitioning of the protein to the lipid phase versus the aqueous phase. Quantification
of the amount of protein present in each phase can be done in a simple SDS-page gel, or
by more sophisticated methods implying for instance radioactive (Buser et al., 1994) or
fluorescence measurements (Ehrlich et al., 2011). Giant Unilamellar vesicles (GUVs) can
be formed by electroporation (Riske and Dimova, 2005). At least three techniques permit
to obtain smaller and unilamellar vesicles. By extruding MLVs through pores of a definite
size, large unilamellar vesicles (LUV) of the size ranging from about 100 nm to 400 nm can
be obtained. By sonicating MLVs, small unilamellar vesicles (SUV) are obtained and have
a diameter ranging from about 20 nm to 80 nm. These liposomes are very useful in many
assays conducted in solution, since they are formed of a single lipid bilayer. Their size or
curvature can be controlled (Hamai et al., 2006) (Wu and Baumgart, 2014), and they do
not diffract light so much, especially at low concentration. A variation of liposomes are
bicelles, in which long chain lipids are mixed with short chain lipids; by hydration of such
a lipid film with an aqueous solution, spontaneously form bicelle-shaped structures, the
short chain lipids situated at the highest curvature position (Pérez et al., 2013). Studying
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the interaction of a protein with liposomes by Isothermal Titration Calorimetry (ITC)
renders a partition coefficient of the interaction (Wu and Baumgart, 2014), and also ther-
modynamics data. Liposomes can be useful in fluorescence assay, giving information of
the partitioning of the protein to the bilayer (Ladokhin et al., 1997); if a stop-flow assay
is used, kinetics information can be derived (Lorch and Booth, 2004) (Daniel R. Dries
and Newton, 2008). Liposomes are also used in NMR experiments (Bensikaddour et al.,
2008), and bicelles can be used when there is need for aligning them in the magnetic field.
Circular Dicroism (CD) enables to study the conformation of the peptide at the liposome
interface, for instance the formation of an alpha helix upon liposome binding (Zhao and
Ta, 2003).
SUV
<100 nm
SUV
100-1000 nm
GUV 
>1 μm
Multilamellar
MLV
Multivesicular
Figure 1.12: Vesicles (multilamellar and unilamellar) and liposomes (SUV and LUV)
A different lipid model consists in depositing lipids at an air water interface, using the
so-called monolayer technique, as illustrated in Figure 1.13-A. The lipids are dissolved
in a solvent, and upon reaching the aqueous surface, spread and organize as a mono-
layer in which the head is in contact with the water, and the tail with the air. The
equivalence between the lateral pressure of this so-called Langmuir monolayer, and lipid
bilayers lateral compressibility, has been established (Marsh, 1996). Langmuir monolay-
ers are widely used to study protein interaction with (Wang et al., 2011) and insertion
into the monolayer (Calvez et al., 2009). Indeed, the surface pressure can be measured
using a Wilhemy plate (Maget-Dan, 1999). By adding a protein in the subphase, protein
insertion is recorded by measuring the change in pressure. The monolayer can also be
compressed and extended thanks to the use of superficial moving barriers (Figure 1.13-B),
rendering for instance the area needed for a peptide to insert in the monolayer (Beschi-
aschvili and Seelig, 1990) (Sugár et al., 2005) (Desmeules et al., 2007). Combining a
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monolayer with another spectroscopic technique, for instance Infrared Reflection Absorp-
tion Spectroscopy (IRRAS), can render information about peptide conformation at the
interface (Annette Meister et al., 2007).
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Figure 1.13: Monolayer set-up
A vast category of membrane mimics take the form of Supported Lipid Bilayers, SLBs,
which is a generic term for mono, bi or multilayers standing over a solid substrate. For
instance, Langmuir monolayers can be transmitted to a substrate (glass, mica, etc) by
using the Langmuir Blodgett or Langmuir Schaeffer techniques (Charitat et al., 1999), as
illustrated in Figure 1.13-C and -D. SLBs can also be formed simply by depositing lipo-
somes over a variety of substrates. One of the most straightforward technique consists in
vesicle fusion over a hydrophilic substrate like glass, mica, silicon, etc (Buss and Sefton,
1985). The liposomes readily adsorb under certain conditions. Many parameters influence
vesicle fusion, such as liposome composition, pH, ionic strength of the buffer (Johnson
et al., 2002), presence of calcium in the buffer, the solid support, etc (Richter et al.,
2006). Functionalized substrates are also used, for example, hydrophobic anchors can be
chemically coupled to capture liposomes, or pegylated glass surfaces containing strepta-
vidin molecules can capture liposomes containing biotin. (Cremer and Boxer, 1999) (Jass
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et al., 2000) (Ehrlich et al., 2011). The liposomes can either spread completely and form
a bilayer, or remain intact over the surface; a mixture of the two cases can also be encoun-
tered (Cremer and Boxer, 1999). Figure 1.14 shows different spreading events (Richter
et al., 2006).
Figure 1.14: Formation of a Supported Lipid Bilayer by liposome deposition, as described
in the text. Figure from Richter et al. (2006)
These SLBs are used in a variety of techniques. In a Surface Plasmon Resonance
(SPR) assay, the kinetics of a protein interacting with a SLB can be followed and the
affinity measured (Daniel R. Dries and Newton, 2011). SLB formation has been widely
studied by Atomic Force Microscopy (AFM) (Jass et al., 2000) and can be further used
to study peptide-SLB interactions (Chaibva et al., 2014). Other spectroscopic methods
use SLBs such as fluorescence microscopy, in which the Total Internal ReFlection (TIRF)
mode is interesting because it focuses at the interface only. ATF-FTIR can also be
conducted to study structural features of the peptide at the SLB interface (Zhao and
Ta, 2003) (Bensikaddour et al., 2008). Solid state NMR is also able to give structural
information (Lindblom and Quist, 1998).
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1.5. Motivations
Recent work demonstrated the biological relevance of the Unique Domain of c-Src
in the enzyme function and regulation (Pérez et al., 2013) (Maffei et al., 2015). The
biophysical characterization of this disordered domain in absence of the myristoylated
tail showed that it was involved in lipid binding, as well as in intramolecular interactions
with the SH3 domain. However, since c-Src is anchored to membranes in its natural form,
characterization of the myristoylated form is highly relevant, specifically when bound to
a lipid bilayer. In this work, we decided to use simple membrane models, and to focus on
the complexity of the interactions between the Unique and SH3 domains and lipid layers
in myristoylated constructs of c-Src.
Anchoring of c-Src to membranes has been attributed to the MyrSH4 peptide only (Mur-
ray et al., 1997). The thermodynamics of MyrSH4 binding to lipid vesicles has been exten-
sively studied (Sigal et al., 1994). The equilibrium constant of c-Src binding to membranes
has been found to be of the same order of magnitude. However, the additional lipid bind-
ing regions in the Unique and SH3 domains are obviously not present in the MyrSH4
construct. Would the binding of longer myristoylated constructs to lipids differ from that
of MyrSH4 because of these additional lipid binding domains? In addition, what is the
kinetics behavior of myristoylated forms of c-Src binding to membranes?
Tethering to the membrane surface, even if the connection is a flexible, long, in-
trinsically disordered domain, creates singular boundary conditions resulting from the
transition between 3D (cytoplasm) and 2D (membrane) environments. Cluster forma-
tion could be facilitated in this boundary region and has already been observed in the
small MyrSH4 peptide (Owen et al., 2010). Can we observe analogous phenomena when
constructs longer than MyrSH4 bind to membranes?
Another challenge of our system is to study low affinity interactions in the presence of
a high affinity lipid binding region (MyrSH4). In many biophysical techniques, the high
affinity interaction is expected to “hide” the weak interactions. The weak interaction
would be difficult to study on its own; it would require high protein amounts in the
assays, often favoring non specific binding. In addition, the actual affinity would probably
be different in the presence or the absence of the high affinity interaction, because of
the entropic advantage gained by belonging to the same peptide: the weak interaction is
expected to be increased or directed in the presence of the strong interaction. Can we find
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ways to study the effect of myristoylation on the lipid binding capacities of the Unique
Lipid Binding Region or the RT loop of USH3? Would these domains have enhanced
affinity to lipid bilayers when the protein is already anchored to it? Do these domains
have selective affinity for specific lipids? Could the Unique Lipid Binding Domain regulate
in some way the distance of the folded domains of c-Src from the membrane, by interacting
or not with lipids?
Deeper characterization of the SH4-Unique-SH3 ensemble in its myristoylated form,
in solution or bound to a lipid bilayer, will increase the understanding of the possible role
of these domains in the regulation mechanisms of c-Src kinase.

Chapter 2
Objectives
Objective 1
Establishing the experimental procedures for the efficient production of
myristoylated proteins
i Set up robust methods, as universal as possible, permitting the expression and pu-
rification of recombinant myristoylated proteins, folded or unfolded, by coexpressing
them with N-myristoyl Transferase in E.coli. Propose strategies to eliminate all pos-
sible sources of contamination.
ii Scale in-vitro myristoylation reactions and identify purification protocols.
iii Produce pure samples at a scale adequate for biophysical studies, in particular obtain-
ing the samples in minimum medium at a concentration suitable for Nuclear Magnetic
Resonance studies.
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Objective 2
Characterizing the binding of myristoylated constructs containing the Unique
Domain of c-Src to lipid bilayers.
i Study the binding kinetics of MyrUSH3 to lipid bilayers; set up an SPR assay to
obtain kinetics and affinity constants of the binding of MyrUSH3 to supported lipid
bilayers of different compositions.
ii Explore the possible clustering of c-Src upon membrane binding. Develop a suitable
assay at the single molecule level, in which a myristoylated construct containing a
fluorescent reporter fused to the Unique Domain is bound to supported lipid bilayers.
iii Examine by NMR the effect of myristoylation at a residue level
• on the USH3 intramolecular interactions
• on the binding of “lipid binding regions”, in the USH3, domain to lipid bilayers
Chapter 3
Protein Myristoylation
3.1. Myristoylation
Myristoylation
Myristoylation is found in low and high eukaryotes. The enzyme catalyzing the
addition of a myristoyl chain at the N-terminal glycine of a protein was identified in
1986 (Towler and Glaser, 1986) and is called N-Myristoyl Transferase (NMT). It cataly-
zes the transfer of the acyl chain of Myristoylated Coenzime A (MyrCoA) to the peptide
substrate. Despite the fact that myristic acid is not abundant in cells, NMT usually cat-
alyzes the acyl addition with high specificity for myristoyl. The initiating methionine is
removed by methionine amino peptidase during translation and glycine 2 becomes the N-
terminal amino acid. The requirement for glycine at the N-terminus is absolute; no other
amino acid will substitute. However, not all proteins with an N-terminal glycine are N-
myristoylated and the ability to be recognized by NMT depends on the downstream amino
acid sequence. The most common N-terminal consensus sequence for NMT substrates is:
Met-Gly-X-X-X-Ser/Thr, with generally serine or threonine being preferred at position 6
and lysine or arginine at positions 7 and/or 8 (Resh, 1999), as illustrated in Figure 3.1.
Still, the universal rules governing the nature of the following amino acid stretch is yet
unclear and variations and exceptions have been described (Boutin, 1997) (Traverso et al.,
2013). Up to the first 17 amino acids may play a role in sequence recognition and exhaus-
tive models are investigated in order to be applied in predictive algorithms (Maurer-Stroh
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et al., 2002a).
G K/T Z Z  Z  Z  Z  Z  Z
small polar
large hydrophobic
often A,C,D,E,G,H,K,N,Q,R,S,T
Z
hydrophilic
often polar
Figure 3.1: Consensus Sequence for NMT N-
terminal peptide recognition
The problem of the specificities of the
NMT is interesting, since it concerns both
substrate and cosubstrate. Though myris-
toyl is very specifically coupled to NMT
substrates in many cases, examples of het-
erogeneously acylated proteins have been
found, for instance recoverin and the α-
subunit of the G protein transducin (Iram
and Cronan, 1992) (Boutin, 1997). In these
proteins and others, lauric acid and C14 fatty acids containing a cis double bond between
C5-C6 (C14:1) or C5-C6 and C8-C9 (C14:2), have been observed; the reduced hydropho-
bicity of these acyl chains compared with that of myristoyl may be required for these
proteins to properly operate (Sonnenburg and Gordon, 2004). The effect of substituting
myristic acid with oxygen incorporated into the fatty acid backbone in place of the posi-
tion 11 methylene group (which reduces the hydrophobicity of the fatty acid with only a
minor effect on chain length) has been studied on different proteins. It resulted in changes
and reductions of the in-vitro peptide catalytic efficiency of one peptide with respect to
another. For most yeast and mammalian N-myristoyl proteins, it did not alter membrane
association, however a few proteins were affected. The 63-kDa N-myristoyl protein in
BC3H1 cells and the tyrosine kinase v-Src both underwent dramatic redistribution from
membrane to cytosolic fractions (Heuckeroth and Gordon, 1989). More than one hun-
dred different chains were tested as possible substitutes of the natural cosubstrates, in
the form of MyrCoA analogues (Boutin, 1997). NMT was able to recognize a wide range
of them as cosubstrates for the acylation of peptide or protein. It can usually accommo-
date shorter acyl chains but not the longer ones, such as palmitic acid (Rudnik et al.,
1992) (Heuckeroth and Gordon, 1989) (Towler and Glaser, 1986). NMT is mainly found
in the cytosol but also in the reticulum endoplasmic, and usually acts cotranslationa-
ly (Deichaite et al., 1988), by modifying the nascent polypeptide chain (Boutin, 1997).
Binding of the MyrCoA cofactor to one site of NMT is a prerequisite, since it induces a
conformational change in the enzyme allowing for peptide recognition. When the ternary
complex NMT:CoA:substrate is formed, the chemical transformation (the nucleophilic
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glycine attacks the thioester carbonyl bond of MyrCoA) is facilitated by NMT. The CoA
is released and the Myristoylated peptide as well (Farazi et al., 2001). Figure 3.2 shows
a schematic representation of the myristoylation reaction.
MyrCoA binding
Conformational change
Peptide binding
Chemical transformation
CoA releaseMyristoylated peptide release
Figure 3.2: Myristoylation mechanism
Recombinant proteins are usually expressed in bacterial system, but since bacteria do
not express NMT, the protein would not be myristoylated in such a system. This limita-
tion is overcome by coexpressing the protein and the enzyme, since MyrCoA is present in
bacteria (used in the β-oxydation pathway of energy production). The standard method
initially consisted in a two-plasmid expression system, but in many instances, partial
myristoylation was achieved. This lowered the protein yield, and also implied separation
of the myristoylated and non-myristoylated proteins (Kroupa et al., 2014) (Ha et al., 2005).
Improvement of the myristoylation efficiency was achieved by using a bicistronic vector,
in which the plasmid contains the sequence of both the enzyme and the substrate (Gluck
et al., 2010). Purification is generally performed in a standard way, by lysing the cells,
centrifugating the lysis product and purifying the supernatant, with (Gluck et al., 2010)
or without detergents (Morgan et al., 2011) (Kroupa et al., 2014). In some protocols, the
protein is extracted from the pellet (Ha et al., 2005).
We used the bicistronic method to express and purify our myristoylated proteins.
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When using this strategy, we encountered several unexpected observation:
• First, the myristoylated protein was forming a tight complex with the enzyme upon
resolubilization during cell lysis. Rebinding of the myristoylated protein to NMT
has also been observed for Nef (Morgan et al., 2011).
• Second, shorter acyl chain, especially lauryl chains, were also attached to the protein
in a non negligible amount, in particular when cells were grown in minimummedium.
This phenomenon has also been observed upon myristoylation of Arf1 (Yizhou Liu
et al., 2009). As explain previously, the length of the acyl chain can influence the
binding properties of the protein to membranes, so this issue should be addressed
in order to obtain pure samples of myristoylated proteins.
• Third, additional protein degradation occurred upon myristoylation. Thus expres-
sion and purification protocols were optimized in order to obtain pure myristoylated
proteins.
We used the coexpression system to produce several constructs of myristoylated forms
of Src. These proteins were expressed in rich medium for most of the assays, and also
in minimum media containing 15N labelled NH4 for further use in NMR experiments.
MyrUSH3 was expressed and used for expression and purification optimization. In order
to conduct fluorescence experiments, the SH3 domain was replaced with a fluorescent
domain, namely the enhanced GFP.
Alternatively, myristoylation can be performed in-vitro, by mixing the NMT enzyme,
the MyrCoA cofactor and the protein substrate (Padovani et al., 2013) (Gaffarogullari
et al., 2011). The different components have to be separately produced before being
mixed. CoA can be chemically myristoylated (Gaffarogullari et al., 2011), and the pro-
tein and NMT can be expressed and purified separately. When the reaction has finished,
the mixture has to be purified from the NMT, the unreacted MyrCoA and the non myris-
toylated protein. This can be achieved by precipitating the protein in ammonium sulfate
(Padovani et al., 2013). We used a chromatographic method instead. We used in-vitro
myristoylation to produce the myristoylated Unique Domain of Src (USrc) since the co-
expresion method failed for this construct. The unfolded character of MyrUSrc allowed
for product separation of the products by reverse phase chromatography (since the pro-
tein forms a tight complex with NMT, ammonium precipitation might not work). If 15N
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labeling was needed, USrc was expressed in minimum medium.
Peptide synthesis constitutes another alternative and can be applied to short myris-
toylated peptides. Using standard solid phase methods, the myristic acid can be coupled
to the last anchored peptide, in a similar method to that described in Geyer et al. (1999).
We used this method to synthesize the peptide corresponding to the 17 first amino acids
of c-Src, Myristoylated SH4 (MyrSH4).
Degradation
Disordered regions are more easily degraded than folded domains. We experimentally
observed that the purified Unique Domain of Src, non-myristoylated, degraded faster
than the SH3 domain. Still, no substantial degradation was observed when conserving
the non-myristoylated forms of USH3 of USrc during several days or weeks. In contrast,
when expressing the myristoylated form, a well-defined cleavage site was observed. In the
second part of this chapter, we will study the degradation phenomena. First, we identified
the location at which the amino acids chain was principally cleaved, and demonstrated
that mutation at that site impeded degradation. We also looked at the factors that can
favor or be the source for degradation, in order to try to understand its mechanism. Then
we developed a method enabling to obtain degradation-free samples of myristoylated c-
Src constructs. Since degradation may have a functional role, we designed an assay to
identify a “marker" peptide as a diagnostic for degradation phenomena. The assay was
tested in vitro, with the aim of extending it to an in-cell assay and verify whether the
degradation may occur in human cells and has a functional role.
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3.2. Coexpression Strategy
3.2.1. Cloning and constructs
• USH3 The original PetDuet I plasmid, was a gift from Julien Glück, and contained
in the first cassette the sequence of yeast NMT, and in the second cassette that
of the Nef protein. The Nef sequence was replaced with that of USH3, terminated
with a C-terminal HisTag composed of six histidines.
• UGFP To obtain the UGFP construct, the sequence of USrc was first inserted in the
original plasmid instead of that of Nef. A second digestion and insertion was needed
to further insert the sequence of eGFP following that of USrc, with a small linker.
The HisTag was added at the GFP C-terminal during the insertion protocole.
3.2.2. Classical expression and purification
Purification of the supernatant (classical purification of soluble proteins) The
most straightforward and standard method to express and purify MyrUSH3 and MyrUGFP
has been firstly applied in rich medium, as described by Gluck et al. (2010). Induction was
allowed in presence of myristic acid, and purification of the supernatant was conducted
(this method will be called the supernatant purification). Final purification of the protein
implied the use of a C-terminal His-tag, retained in a nickel column and eluted with imida-
zole. By applying the elution product to a size exclusion chromatography (SEC) column,
several peaks were obtained (Figure 3.3-A); the fractions of each peak were pooled and
analyzed by SDS page and Liquid Chromatography/Mass Spectrometry (LC/MS), which
gave insight on the different species present in each peak. The SDS-page indicated that
the first peak contained two species, with sizes corresponded to a “USH3” form and NMT
respectively; the second peak only a“USH3” form; and the last peak a “USH3” form but
also a smaller product. LC/MS clarified which were the actual species:
• The two species of peak 1 were separated by LC (Figures 3.4-A), and one species was
found by MS analysis in each peak: a mass of 16628 Da corresponding to MyrUSH3,
and a mass of 48140 Da corresponding to NMT. Figures 3.4-B and -C. This indicates
that the protein, under solubilization during the sonication step, probably rebound
to the enzyme.
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• LC of peak 2 gave rise to a single elution peak (Figures 3.4-D), which actually con-
tained several species as revealed by the MS analysis. A first mass of 16432 Da was
found, which corresponds to USH3 with the first methionine processed (Figures 3.4-
B), but without further acylation. The second mass of 16600 Da corresponds to
myristoylated species missing 28 Da. (Figures 3.4-E). This mass is compatible with
that of MyrUSH3 having lost two carbons in the acyl chain: we may observe the
N-terminal incorporation of lauric acid. The corresponding species would be Lau-
rylated USH3 (LaurUSH3).
• LC of peak 3 gave rise to a single elution peak Figures 3.4-F), containing mainly
a molecule of 10542 Da Figures 3.4 G). The SDS-page of the fractions showed
the presence of “USH3” form, but no corresponding mass was detected by LC/MS
analysis.
Figure 3.5 shows a similar outcome when expressing and purifying the UGFP construct.
The SEC profile contained only two peaks (Figure 3.5-A). Indeed, the molecular weight of
GFP is much higher than that of SH3 and did not enable to achieve as much separation
as for the USH3 construct. The SDS-page (Figure 3.5-B) showed that peak 1 contained
two species, while peak two contained a “UGFP” form and a smaller product.
• The two species of peak 1, separated by LC (Figures 3.6-A), contained one specie
in each peak: MyrUGFP (37889 Da1 and NMT (48140 Da) – Figures 3.6-B and -C.
• MC/LS from peak 2 only enabled to detect a smaller product of 31517 Da Fig-
ures 3.5 C). The SDS-page of the fractions showed the presence of UGFP, but no
corresponding mass was detected by LC/MS analysis.
This result points out several difficulties arising from such a method: MyrUSH3 or
MyrUGFP remain intact upon solubilization if they are complexed with NMT, neverthe-
less they seem to undergo degradation in absence of “protection”. Degradation is treated
in a separate part of this chapter (Part 3.5). Obtaining a pure myristoylated sample
means that the protein must be further separated from NMT.
1The experimental mass of UGFP is 22 Da lower than its theoretical mass because of chromophore
maturation (See part 5.3)). The mass of non processed UGFP is 37828 Da, that of unprocessed MyrUGFP
is 39707 Da.
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As previously said, NMT can accept different cofactor substrates, especially cofactors
possessing shorter acyl chains. Since, MyrCoA is also used in the β-oxidation pathway
of the bacteria as one of the carbon sources to produce energy, degradation of MyrCoA
into Laurylated CoA (LaurCoA) can take place if this pathway is initiated. The pool
of LaurCoA created is ultimately used by NMT. Further evidences of the presence of
laurylated species through this process are found in the subsequent parts of this chapter.
It is interesting to note that NMT preferentially rebinds to MyrUSH3, which explains
why the laurylated species are separated in peak 2 of the SEC.
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Complex separation methods The first peak eluting in the SEC contains the myris-
toylated protein, together with NMT. The fractions were pooled and attempts have been
made to separate the NMT-protein complex. Here are listed some methods in which
partial success occurred.
Reverse phase chromatography Reverse phase chromatography successfully a-
chieved enzyme denaturation and complex separation. The data obtained from MC/LS
presented previously (Figure 3.4-A and Figure 3.6-A) shows the separation of the myris-
toylated proteins from the enzyme by HPLC. To further recover the protein sample, the
elution fractions of MyrUSH3 or MyrUGFP should be collected, and a subsequent refold-
ing step applied. It might be simple when applied to the SH3 domain, but would not work
in case of the GFP domain. Thus this method did not constitute a satisfactory solution.
Hydrophobic Interaction Chromatography (HIC) The complex was applied to
an hydrophobic matrix in presence of a high concentration of salt; hydrophobic molecules,
depending on the matrix, bind to the column and the non hydrophobic species are not
trapped. After trial of several hydrophobic matrices, a isopropyl matrix was chosen and
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protein was injected in a 1.5 M ammonium sulfate containing buffer. Resolubilization was
achieved with a gradient of salt free buffer. Figure 3.7-B shows the HIC profile obtained
when applying steps of decreasing salt concentration. Several elution peaks were obtained,
as illustrated in the SDS-page of Figure 3.7-A; the first peak contained NMT, the second
still contained the complex, and the last one contained the protein alone. The procedure
was also applied to MyrUSH3 with a gradient of decreasing salt. The fractions containing
mainly MyrUSH3 still contained some enzyme (first three columns of the SDS-page in
Figure 3.7-B). By adding triton as a detergent in the solubilization buffer, the throughput
and purity were improved, as demonstrated in the last two raws of the SDS-page of
Figure 3.7-B; no trace of NMT was found. After elution and collection of the fractions,
the ammonium sulfate, and the Triton if it is the case, had to be removed from the sample,
e.g. by dialysis. This separation protocol was only partially successful since some proteins
remained complexed; the yield of pure proteins was pretty low and the overall protein
purification was very time consuming.
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Competition with MyrCoA Another method already used by others (Morgan
et al., 2011) consisted in using MyrCoA as a competitor. The NMT/protein complex was
rebound to the nickel resin, and MyrCoA was applied; as a consequence, a substantial
amount of NMT was eluted as a pure product, as shown in the SDS-page of Figure 3.8-A,
line 2 to 4. After extensive washing with the MyrCoA solution, the protein was eluted
with imidazole, but still contained enzyme contamination (Same gel, Figure 3.8-A, line 5).
The same protocol was applied to MyrUSH3 and rendered similar species, pure NMT and
non pure MyrUSH3 (same gel, lines 6 and 8). To further purify the MyrUSH3 protein,
the product eluted with imidazole was injected in SEC and leaded to a small amount of
pure protein, accompanied with degradation, as shown in the SEC profile and SDS page
of the corresponding fractions shown in Figure 3.8-B and -C. This method is costful, time
consuming, with low sample yield.
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3.2.3. “Triton wash” purification
Extraction from Pellet To overcome the separation issue, another strategy was adopt-
ed. Advantage was taken of the binding of myristoylated proteins to membranes: the
bacterial pellet (obtained after lysis and centrifugation) was used for further protein ex-
traction. A substantial amount of acylated proteins remained in the lipid phase after lysis
and centrifugation. Thus, the supernatant was discarded and the pellet was resuspended
in buffer supplemented with 1 % Triton X100. After centrifugation of the resuspended
pellet, the supernatant was free of NMT – which had been eliminated in the discarded
supernatant – and contained acylated proteins. By repeating the triton wash cycle several
times, as much protein as possible was recovered. The proteins were subsequently bound
to the nickel resin and Triton X100 could be washed away by passing an extensive amount
of buffer. After washing and elution with imidazole, the product was further purified by
SEC. This method will be designated as “Triton wash” purification.
Figure 3.9-A, red curve, presents the SEC profile after such a protocol. Two main
peaks were obtained; LC/MS analysis reveal that they were pure (Figure 3.9-B and -D)
and that they corresponded to the two different acylated species, LaurUSH3 3.9-C and
MyrUSH3 3.9-E. With this method, MyrUSH3 and LaurUSH3 could be easily separated
by SEC; surprisingly, the laurylated species were eluted with an apparent size higher than
that of myristoylated species. NMT was successfully excluded with this method. However,
some degradation was still present and eluted in the same fractions as the myristoylated
proteins, as illustrated in the SDS page of the SEC fractions (Figure 3.9 B) and MS
analysis (Figure 3.9 E).
Though acylated species could be separated by size in the case of USH3, it may not
be the case for other acylated proteins, to which similar heterogeneous acylation may
occur. In addition, in the case of too high amounts of laurylated forms, the separation
was not successful anymore. Figure 3.9 A, green curve, shows a case in which separation
was not satisfactorily achieved. Three peaks were obtained, and the two acylated species
were mixed. More dramatically, when proteins are expressed in minimum media, this
protocol rendered almost only degraded or laurylated species. Since we suggest that
laurylation comes from MyrCoA degradation into LaurCoA, several relevant parameters
were explored in order to optimize the myristoylation yield.
CHAPTER 3. PROTEIN MYRISTOYLATION 62
10000 12000 14000 16000
0
20
40
60
80
10
0
Mass (Da)
R
el
at
iv
e 
A
bu
nd
an
ce
 (%
)
16450 16550 16650 16750
0
20
40
60
80
10
0
Mass (Da)
R
el
at
iv
e 
A
bu
nd
an
ce
 (%
)
16400 16600 16800
0
20
40
60
80
10
0
Mass (Da)
R
el
at
iv
e 
A
bu
nd
an
ce
 (%
)
USH3
De
gr
ad
at
io
n
La
ur
US
H3
   
 
M
yr
US
H3
,  
   
   
 
36 kDa
21 kDa
14 kDa
  6 kDa
0 50 100 150
0
10
20
30
40
50
Volume (mL)
U
V
28
0n
m
 A
bs
or
ba
nc
e MyrUSH3 20 h 20 ºC 
Myristic+Palmitic acid
MyrUSH3 20 h 20 ºC 
Myristic acid
1
2 3
1
2
0 10 20 30 40 50 60
0
20
40
60
80
10
0
Time (min)
R
el
at
iv
e 
A
bu
nd
an
ce
 (%
)
0 10 20 30 40 50 60
0
20
40
60
80
10
0
Time (min)
R
el
at
iv
e 
A
bu
nd
an
ce
 (%
)
1  2
Degradation
10254 Da
MyrUSH3
MyrUSH3
16628 Da
LauUSH3
16600 DaLauUSH3
MyrUSH3
A) C) D)
F)
E)
B)
Figure 3.9: A) SEC (Red and Green curves, low and high amount of laurylated species,
respectively) and B) SDS page of the corresponding fractions after the “Triton wash”
purification of MyrUSH3, red curve. C) LC and D) MS of peak 1 of the SEC, red curve.
E) LC and F) MS of peak 2 of the SEC.
Optimization of the conditions of MyrUSH3 expression in rich medium Dif-
ferent parameters were varied to verify their contribution to the type of acylated product
obtained, with the final aim of achieving samples containing proteins free of laurylation
products. The expression conditions were first optimized in rich medium. Three param-
eters were explored.
• The cell line; another protein, BASP, was not found to be laurylated when expressed
in rich medium, when using T7 cells instead of Rosetta cells. Thus T7 cells were
tested to MyrUSH3 expression.
• The addition of another acyl chain, palmitic acid. As discussed in the introduction,
NMT can use shorter acyl chains as substrates, but Palmitoyl Coenzyme A (Palm-
CoA) is not binding the enzyme; however, PalmCoA may be degraded to MyrCoA
in the β-oxidation cycle. The addition of palmitic acid is expected to increase the
pool of MyrCoA in the event the cell uses the β-oxydation pathway as mean of
energy supply.
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• The duration of the expression. This duration is highly variable according to the
expression protocol, usually optimized for the particular protein to be produced.
Some proteins can be expressed using a short time at high temperature (for instance
4 h at 30 ◦C), but many proteins need milder conditions (for instance overnight at
20 ◦C).
These parameters were varied during the expression of MyrUSH3. Expression was
done in comparable conditions in the two E. coli lines Rosetta and T7. Expression was
also always done in presence of myristic acid, to which palmitic acid was added or not.
The duration after induction was either 5 h at 28 ◦C or 20 h at 20 ◦C. After purification
and size exclusion chromatography, the relative amount of the two acylated species was
assessed. The results from all the conditions are gathered in table 3.1. The relative amount
of myristoylated and laurylated USH3 were determined by integrating the elution peak
from the size exclusion chromatography performed on the mixture obtain after the Triton
wash purification. The main trends are detailed and exemplified below.
• The cell line had a certain influence. Figure 3.10-A compares the SEC profiles
obtained in T7 or Rosetta cells with otherwise similar conditions. The laurylation
peak was reduced in T7 cells. In general, laurylation was a bit reduced in T7 cells.
Rosetta cells are optimized for rare codons, and the expression of NMT and USH3
may be faster, leading to a faster exhaustion of the energy sources and initiation of
β oxidation pathway.
• Addition of palmitic acid in the medium significantly improved the myristoylation
yield. Figure 3.10-B compares the SEC profile obtained when palmitic was supple-
mented to the medium or not during expression. The laurylation was significantly
reduced when palmitic acid was use. This results strengthen the hypothesis of
LaurCoA coming from MyrCoA degradation in the β-oxydation pathway.
• Expression duration was crucial. Figure 3.10-C compares the outcome from a short
(5 h) versus long (20 h) expression. The amount of laurylated species dramatically
increased in the long expression time experiment. Long expression time also mean
exhaustion of the carbon sources contained in the medium; this result also reinforces
the hypothesis under which degradation of MyrCoA in the β-oxydation pathway
generates LaurCoA species. Short expression is a key factor to prevent laurylation.
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Table 3.1: Expression factors and their effects on the relative amounts of myristoylated
and lauroylated USH3 obtained after Triton wash purification.
Cell Type Additive Time LaurUSH3 MyrUSH3
Rosetta Myristic acid 5 h 28 ◦C 20 % 80 %
T7 Myristic acid 5 h 28 ◦C 20 % 80 %
Rosetta Myristic + Palmitic acid 5 h 28 ◦C 5 % 95 %
T7 Myristic + Palmitic acid 5 h 28 ◦C 2 % 98 %
Rosetta Myristic acid 20 h 20 ◦C 80 % 20 %
T7 Myristic acid 20 h 20 ◦C 65 % 35 %
Rosetta Myristic + Palmitic acid 20 h 20 ◦C 18 % 72 %
T7 Myristic + Palmitic acid 20 h 20 ◦C 3 % 97 %
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Altogether, using a short expression (5 h at 28 ◦C) and supplementing the medium
with myristic and palmitic acid enabled to obtain high myristoylation yields. Figure 3.11
and 3.12 show SEC profiles (A), SDS-pages (B) of the fractions in the peak, and LC/MS
analysis (C and D) of the pooled fractions, corresponding to the expression and purifi-
cation of USH3 or UGFP in these conditions. A mass of 16628 Da was obtained for
MyrUSH3 and 37888 Da for MyrUGFP. In both cases, some degraded molecules were
also present.
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Figure 3.11: A) SEC profile (red curve) after the “Triton wash” purification of MyrUSH3
expressed in optimal conditions, and B) SDS page of the corresponding fractions. C) LC
and D) MS of the SEC, pooled fractions from the unique peak of the red curve.
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Figure 3.12: SEC profile (red curve) after the “Triton wash” purification of MyrUGFP
expressed in optimal conditions, and B) SDS page of the corresponding fractions. C) LC
and D) MS of the SEC, pooled fractions from the unique peak of the red curve
Optimization of the conditions in minimum medium Applying the “optimum
conditions” to protein expression in minimum medium failed to render MyrUSH3, most
probably because of the insufficiency of the energy sources in such a growth medium. To
compensate for the very limited carbon sources, the Marley method (Marley et al., 2001)
was used, which consisted in generating cell mass in rich medium that was subsequently
transferred to a labeled minimum medium, just before induction. The quantity of glucose
was also increased.
Figure 3.13 A and B show the SEC profile and SDS-page of the purified MyrUSH3 frac-
tions after expression in minimum medium using the Marley method and the previously
optimized conditions.
15N labeling implies that the mass of the protein is larger; since basal expression in rich
medium during cell growth may occur, a small part of the proteins may be unlabeled. The
theoretical mass of fully labeled MyrUSH3 is 16842 Da, and LC/MS analysis rendered
amass of 16835 Da, 7 Da smaller (Figure 3.13-C). This indicated that probably about
95 % of the population was 15N labeled. In consequence, despite of the basal expression,
this method generated a sufficient amount of 15N labeled myristoylated proteins.
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Figure 3.13: MyrUSH3 minimum medium
In fact, it would also be valuable to apply this method in rich medium, especially in
case of need for long expression times.
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3.3. Importance of using the correct acyl chain length
As introduced in the beginning of this chapter, despite of the very small difference
between myristoyl and lauryl (14 carbons and 12 carbons respectively), working with the
incorrect acyl chain may affect the binding behavior of the species under study. Thus,
binding of myristoylated versus laurylated proteins to vesicles or liposomes was explored in
a Lipid Sedimentation Assay (LSA), or in Surface Plasmon Resonance (SPR) experiments.
Even in a very simple assay such as a LSA, a strong difference in the binding to vesicles
of the two acylated species was striking. The SDS page of Figure 3.14 compares binding of
MyrUSH3 and LaurUSH3 to DMPC:DMPG 2:1 vesicles. All MyrUSH3 proteins were in
the pellet fractions, while part of them remained in the supernatant in case of LaurUSH3.
In the MyrUSh3 lines, degradation was present and remained in the supernatant, since
it is not myristoylated – degradation is not present in LaurUSH3 since it eluted with an
apparent size close to that of MyrUSH3.
LaurUSH3
36 kDa
21 kDa
14 kDa
  6 kDa
MyrUSH3
Super   Pellet   Super   Pellet
natant               natant
USH3
Figure 3.14: SDS page after a LSA of MyrUSH3 or LaurUSH3 binding to DMPC:DMPG
2:1 MLVs.
In the SPR assay, binding to liposomes of two laurylated and myristoylated forms
of two different proteins (USH3 and BASP) was compared. In Figure 3.15-A, binding
to DMPC:DMPG 2:1 liposomes of LaurUSH3 and MyrUSH3 is compared; LaurUSH3
showed significantly reduced binding when compared with MyrUSH3; a 20 μM injection
of LaurUSH3 gave a binding response comparable with that of a 1 μMMyrUSH3 injection,
and had a four times reduced level compared with a 20 μMMyrUSH3 injection. Laurylated
BASP (LaurBASP) also showed a reduced binding compared with Myristoylated BASP
(MyrBASP) (Figure 3.15-B), but in a more subtle manner than for USH3. MyrBASP
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also attaches to membranes via a dual myristoylation and PCD signal, but formation of
an alpha helix upon membrane binding probably balances the effect of the acyl chain,
which role might be mainly membrane targeting.
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Figure 3.15: SPR assay monitoring A) the binding of MyrUSH3 and LaurUSH3 to immo-
bilized liposomes of DMPC:DMPG 2:1, monitored by SPR. B) the binding of MyrBASP
and LaurBASP to immobilized liposomes of DMPC:PS 3:1 (plain lines) or DMPS:PS 3:1
supplemented with 2 %PI(4,5)P2 (dashed lines).
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3.4. In-vitro myristoylation
Another method leading to pure myristoylated samples is to perform the enzymatic
reaction“in-vitro” by mixing the three species previously purified. This procedure was
used for the production of MyrUSrc, for which the coexpression method had failed.
The components were obtained separately:
USrc The recombinant USrc protein was obtained by standard methods. Proteins were
expressed in E. coli and purified with a streptactin resin recognizing a streptag added at
the C-terminal of USrc. Figure 3.16-A shows the SDS-page from the fractions of USrc
peak eluted after final purification by SEC.
NMT NMT was recovered from the MyrCoA competition assay, as explained in the
competition assay of Part 3.2.2. The enzyme itself could be obtained as a tag-free, pure
sample, confirmed by the SDS page, but also by MS analysis. Figure 3.16-B shows the
SDS-page corresponding to a pure NMT sample.
MyrCoA CoA was chemically coupled to myristoyl as described in Gaffarogullari et al.
(2011). Myristic acid was first activated by carboxydiimidazole, and subsequently cou-
pled to CoA in a NaCO3 buffer. Figure 3.16-C shows the mass analysis by MALDI of
the MyrCoA product. A mass of 977 Da, corresponding to MyrCoA, was dominantly
measured.
The myristoylation reaction consists in mixing the three components, USrc, MyrCoA
and NMT, as illustrated in Figure 3.17-A. NMT was first incubated with an excess Myr-
CoA. Then an excess protein (relative with NMT, but not with MyrCoA), was added and
the reactants were incubated 2 h at 37 ◦C and subsequently overnight at 4 ◦C. A simple
assay to verify if the reaction had been achieved consisted in a LSA. USrc or MyrUSrc were
incubated with DMPC:DMPG 2:1 MLVs. After incubation and ultracentrifugation, the
supernatant and the pellet were separated and loaded in an acrylamide gel. Figure 3.17-B
shows a SDS page of a LSA performed before and after the in-vitro myristoylation of USrc.
In case of USrc, all proteins remained in the supernatant (lines 1 and 2), while in case
the myristoylation reaction product, a higher amount of USrc was in the pellet compared
with the supernatant (line 3 and 4) . The proteins present in the pellet correspond to
the myristoylated species, the ones in the supernatant to non-reacted USrc species. NMT
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Figure 3.16: A) SDS page of the fractions eluted in the SEC after final purification B)
SDS page of the NMT sample obtained in the MyrCoA competition assay described earlier.
C) MS analysis by Maldi of MyrCoA.
was also found in the supernatant. This simple assay indicated that the myristoylation
reaction was successful, with some unreacted species. Further LC/MS analysis confirmed
these results. Figure 3.18-A and -B show the LC and MS results of USrc before the re-
action, confirming a mass of 9481 Da. Figure 3.18-C shows the LC of the sample after
the reaction MS analysis: three species were separated, USrc, MyrUSrc and NMT. The
correct mass of MyrUSrc was confirmed by the MS analysis, 9691 Da (Figure 3.18-D).
To separately collect the three species from the reaction product, a C18-LC column was
used with a 0-80 % H20-acetonitrile. Figure 3.17-C shows that the three species, USrc,
MyrUSrc and NMT were separated in the liquid chromatography. MyrUSrc was collected
and lyophilized, and subsequently resuspended in the correct buffer.
The methodology was also applied to USH3, and produced a partially myristoylated
USH3 sample. Figure 3.19-A shows the LC of the reacted products: The first peak
corresponded to USH3 (See MS from Figure 3.19-B) while the second corresponded to
MyrUSH3 (See MS from Figure 3.19-C). NMT was detected in the last peak. The reaction
was partial, and implied further lyophilization and refolding of the MyrUSH3 product.
This method was not used because of the much more straightforward use of coexpression
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Figure 3.17: A) Scheme of the in-vitro myristoylation reaction B) SDS page after a LSA
of the reacted myristoylation product eith DMPC:DMPG 2:1 MLVs. C) Separation of the
different species in the myristoylation prodcut, using a C18-LC column.
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methods in optimized conditions.
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Figure 3.19: A) LC of the reacted products in USH3 myrisotylation B) MS of peak 1
separated by LC C) MS of peak 2 separated by LC.
CHAPTER 3. PROTEIN MYRISTOYLATION 74
3.5. Degradation
Degradation: where?
Upon expression of MyrUSH3 or MyrUGFP, a fraction of a degraded product was
found. This degradation product was not a generalized protein degradation, but consisted
in a well-defined species, as indicated by SDS-page gels of the fractions (Figure 3.3-B or
3.5-B). Since we collected the elution products after a nickel column step, we only obtained
a product containing the C-terminal His-Tag. Further characterization of the degradation-
containing sample was achieved by performing on one hand a LSA, and on the other hand
a western blot with an antiSH4 antibody secondary detection. The LSA clearly showed
that the degraded form was not binding to vesicles (Figure 3.20-A), therefore did not
contain the myristoyl part. The Western Blot confirmed that the degradation was not
detected by the antiSH4 antibody, thus degradation lacked the N-terminal part of the
protein (Figure 3.20-B). In consequence, the purified degradation that contaminates our
samples is thus a non-myristoylated C-terminal fragment of USH3.
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Figure 3.20: A) SDS page before (line 1) and after (line 2 and 3) a LSA of MyrUSH3
binding to DMPC:DMPG 2:1 MLVs B) Western Blot of MyrUSH3 fractions, containing
degradation, with antiSH4 antibody detection C) Schematic representation of the cleavage
site leading to the degraded MyrUSH3 product.
MS analysis of the degraded sample from MyrUSH3 purification gave a set of masses
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that could be related to possible shorter USH3 peptides (Figure 3.4-G). The most abun-
dant mass of 10257 Da exactly corresponded to a peptide starting after lysine 63 until
the HisTag, as illustrated in Figure 3.20-C. Therefore, an exact cleavage site exists, and
it is probably significant to find that corresponds to the ULBR region. Some additional
masses were found in the MS analysis, corresponding to other cleavage points around the
main one. The cleavage process observed occurs at a specific amino acid site, but is also
found in a a minor way in surrounding amino acids.
To further verify the specific amino acid sequence requirement for degradation to occur,
a mutant in the ULBR region was expressed. A so-called “A3” mutant (MyrUSH3A3), in
which the 64LFG66 amino acids were replaced with 64AAA66, was already available as one
of the tool used to study the effect of the absence of ULBR in diverse experiments. The
mutation replaces the amino acids involved in the cleavage site by alanines. We expressed
it in its myristoylated form. Figure 3.21-A compares the SEC profiles of MyrUSH3 and
MyrUSH3A3 after purification by the supernatant method (as in Part 3.2.2). The third
peak was inexistent in the case of the mutant. The corresponding SDS page of the
eluted fractions did not show significant degradation (Figure 3.21-B). This experiment
confirms that the degradation takes place at a specific amino acid site and is prevented
by modifying the amino acid sequence. Working with this mutant is actually a method
to obtain degradation free samples. This mutation also prevented degradation in the
MyrUGFP construct, as illustrated in Figure 3.21-C and -D.
When applying the triton wash purification procedure to MyrUSH3 or MyrUGFP (af-
ter expression in optimized conditions), a single peak was eluted in the SEC (Figure 3.22-A
and 3.23-A). The corresponding SDS page (Figures 3.22-B and 3.23-B) confirmed that
these fractions were degradation-free. LC-MS analysis of MyrUSH3A3 confirmed the pu-
rity and integrity of the product; a single LC peak was obtained (Figures 3.22-C) rendering
a single mass of 16624 Da (Figure 3.23-D).
Mutants screening for neighbouring effects
Degradation might come from proteolysis; nevertheless, protease inhibitors were used
during purification, and spontaneous degradation of MyrUSH3 was observed in some in-
stances. Thus a set of mutants in the region adjacent to the ULBR was developed, in
an attempt to search for other amino acids that could be responsible for the chemical
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Figure 3.21: SEC and MS after the supernatant purification A) and B) of MyrUSH3A3,
C) and D) of MyrUGFPA3
proteolysis. We focused on the stretch of polar residues following the ULBR under the
hypothesis that proximity of the reactive side chain of aspartic, arginine or serine may
promote cleavage. Table 3.2 lists the different mutants used: spanning of the different
amino acids next o the ULBR was ensured in this set of mutants. All mutant forms were
expressed and purified by the supernatant purification method. None of them showed
reduced degradation: both the SEC profile and the SDS page of the corresponding frac-
tions resembled the outcome of that of the wild type (WT). This assay discards the direct
chemical role of this region in the degradation phenomena.
Table 3.2: Mutants around the ULBR of USrc
Mutant Amino acid sequence
USH3 WT L F G G F N S S D
USH3 N68A L F G G F A S S D
USH3 D71A L F G G F N S S A
USH3 N68A D71A L F G G F A S S A
USH3 S69A S70A L F G G F N A A D
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Figure 3.22: A) SEC and B) SDS page of MyrUSH3A3 by the triton wash purification.
C) LC and D) MS analysis of the purified MyrUSH3A3 fractions.
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Purification of degradation free samples
MyrUSH3 and the degradation products coeluted in the SEC under the standard
purification protocol used. Thus, strategies to separate these degradation products from
the MyrUSH3 sample have been explored.
pH change
The observation that the SH4 and SH3 domains are interacting in non myristoylated
USH3 (Maffei et al., 2015) suggested a possible method to separate MyrUSH3 (where this
interaction may still be present) from the degradation products, lacking the SH4 domain.
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Figure 3.24: A) Schematic representation of MyrUSH3 supposed “conformation” at pH 6
or pH 7 B) SEC and C) SDS page of MyrUSH3 injected at pH 6
In our construct, the C-terminal contained 6 histidines, that are neutral at pH 7.5.
By reducing the pH to 6 or lower, the histidine gets protonated. According to Maffei
et al. (2015), USH3 is in a “closed” conformation in which the SH3 interacts with the
SH4 domain. If the histidine residues get positively charged, they are expected to create
electrostatic repulsion with the positively charged SH4 domain which is in turn expected
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to favor a more open conformation of MyrUSH3. Figure 3.24-A illustrates the possible
conformational change. At low pH, the different apparent sizes between the degraded
form and MyrUSH3 may allow separation of the two species by SEC.
A MyrUSH3 sample purified by the triton wash method, which always contained a
fraction of degraded forms, was injected in a SEC at a buffer adjusted to pH 6. Two peaks
were obtained, instead of a single peak at pH 7. The first peak contained the proteins with
a higher apparent size (MyrUSH3 in this case) and the second the protein with a lower
apparent size (the degraded form). Figure 3.24 B displays the SEC profile and Figure 3.24
C the corresponding SDSpage of the fractions. This experiment shows that the method
is valid, but that perfect separation is not achieved. Optimization of this protocole did
not give significant improvement. A lower pH lead to protein destabilization, and lower
flow rates did not significantly improve separation. This procedure was not used because
of its too low throughput, but gave insights on MyrUSH3 intramolecular interactions.
Imidazole gradient A more effective method was based on a peculiarity occurring
during protein elution from the nickel resin when applying the imidazole solution. Imida-
zole elution is usually very efficient and almost all resin-bound protein species are washed
when a reasonable volume of imidazole is passed. It was the not the case for MyrUSH3 or
MyrUGFP: large volumes of imidazole solution were needed to elute enough protein, and
a lot of protein remained attached to the resin. Increasing the imidazole concentration
did elute more proteins but not in a complete manner. This feature might come from
the local formation of high affinity clusters of proteins bound to the resin. The benefit
of this peculiar behavior was that the non-myristoylated degraded forms of the protein
were eluted at low imidazole concentration using a small volume of imidazole solution,
therefore could be eliminated. A subsequent increase in the imidazole gradient and resin
elution with more buffer enabled to elute degradation free proteins. To collect separately
the fractions, a Histrap column was used with an imidazole gradient. The fractions could
be collected separately and the protein absorption monitored. In optimized condition,
imidazole steps where used instead of a gradient of imidazole. At 200 mM imidazole, all
degradation was eluted. At higher imidazole concentrations, the myristoylated protein
alone was eluted and collected separately. Figure 3.25-A shows the imidazole steps used,
and the elution profile of the protein. Figure 3.25-A shows the corresponding SDS page
of the fractions of a MyrUSH3 purification by triton wash. In the first line corresponding
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to 200 mM elution, MyrUSH3 was accompanied by a high amount of degradation. Nev-
ertheless, all subsequent fractions, at 400 mM imidazole or more, were degradation free.
These fractions were collected; separation of MyrUSH3 from its degradation was achieved
by this method.
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Figure 3.25: A) Histrap chromatography column, used with imidazole steps from 200mM
to 1 M, used to elute MyrUSH3 extracted with triton. B) SDS page of the eluted fractions.
C) SEC of the MyrUSH3 degradation free sample D) SDS pages of MyrUSH3 fractions
from the SEC (first gel) and after lyophilization/dyalisis cycles (second gel).
Avoiding concentrators After obtaining a degradation free sample, mainly using the
previous method (part 3.5), the obtained volume needed to be concentrated. Use of
concentrators is the standard method, but in our case seemed to be able to induce degra-
dation. Indeed, degradation might be a concentration-dependent phenomenon – no direct
evidence has been found. The creation of high local protein concentrations may explain
why concentrators induce degradation. To avoid the use of concentrators, samples were
lyophilized and redissolved in a minimum volume of water given by the solubility of the
salts present in the lyophilized product. Imidazole salts were removed by SEC, giving
very pure, degradation free fractions (Figure 3.25-C shows the single peak obtained in
the SEC and Figure 3.25-D, first gel, the pure MyrUSH3 fractions). If required, further
concentration was achieved by lyophilizing the fractions, resuspending them in water, and
subsequently removing the excess salt by dyalisis. Additional lyophilization/dialysis steps
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were performed until the sample was concentrated enough. This method successfully ren-
dered degradation free proteins at sufficient yield. The second SDS page of Figure 3.25-D
shows the MyrUSH3 concentrated sample after several lyophilization/dyalisis steps.
Degradation features
Until now, degradation of the myristoylated protein has not been successfully under-
stood and controlled but some interesting features have been observed.
NMT protects the myristoylated protein from degradation As seen in the su-
pernatant purification results, the formation of a complex between NMT and the myris-
toylated protein happened during proteins resolubilization in the cell lysis step. Thus,
preventing NMT to rebind the protein was attempted by adding MyrCoA directly during
the lysis, to compete with protein rebinding. After purification of the obtained super-
natant, the elution products were separated by SEC, as shown in Figure 3.26-A. Two
peaks were obtained, and this time, the peak corresponding to enzyme elution had disap-
peared. However, the large peak corresponding to the myristoylated product contained
in fact a huge amount of degradation, as revealed by the SDS page of the SEC fractions
(Figure 3.26-B). This method highlights the protective effect of NMT during lysis, in
which the myristoylated species complexed with NMT are not subject to degradation.
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The RT loop in SH3 has a protecting effect A mutant of MyrUSH3 (called
MyrUSH3IHH) was designed, in which the 98RTE100 amino acids of the SH3 domain
were replaced by a 98IHH100 sequence (it is a naturally occurring sequence in the SH3
domain of Hck – previous structural studies had shown that the absence of the RT loop
in Hck renders the RT-loop much more flexible (Arold et al., 1998)). The expression and
purification of this mutant, by the triton wash method, rendered a much higher amount
of degradation in the final product. Figure 3.27-A displays the separation of the degrada-
tion from MyrUSH3IHH at low pH by SEC (as explained in Part 3.5). A large amount of
degradation was obtained, as confirmed by the SDS page of the fractions (Figure 3.27-B).
We can see that a change in the RT loop affects the way degradation occurs in the ULBR
region.
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Is degradation functional?
It is striking that degradation only occurs in the myristoylated form, and is very
specific:MyrUSH3 is cleaved between amino acids of the ULBR, demonstrated to be a
functional region of c-Src.
We developed an assay with the aim of verifying whether the observed degradation
occurred as an artifact from the E. coli expression, or is also observed in human cells, on
the entire Src protein. If it is the case, we could suggest that this degradation is functional
within the c-Src regulation mechanisms.
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The assay consisted in defining a diagnostic peptide which would be obtained from
an enzymatic digestion. The digested peptide includes the cleavage point and would be
different in the degraded form and the intact protein. Digestion of the degradation alone,
or in the intact protein, or in a mixture of both, was performed with the enzyme GluC.
The digestion product was analyzed by MS and all the peptides coming from the digested
product that were detected were listed.
Table 3.3: Digestion Results
MyrUSH3 Degradation Mixture Amino Acid Sequence
NO YES YES F G G F N S S D T V T
NO YES YES F G G F N S S D T V T S P Q R
NO YES YES F G G F N S S D T V T S P Q R A
NO YES YES F G G F N S S D T V T S P Q R A G P L
NO YES YES F G G F N S S D T V T S P Q R A G P L A
NO YES YES F G G F N S S D T V T S P Q R A G P L A G
YES YES YES P K L F G G F N S S D
YES YES YES P K L F G G F N S S D T V T
YES YES YES P K L F G G F N S S D T V T S P Q
YES YES YES P K L F G G F N S S D T V T S P Q R A G P L A
Several peptides were obtained that satisfactorily behaved as expected: they were
detected differently in case of a degraded protein or MyrUSH3. Four short peptides
which contain the sequence PKLFGGFNSSD were detected both in the MyrUSH3 and
in the Mixture (MyrUSH3 + Degradation). Six short peptides which contain the se-
quence FGGFNSSD were detected among the Degradation and Mixture samples. Ta-
ble 3.3 shows the list of peptides found. Four diagnostic peptides were thus selected,
namely PKLFGGFNSSDTVT and PKLFGGFNSSDTVTSPQ for MyrUSH3 and
FGGFNSSDTVT and FGGFNSSDTVTSPQR for the degraded form.
This protocol is aimed at being applied in the context of human cell lines. By using
the selected diagnostic peptides, a protocol in the MS detection can be used to enhance
the sensitivity of the assay: only the four diagnostic peptides will be searched for during
the MS analysis. Thus a high sensitivity method is now available to apply to in-vivo
systems, in which human cell lines can be transfected by c-Src and analyzed by MS after
cell lysis.
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3.6. Conclusion and Discussion
A library of different constructs of N-terminal myristoylated c-Src proteins has been
created. It mainly consists in MyrSH4, MyrUSrc, MyrUSH3 but also in a variety of
mutants or chimeric constructs, such as the MyrUGFP or the A3 mutants variants. The
constructs are listed in Table 3.4, together with the method used to produce them, among
the different methods described in this chapter. The list of the constructs with their exact
amino acid sequence is available in appendix 9.1.
Table 3.4: Library of c-Src constructs
Protein Method Remark
MyrSH4 Peptide Synthesis
MyrUSrc WT In-Vitro
MyrUSrc A3 In-Vitro Mutant in the ULBR region
MyrUSH3 WT Coexpression
USH3 A2G Standard Non myristoylated
MyrUSH3 A3 Coexpression Mutant in the ULBR region
MyrUSH3 IHH Coexpression Mutant in the RT loop
MyrUGFP Standard
UGFP A2G Coexpression Non myristoylated
MyrUGFP A3 Coexpression Mutant in the ULBR region
Peptide synthesis is straightforward but limited to small peptides. In-vitro methods
permit myristoylation of disordered proteins, but are not very appropriate for folded do-
mains. In addition, they are quite costful and time consuming. Coexpression methods
are much more interesting in terms of yield, and easiness of the process, but one must
be careful with the purity of the final product. In general, laurylation is the most fre-
quent problem that can arise from bacterial expression in E. coli. In our specific system,
coelution with NMT and degradation also occurred. All our experimental data supports
the fact that the source of laurylation is the degradation of MyrCoA to LaurCoA in the
β-oxidation cycle. Interestingly, if the medium is not supplied with myristic acid, Lau-
rUSH3 is found to coelute with NMT, and a C:10 acylated protein is also obtained. Thus
specificity of NMT is higher for MyrCoA than for LaurCoA, and for LaurCoA to C:10-
CoA. This ensures that NMT will not put a third acyl chain type until the other two
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are totally exhausted. The situation could be different in other organisms. E. coli does
not significantly produces shorter than C:10 acylated cofactor in the β-oxydation, but
Salmonella does (Iram and Cronan, 2006); if E. coli would use the Salmonella system, a
wider mixture of acylated proteins might have been obtained. The palmitic acid addition
to enhance the MyrCoA pool is also very efficient in E. coli (Iram and Cronan, 2006),
but might not have the same effect in other organisms. A universal feature to prevent
laurylation consists in ensuring that the amount of energy sources is always large enough
so that β-oxydation is not initiated. Exchanging the growth medium to a fresh one and
use short times of expression limit the exhaustion of the energy sources.
The elution profile in a SEC of MyrUSH3 versus the laurylated or non acylated forms
point out that the presence of the myristoyl chain affects the structure of USH3. In the
USH3 protein, interactions between the Unique Domain and the SH3 domain suggest
that the disordered Unique Domain is sampling a restricted conformational space. The
apparent size of MyrUSH3 in the SEC corresponds to a USH3 lacking a large part of the
Unique Domain, thus a constructs resembling the SH3 domain alone. Therefore, the SEC
profiles obtained in our experiments seem to reflect an even more restricted configuration
of USH3 in presence of myristoyl. The laurylated chain is not sufficient to provide this
additional restriction. These results suggest that the myristoyl chain is also participating
in intramolecular interactions probably stabilizing the protein conformation. This was
later confirmed in our NMR study (See chapter 6). The fact that by playing on elec-
trostatic repulsions between the C-terminal HisTag and the SH4 domain, the MyrUSH3
complex can be "opened" also supports this model. In our specific case, this features
enables to separate myristoylated species from laurylated species or degraded forms by
SEC. Working with the correct acyl chain seems to be of great importance in case of c-
Src, as it was already suggested in other assays presented in the introduction (Heuckeroth
and Gordon, 1989). It may not be so crucial for some proteins, and actually reflects the
different roles of myristoyl in protein binding. For example, the effect was less striking
in BASP than in Src in our SPR experiments. Myristoyl seems to play a crucial role
in providing a hydrophobic anchoring of c-Src to the membrane. In the case of BASP,
it might only be required to concentrate the protein near the membrane, which triggers
alpha helix formation enhancing membrane binding. Laurylation might act almost as
good as myristoylation for this purpose too. In fact, studying the effect of the acyl chain
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length on protein binding behavior constitutes a biophysical tool to better understand
the role of myristoylation in each protein, since as we have seen, it is versatile, even more
when the subsequent N-terminal domain is disordered.
The degradation that occurs only in the case of myristoylated form of USH3 constitutes
a complication in the purification process. It is still not clear for us what mechanisms
triggers it, but we developed some methods in which degradation can be excluded from
the sample. We have characterized precisely the cleavage site and used a mutant in which
no degradation occurred. Unfortunately, the mutant was designed to eliminate other
interactions that involve the ULBR, so the study of wild type USH3 without degradation
was challenging, although it could be achieved by the Histrap chromatography method.
The fact that degradation occurs in a functional region of the Unique Domain is peculiar,
thus efforts have been made to develop a method to test whether degradation also occurs
in the full c-Src form in human cells. A MS related assay implying protein digestion and
peptide detection was established and a diagnostic peptides has been identified. This assay
is ready to apply to transfected human cells transfected with c-Src. This myristoylation-
dependent degradation may have a functional role, and a similar phenomena has also been
observed in MARCKS protein (Brauna et al., 2000). A study comparing myristoylated and
non-myristoylated forms of c-Src found that the non-myristoylated form exhibited reduced
kinase activity but had enhanced stability compared to myristoylated c-Src (Patwardhan
and Resh, 2010). This would be compatible with our finding that the Unique Domain of
Src has a favored cleavage site at the ULBR region in its amino acid sequence.
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3.7. Experimental Methods
Cloning of USH3 and UGFP The original pETDuet-1Δ—6His—hNMT-Nef was a
gift from J. Glück.
It originally contained the NMT sequence in one cassette, to which the HisTag had
been removed, and the Nef sequence in the second cassette. The amino acid sequence
of USH3 was PCR amplified from an original pETM30 vector. The C-terminal primer
coded for a 6His sequence. The pEtDuet-1Δ-6His—hNMT—Nef was digested by NdEI
and XhoI enzymes and the USH3 amplified product was ligated overnight in place of the
Nef sequence in the PetDuet1 plasmid, using the T4 ligase enzyme. The pETDuet-1Δ-
6His—hNMT—USH3—6His plasmid was obtained. The amino acid sequence of USrc was
PCR amplified from an original pET-14b vector. The petDuet-1Δ-6His—hNMT—Nef was
digested by NdEI and XhoI enzymes and the USrc amplified product was ligated overnight
in place of the Nef sequence in the PetDuet1 plasmid, using the T4 ligase enzyme. The
pETDuet-1Δ-6His—hNMT—USrc plasmid was obtained. Subsequently, the amino acid
sequence of eGFP was PCR amplified from its original vector The C-terminal primer
coded for a 6His sequence. The pETDuet-1Δ-6His—hNMT—USrc was digested by NdEI
and PacI enzymes and the eGFP amplified product was ligated overnight just afterwards
the sequence of USrc, using the T4 ligase enzyme. The pETDuet-1Δ-6His—hNMT—
UGFP-6His was obtained. After production of the plasmids, they were transformed into
E. coli X-Gold (BL21) cells (Novagen) and plated over an agarose plate containing ampi-
cillin resistance (plasmids are designed with this ampicillin resistance). Cells were grown
overnight and the next day, the DNA was extracted and purified. Minipreps were pre-
pared with the Qiagen miniprep kit. The purified plasmids were sent for sequencing to
Macrogene, and the preparations containing the correctly modified sequences were se-
lected.
Site directed mutagenesis to obtain AAA, mutants adjacent to ULBR, and
RT mutants Mainly site directed mutagenesis were performed in order to obtain a
library of mutants. The original USrc and USH3 vectors contained an alanine in position
2, which was replaced by a glycine to permit myristoylation. In the different constructs,
the A3 mutant was obtained by substituting the KLF by AAA amino acids by site di-
rected mutagenesis. The RT mutant of the USH3 construct was also obtained by site
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directed mutagenesis. Finally, the mutants in the region adjacent to the ULBR were also
obtained by this method. The primers corresponding to the amino acids to exchange were
designed and ordered to Sigma. Site directed mutagenesis were performed using the Quik
site mutagenesis kit from Strategene. After PCR amplification of the original plasmid
with the correct primers, digestion with NdE1 was performed to remove the methylated
original plasmid. The digested product was subsequently transformed in E. coli X-Gold
BL21 cells (Novagen) and plated over an agarose plate containing ampicillin. Cells were
grown overnight and the next day, the DNA was extracted and purified. Minipreps were
prepared with the Qiagen miniprep kit. The purified plasmids were sent for sequenc-
ing to Macrogene, and the preparations containing the correctly modified sequences were
selected.
USrc expression and purification pET-14b plasmids carrying the sequence of USrc
(followed by a StrepTag for purification purposes) were transformed in E. coli RosettaTM
(DE3)pLysS cells (Novagen). Cells were plated on an agarose plate containing ampicillin
and cloramphilicol. Colonies were grown at 37 ◦C in Luria Broth (LB) medium until
reaching an OD600 of 0.6-0.8. For 15N isotopic labeling, cells were grown in M9 minimal
medium supplemented with 15NH4Cl (Cambridge Isotope Laboratories, UK). Induction
was performed by adding 1 mM of IPTG and expression was allowed at 25 ◦C overnight.
Cells were harvested by centrifugation and resuspended in the USrc Lysis buffer 100 mM
Tris-HCl, 150 mM NaCl, 1 mM EDTA, 0,1 % NaN3, pH 7.5 to which protease inhibitors
were added (Protein Inhibitor Cocktail2, and 1 mM PMSF, both from Sigma), and 1mM
PMSF, both from Sigma). This lysis product was sonicated on ice, treated with DNAse
(Roche) for 20 min and centrifugated at 25000 rpm for 45 min. The supernatant was
subsequently incubated with the Streptag Resin (IBA) and USrc protein was allowed to
bind the resin overnight. The resin was subsequently washed with the USrc lysis pH buffer
adjusted at pH 8. Elution was achieved with the USrc Lysis buffer pH 8 containing 2,5 mM
Desthibiotin. The elution product was further purified by Size Exclusion Chromatography
(SEC) on a Superdex 75 26/60 (GE Healthcare, Spain) in 50 mM sodium phosphate,
0.2 mM EDTA, 0,01 % NaN3, pH 7.
2Protein cocktail inhibitor: 23 mM AEBSF, 1 mM EDTA, 20 μM Bestatin, 3μM Pepstatin A, 3 μM
E64 (final concentrations in lysis buffer)
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USH3 expression and purification PetDuet1 plasmids carrying the sequence of
USH3 with an alanine at position 2 was used to expressed non myristoylated USH3. They
were transformed in E. coli RosettaTM (DE3)pLysS cells (Novagen). Cells were plated
over an agarose plate containing ampicillin and cloramphilicol. Colonies were grown at
37 ◦C in Luria Broth (LB) medium until reaching an OD600 of 0.6-0.8. Induction was
performed by adding 1mM of IPTG and expression was allowed at 28 ◦C overnight. Cells
were harvested by centrifugation and resuspended in the USH3 Lysis buffer 20 mM Tris-
HCl, 300 mM NaCl, 5 mM imidazole, 0,1 % NaN3, pH 8, to which protease inhibitors
were added (Protein Inhibitor Cocktail3, and 1 mM PMSF, both from Sigma). This lysis
product was sonicated on ice, treated with DNAse (Roche) for 20 min and centrifugated
at 25000 rpm for 45 min. The supernatant was subsequently applied to a Ni-NTA column
(Qiagen) and USH3 protein was allowed to bind the resine for 1 h. The resine was sub-
sequently washed with the USH3 lysis pH buffer. Elution was achieved with the USH3
Lysis buffer containing 400 mM imidazole. The elution product was further purified by
Size Exclusion Chromatography (SEC) on a Superdex 75 26/60 (GE Healthcare, Spain)
in 50 mM sodium phosphate, 150 mM NaCl, 0.2 mM EDTA, 0.01 % NaN3, pH 7.5.
Myristoylated USH3 and UGFP expression The bicistronic petDuet 1 plasmids
with the sequence of interest were transformed in E. coli RosettaTM (DE3)pLysS cells
(Novagen) or T7 Express (New England BioLabs). The cells were grown at 37 ◦C to an
OD600 of 0.8. Cells were plated over an agarose plate containing ampicillin and cloram-
philicol. Colonies were grown at 37 ◦C. Ten minutes before induction with IPTG (final
concentration 1 mM, Melford), freshly prepared myristic and/or palmitic acid (Sigma)
were added to the cell culture, at a final concentration of 200 μM; the solutions also
contained BSA as a carrier at a final concentration of 0,6 M. In the case of expression
in minimal medium, cells were centrifuged at 1000 g at 4 ◦C for 20 min. The pellet was
resuspended in half the volume of M9 minimal medium supplemented with 15NH4Cl, in
which the glucose was increased to 6 g/L. After 20 min at 37 ◦C, myristic and palmitic
acid were added as described above. The temperature after induction was set to 28 ◦C
for 5 h or 20 ◦C for 20 h. The cells were harvested by centrifugation at 4000 rpm at 4 ◦C
for 30 min. The pellet was resuspended in USH3 Lysis buffer (20mM TrisHCl, 300 mM
3Protein cocktail inhibitor: 23 mM AEBSF, 1 mM EDTA, 20 μM Bestatin, 3μM Pepstatin A, 3 μM
E64 (final concentrations in lysis buffer)
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NaCl, 5 mM Imidazole, pH 8), to which protease inhibitors were added (Protein Inhibitor
Cocktail4, and 1 mM PMSF, both from Sigma), and 1 mM PMSF, both from Sigma).
MyrUSH3 or MyrUGFP Purification The cell lysis was sonicated on ice before
centrifugation at 25000 rpm for 45 min at 4 ◦C. The protein was distributed between the
supernatant and the pellet. Thus, two different purification methods were used.
Supernatant purification On the one hand, the supernatant was applied to a Ni-
NTA column (Qiagen) and the myristoylated protein was allowed to bind the resin for
1 h. The resin was subsequently washed with the USH3 lysis pH buffer. The elution
product was further purified by Size Exclusion Chromatography (SEC) on a Superdex
75 26/60 (GE Healthcare, Spain) in 50 mM sodium phosphate, 150 mM NaCl, 0.2 mM
EDTA, 0.01 % NaN3, pH 7.5.
Triton wash purification On the other hand, the pellet was resuspended in USH3
lysis buffer containing 1 % of Triton X-100. The resuspended pellet was centrifuged
again 30 min at 25000 rpm and the procedure was repeated twice or three times. The
supernatant of the "Triton-washes" was purified via immobilized metal affinity and SEC
as described above. If lauroylated species were present, they eluted at an apparent higher
molecular weight than the myristoylated ones from the size exclusion chromatography.
This method enabled to separate the two different acylated species and to quantify their
respective amount. The purity and identity of the products was established by LC/MS
as described in the Mass Analysis section.
MyrCoA competition assay An alternative protocole consisted in sonicating the
cell lysis containing MyrUGFP in presence of an excess MyrCoA.
MyrUSH3 degradation Separation
SEC method at low pH After purification of MyrUSH3 by the triton wash methods,
protein fractions were collected in concentrated to 500 μL in 50 mM sodium phosphate
pH 7.5. They contained MyrUSH3 and its degradation form. The mixture was injected in
4Protein cocktail inhibitor: 23 mM AEBSF, 1 mM EDTA, 20 μM Bestatin, 3μM Pepstatin A, 3 μM
E64 (final concentrations in lysis buffer)
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a SEC (superdex 10/300 GL analytical) in 50 mM sodium phosphate pH 6. Two distinct
peaks were obtained.
Histrap Chromatography purification method The triton wash purification
protocol was modified as follows: the product extracted from the pellet, containing
MyrUSH3, was loaded into a histrap chromatography column. after washing with the
USH3 lysis buffer, elution was performed by using steps of imidazole starting from 200 mM,
increased to 400 mM, 800 mM and 1 M. The first fractions containing contamination from
degradation were discarded. All the subsequent fractions were degradation-free MyrUSH3.
These fractions were lyophilised and resuspended in water, and further purified by SEC
on a Superdex 75 26/60 in 20 mM sodium phosphate, 50 mM NaCl, pH 7.5. The pure
MyrUSH3 fractions were collected and lyophilized before resuspending them in water.
This product was then dialyzed against 50 mM sodium phosphate buffer, pH 7. If needed,
lyophilization/dialysis cycles were repeated until the desired concentration was reached.
Separation of the NMT-Myristoylated complex The fractions containing MyrUSH3
or MyrUGFP complexed with NMT were concentrated and subjected to one of the fol-
lowing protocols:
HIC protocol The sample was applied to an isopropanol hydrophobic column in
50mM NaP + 150 mM NaCl with or without 1 % Triton X100. The proteins were then
eluted by decreasing the (NH4)2SO4 concentration from 1.5 M to 0 M.
MyrCoA competition protocol The complex MyrUSH3-NMT was applied to
the nickel resin. A solution of 5 mM MyrCoA was applied and NMT was eluted. The
operation was repeated until almost no more NMT was eluted. NMT was obtained as
a pure product and further concentrated. Subsequently, MyrUSH3 or MyrUGFP was
eluted with 400 mM imidazole. The elution product still contained NMT. The MyrUSH3
eluted product was concentrated and separated from NMT by SEC, through injection in a
Superdex 10/300 GL analytical. Since NMT was not in excess, MyrUSH3 was separated,
but a portion of MyrUSH3 also underwent degradation.
Reverse phase chromatography The sample was separated using reverse phase
chromatography. The conditions are detailed in the "Mass Analysis" section.
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In-vitro myristoylation protocol
MyrCoA synthesis Myristic acid, 6 mg/ml, was dissolved in DCM and carboxy-
diimidazole, 4,1 mg/ml in THF, and they were mixed with agitation for 30 min. The
solvent was removed in a rotavapor and subsequently resuspended in 2 mL THF. Coen-
zymeA (Tebubio), 10 mg/ml, was dissolved in 0,5M NaHCO3. CoA was reacted with
myristic-carboxydiimidazole product for 2 h with agitation. The Myristoylated Coen-
zyme A (MyrCoA) solution was used without further purification. The reaction can be
followed via HPLC injections. 50 μl of the reaction product is injected in a Sunfire C18
column with a 0-60 % H20:ACN gradient
USrc expression and purification See part 3.7
NMT See part 3.7
Myristoylation protocol USrc, NMT and MyrCoA were obtained as described
in the previous sections. NMT was allowed to react with MyrCoA for 20 min at room
temperature. TheNMT:MyrCoA complex was then reacted with USrc for 2 h at 37 ◦C
followed by an overnight reaction at 4 ◦C. The products were separated by reverse phase
chromatography. 200 μL of product was applied to a Sunfire C18 LC column with a 0-80 %
H2O:acetonitrile gradient. Several injections were performed. The fraction corresponding
to MyrUSrc was collected and lyophilised, before being resuspended in 50 mM sodium
phosphate, pH 7. The purity and integrity of the product was verified by LC/MS as
described in the Mass Analysis section.
Liposome preparation 1,2-Dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1,2- Di
myristoyl-sn-glycero-3-phospho-rac-(1-glycerol) (DMPG) and L-α-phosphatidylserine (PS)
were purchased from Avanti Polar Lipids, Inc. The lipids were dissolved in chloroform or
in the case of DMPG in chloroform:methanol:H2O 65:35:8. Liposomes were prepared by
mixing the appropriate amount of lipids in the solvent. The solvent was evaporated in a
rotavapor followed by rehydration and vortexing at 40 ◦C with the buffer used for SPR
with a final lipid concentration of 1 mM lipids, and Multilamellar Large Vesicles were
obtained. The different liposomes were prepared with a DMPC:DMPG ratio of 2:1 or a
DMPC:PS ratio of 4:1. Large unilamellar vesicles were mechanically extruded at 40 ◦C
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using a 10-mL Thermobarrel extruder (LipexTM. Northerns Lipids Inc.) with at least ten
cycles of extrusion using a 100 nm polycarbonate filter. To verify the appropriate size of
the liposomes, the mean diameter was checked using Dynamic Light Scattering (Zetasizer
Nanoseries S, Malvern instruments).
Lipid Sedimentation Assay DMPC:DMPG Multilamellar Large Vesicles were ob-
tained as previously described in the “liposome" protocole part. Acylated proteins were
mixed with the vesicles and allowed to interact with the lipids at ambient temperature for
30 min. The mixture was ultracentrifugated for 20 min at 55000 rpm. The supernatant
was subsequently collected and the pellet was washed three times with buffer before resus-
pension. The two fractions were loaded in a SDS page in order to visualize if the protein
was in the aqueous or in the lipid phase.
Surface Plasmon Resonance (SPR) SPR experiments of BASP were carried out in
a Biacore 2000 instrument from Biacore, GE Healthcare using the SPR Sensor chip (L1)
from Biacore, GE Healthcare. Liposomes were injected for 500 s at a flow rate of 5 μl/min.
The reference channel was coated with BSA with a 200 s injection of 1 mg/ml BSA (Sigma,
fatty acid free) at a flow rate of 10 μl/min. Protein binding experiments were performed
at a 50 μl/min. The interaction of MyrBASP or LaurBASP with liposomes was followed
by observing the SPR response when a solution of protein was injected for 100 s (associ-
ation phase), followed by a 300 s washing period (dissociation phase). MyrBASP binding
to DMPC:PS liposomes was injected at concentrations ranging from 10 nM to 2.5μM.
LaurBASP binding to DMPC:PS liposomes was injected at concentrations ranging from
20 nM to 7.5 μM. All experiments were performed in the running buffer, which comprised
20mM NaP, 50mM NaCl, pH 7.4. The surface was regenerated with a series of detergent
injections at 100 μl/min (20 mM CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-
propanesulfonate), each pulse lasting 30 s. Each experiment was started with freshly
captured liposomes. Liposome coating was reproducible, with a variation smaller than
4 % between the subsequent coatings, ensuring very reproducible protein binding curves.
SPR experiments of MyrUSH3 were performed in a very similar fashion, with slight modi-
fications. The SPR chip (a 2D carboxymethyldextran surface) was purchased from Xantec
and modified by covalent attachment of phytosphingosine (TebuBio) to allow the capture
of DMPC:DMPG (2:1) liposomes. Liposomes were injected at 10 μl/min for 200 s before
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protein binding experiment: MyrUSH3 or LaurUSH3 were injected at 50 μl/min for 60 s
and dissociation was allowed for 300 s. The running buffer was composed of 50 mM NaP,
150 mM NaCl, 0.2 mM EDTA, pH 7.5. Liposome coating was reproducible, with a vari-
ation of about 1 % between the subsequent coatings, ensuring very reproducible protein
binding curves. Data analysis was performed in the Biaevalution software from Biacore.
Mass Analysis LC Conditions: Chromatograph: Acquity UPLC Binary Sol MGR
(Waters Corporation) Autosampler: Acquity UPLC Autosampler MO (Waters Corpora-
tion) Column: BioSuite pPhenyl 1000RPC 2.0 x 75 mm; 10 mm Eluents: A: Water 1 %
F.A B: Acetonitrile 1 % F.A Gradient: 5 % to 80 % of B in 60 min. Total chromatographic
time: 80 min.
MS Conditions: Mass Spectrometer: LCT-Premier (Waters) - Sample introduction:
LC-MS coupling - Polarity: ESI positive - Analyzer: V - Capillary voltage: 3000 V -
Sample Cone: 80V - Desolvation Temperature: 400 ◦C - Source temperature: 120 ◦C -
Cone gas flow: 50 - Desolvation gas flow: 750 - Pirani Pressure (mbar): 2.65 e0 - Penning
Pressure (mbar): 9.90 e-7 - Argon: 7.0e-3 - m/z 400-4000
Digestion assay
Sample preparation MyrUSH3 was obtained by using the Histrap Chromatogra-
phy protocol. It was free of degradation. Degradation was obtained by using a sample
of MyrUSH3 purified by the standard triton wash protocol. It contained both MyrUSH3
and degradation. A lipid sedimentation assay was performed and the supernatant was
collected; it contained only the degraded form. 5 μL of MyrUSH3, 5 μL of diluted Degra-
dation, and a mixture of MyrUSH3 and diluted Degradation (5 μL + 5 μL) were digested
(all proteins at 100μM concentration) with GluC (4 % w/w) at 25 ◦C during 24 h.
MS method The nano-LC-MS/MS set up was as follows. Digested peptides were
diluted in 1% FA. Samples were loaded to a 180 µm × 2 cm C18 Symmetry trap column
(Waters) at a flow rate of 15 μL/min using a nanoAcquity Ultra Performance LCTM
chromatographic system (Waters Corp., Milford, MA). Peptides were separated using a
C18 analytical column (BEH130 C18 75 mm × 25 cm, 1.7 μm, Waters Corp.) with a
80 min run, comprising three consecutive steps with linear gradients from 1 to 35 % B
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in 60 4min, from 35 to 50% B in 5 min, and from 50 % to 85 % B in 3 min, followed by
isocratic elution at 85 % B in 10 min and stabilization to initial conditions (A= 0.1 %
FA in water, B= 0.1 % FA in CH3CN). The column outlet was directly connected to
an Advion TriVersa NanoMate (Advion) fitted on an LTQ-FT Ultra mass spectrometer
(Thermo). The mass spectrometer was operated in a data-dependent acquisition (DDA)
mode. Survey MS scans were acquired in the FT with the resolution (defined at 400
m/z) set to 100,000. Up to six of the most intense ions per scan were fragmented and
detected in the linear ion trap. The ion count target value was 1,000,000 for the survey
scan and 50,000 for the MS/MS scan. Target ions already selected for MS/MS were dy-
namically excluded for 30 s. Spray voltage in the NanoMate source was set to 1.70 kV.
Capillary voltage and tube lens on the LTQ-FT were tuned to 40 V and 120 V. Minimal
signal required to trigger MS to MS/MS switch was set to 1000 and activation Q was
0.250. The spectrometer was working in positive polarity mode and singly charge state
precursors were rejected for fragmentation. A database search was performed with Pro-
teome Discoverer software v1.4 (Thermo Scentific) using Sequest HT search engine and
SwissProt database (Human, release 2015-01 and the common Repository of Adventitious
Proteins (cRAP database) and manually introduced the sequence of myristoylated USH3).
Searches were run against targeted and decoy databases to determine the false discovery
rate (FDR). Search parameters included non-enzyme specificity, myristoyl in N-terminal
as static modification and methionine oxidation as dynamic modifications. Peptide mass
tolerance was 10 ppm and the MS/MS tolerance was 0.6 Da.

Chapter 4
MyrUSH3 binding to
Liposomes
4.1. Surface Plasmon Resonance
Surface Plasmon Resonance (SPR) biosensors have a wide range of applications, among
which the characterization of biomolecular interactions. These biosensors permit to mon-
itor in-situ, in real time, the interactions between label-free molecules. Information that
can be extracted include the kinetics and affinity of the interaction; thermodynamic de-
composition into enthalpy and entropy can be obtained if temperature is varied. The
biomolecules intervening in these interactions can be proteins, DNA, small molecules,
carbohydrates, liposomes, etc (Bakhtiar, 2013).
The SPR technique is based on Total Internal Reflection (TIR) of an incident beam
light at an interface between two media of different refractive index (RI). When the beam
propagates from the medium of higher RI to that of lower RI, it can be totally reflected
(TIR), as long as its incident angle is greater than a critical angle depending on the RI
of the two media (Zeng and Liang, 2010).
When the incident light interacts with the mobile free electrons at the surface of the
metal, surface plasmon polaritons (SPP) arise as transverse magnetic waves that can
propagate along the interface between two material of opposite permittivities (a metal
and a dielectric material, for example an aqueous medium) (Daghestani and Day, 2010).
SPR conditions are achieved when the angle of incident light is such that its wavevector
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component parallel to the metal surface matches that of the SPPs and is detected as a
drop in the reflectivity of the incident light occurs (Homola, 2003). In SPR conditions, a
change on the dielectric sensor surface will result in a change in the angle of reflectivity,
which is the parameter that is ultimately detected. A so-called evanescent field is created
in both media, but the majority of the generated field is present in the dielectric medium.
This evanescent field decays exponentially with the distance in z; therefore the depth of
the evanescent wave useful for measurements is very limited – about 300 nm of the sensor
surface (Akimoto et al., 2000).
Different set-ups can be used to obtain SPR (Homola et al., 1999). A common one is
called the Kretschmann configuration, in which a gold layer is placed in the interface of
two dielectric media, a glass prism and an aqueous phase, as illustrated in Figure 4.1. The
optical light source (often a near-infrared high-efficiency LED) passes through the prism
in TIR mode and creates an evanescent wave which propagates into the aqueous phase;
the angle is tuned to match the evanescent wave propagation rate with that of the SPP.
The resonant angle can be measured very precisely (Akimoto et al., 2000). The sensor is
placed in a microfluidic chamber of very small dimensions with the gold layer in contact
with a flow of aqueous solution, in which molecules can be injected. If the molecule that
is flown in the chamber deposits over the gold surface, a change of the refractive index
occurs and is measured as a change in resonance angle induced by the SPR. The change
in refractive index on the surface is linear with the number of molecules bound to the
sensor surface in most of the cases (Stenberg et al., 1991). A shift in the SPR angle by
0.0001 degree corresponds to one unit shift in SPR signal (Bakhtiar, 2013)
Prism
Light Source Detector
Polarized light Reflected light
Surface sensor 
with gold film
Analyte flow
Immobilized ligand
Figure 4.1: Surface Plasmon Resonance Set Up
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A SPR sensor can be used as a biorecognition transducer, where the gold surface is
functionalized by the immobilization of one of the interacting partners, called the ligand.
The other interacting partner, called the analyte, is injected in the continuous flow of
running buffer and delivered near the sensor gold surface (Myszka, 1997). If the analyte
interacts with the ligand, it induces a change of RI near the surface of the gold layer
and generates a shift in the resonance angle, that is measured in Response Units, RU.
Therefore, the technique enables to monitor over time the association of the analyte to
the ligand. When the ligand injection has finished to flow and is replaced by the running
buffer, the dissociation of the complex is monitored (as illustrated in Figure 4.3-A). Since
the presence of the molecule itself over the surface is what affects the SPR signal, no
labeling of the molecules is needed. However, one has to take care that the ligand is
immobilized without hampering its biological function.
There are normally several channels in which the analyte can pass simultaneously
over the same or different ligands immobilized in each channel. Since changes in refrac-
tive index can be generated by other factors than the binding of the analyte it self, one
channel is usually set up as a reference and the experimental data are corrected from the
SPR responses of the reference (Rich and Myszka, 2000). The gold layer is chemically
functionalized to permit ligand immobilization and the ligands can be covalently coupled
to the surface (Thillaivinayagalingam et al., 2010); Figure 4.2 shows different immobi-
lization strategies. A carboxylated coated surface can be activated in order to covalently
couple the amine group of a protein (Figure 4.2-A). The ligand can also be captured
by high affinity binding molecules – a common set up consists in a streptavidin coated
surface able to capture biotinylated ligands (Dutra and Kubota, 2007), as illustrated in
Figure 4.2-B. Liposomes or liposome-containing membrane proteins (Cooper et al., 2000)
can adsorb to a functionalized surface, by e.g. use of biotinylated liposomes binding to
streptavidin coated surfaces (Eva-Maria Erb et al., 2000), or through hydrophobic anchors
coating (174) Figure 4.2-C and -D).
By following in real time the association of the analyte to the ligand and its dissoci-
ation, one can obtain information about the kinetics and the affinity of the interaction.
Specifically, the analyte has to be injected over the ligand at different concentrations.
The concentration range to be used is given by the equilibrium constant of the interaction
KD. A signal will be detected at concentrations over 0, 1 · KD, and saturation of all the
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Figure 4.2: Exemples of immobilization schemes. A) Amine coupling mechanism B)
Biotin-Streptavidin affinity capture C) Hydrophobic surface leading to the formation of
a lipid monolayer D) Hydrophobic anchors capturing liposomes, that may fuse to a bi-
layer
immobilized ligands will occur at concentrations about 10 ·KD. If the dissociation is slow,
the analyte can be removed by injecting a solution able to disrupt the interacting complex
– mild enough to not affect ligand integrity. By recording the association and dissociation
of the analyte at different concentrations a set of so-called binding curves are obtained
(Figure 4.3-B). By comparing the experimental curves to simple kinetic models, fitting of
the curves finally renders a set up of best-fit parameters corresponding to the equilibrium
constant and the association or dissociation rate constants.
The assay has to be optimized for each interacting pair in order to obtain reliable data,
by choosing the ligand density, the analyte concentration, the injection time, the flow rate,
and the regeneration conditions leading to a good set of binding data. A too high ligand
density may favor rebinding effects, especially in the case of fast associating molecules.
The analyte concentration must be in the correct range. The injection time must be
sufficient during the association phase, so that the binding equilibrium is reached, seen
as a plateau. The flow rate should be set as high as a possible to diminish mas transport
effects, especially in the case of high association or dissociation rates. Indeed, a constant
analyte concentration is assumed in the chamber, but if the transport of the depleted
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analytes to the surface is slower than the association rate, the latter is seen with an
effective slower rate (Myszka, 1997). If mass transport phenomena cannot be eliminated,
a mass transport rate can be included in the kinetics model. A multitude of interactions
can be monitored by SPR, but some are very challenging, namely the interactions with
low affinity or with very fast kinetics. Low affinity interactions require a high analyte
concentration that can favor non specific binding, not always corrected by the reference
channel. Fast kinetics can be limited by mass transport phenomena. Very low molecular
weight ligands are challenging in term of sensitivity. We used the Biacore instrument,
widely spread over the market in SPR, which has a very good fluidics and sensitivity.
Sensorgram
Association
Baseline
Equilibrium
Dissociation
Regeneration
Time (s)
Response 
Unit (RU)
Time (s)
Response 
Unit (RU)
Saturation Rmax
C = 100.KD
C = 0.1.KD
Equilibrium Req
Figure 4.3: A) Example of binding curves of an analyte to an immobilized ligand. During
the association phase, the analyte binds to the ligand until equilibrium is reached (recorded
as a plateau). Dissociation starts when the analyte is replaced with buffer. B) Example
of binding curves recorded at different analyte concentrations, with the same amount of
immobilized ligands
The most common model used to monitor a simple interaction is the Langmuir model,
in which a protein P interacts with a ligand L (Homola, 2003):
P + L PL (reaction 1)
where P represents the MyrUSH3 protein, L the ligand, and PL the protein-ligand
complex, the latter forming with the association and dissociation rate constants ka and
kd respectively.
The SPR response is proportional to [PL], obeying the equation:
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[PL](t) = Leq · (1 – exp(–(ka · [P] + kd) · t)) (equation 1)
with
Leq = Lmax · ka · [P]ka · [P] + kd
(equation 2)
The highest protein response possible, proportional to Lmax, is limited by the number
of immobilized liposomes. The rate constants can be estimated by globally fitting the
binding curves at various concentrations. The equilibrium constant Ka can be obtained
from the ratio of rate constants Ka = ka/kd.
Ka can also be obtained by fitting the equilibrium SPR responses (Leq) obtained at
various protein concentrations [P]. In the 1:1 Langmuir model, the relevant equation is a
modification of (equation3):
Leq = Lmax · [P]
[P] + 1Ka
(equation3)
One of the SPR application is the study of the binding of proteins to membranes (Be-
senicar et al., 2006), which is the scope of our work: monitor the interaction of MyrUSH3
to lipid bilayers. As already introduced, the membrane models in SPR consist in SLBs.
There are several ways of forming SLBs over the sensor chips, but they often consists in
liposome deposition. A very standard one consists in the capture of SUVs or LUVs over
a chip functionalized with lipophilic anchors – precoated surfaces with such anchors are
sold by Biacore. In our set up, we performed the functionalization ourselves, by using a
two-dimensional carboxyl coated surface, to which the amine of a lipid (phytosphingosine)
was covalently coupled via the “amine-coupling” procedure. Liposome injection was mon-
itored by an increase in the SPR response, and subsequent binding curves of MyrUSH3
to liposomes was recorded. The surface can be regenerated with detergent; liposomes are
removed and the surface is free for a next cycle of liposome coating / protein injection
/ regeneration. Liposomes were either zwitterionic or negatively charged, composed re-
spectively of DMPC alone or DMPC:DMPG 2:1, and the assays were conducted at 25 ◦C,
temperature at which the lipids are in their fluid state.
Though the lipid bilayer can not be described as a discrete ligand as it is the case
in many others ligand/analyte interactions, the kinetic modeling has been applied to get
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Figure 4.4: Liposome immobilization scheme: phytosphyngosine covalent coupling, lipo-
some capture, protein binding, liposome-protein regeneration with detergent.
information about the affinity and kinetics of peptides or proteins to membranes (Eva-
Maria Erb et al., 2000), and especially of myristoylated protein (Lange and Koch, 1997)
(Gohlke et al., 2010).
Here we show that c-Src anchoring involves two kinetically well separated events,
namely: a rapid reversible binding step followed by the formation of a persistently bound
(PB) species.
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4.2. Persistent binding of MyrUSH3 to liposomes
MyrUSH3 binding to immobilized liposomes was followed by SPR. This approach
consisted of the following steps:
i ) liposome immobilization
ii ) injection of MyrUSH3 (association phase)
iii ) washing with a protein-free buffer (dissociation phase)
iv ) antiSH4 antibody injection
v ) surface regeneration by washing away the liposomes.
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Figure 4.5: A) The cycle consists in (i) liposome coating, (ii) MyrUSH3 associating
with and (iii) dissociating from liposomes, and (iv) antiSH4 antibody secondary detec-
tion. Complete regeneration of liposomes and proteins is achieved at the end of the cycle
(v) B) Association and dissociation of 10 and 100μM of MyrUSH3 to DOPC:DOPG 2:1
liposomes, and secondaru antiSH4-antibody injection
A complete cycle of MyrUSH3 binding to liposomes is shown in Figure 4.5-A. The
association phase revealed rapid binding and equilibrium was reached quickly. The re-
sponse curve also revealed a rapid dissociation. However, the baseline did not return to
its original value (the liposome capture value), but remained stable at a slightly higher
level, thereby indicating the presence of PB MyrUSH3 proteins that were not removed by
washing with the running buffer. Due to the small population of PB species, a secondary
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detection was used to confirm their presence and to quantify them. In this regards, 350 s
after the beginning of the dissociation phase, antiSH4 antibody was injected over 60 s.
As a control, the antibody was also injected over protein free liposomes. In this case, no
response was observed: MyrUSH3 and antiSH4 antibody were completely removed with
the lipids when applying the regeneration conditions as described in the method section.
Control experiments with the equivalent unsaturated oleyl lipids DOPC-DOPG (2:1) with
a transition temperature of –40 ◦C gave very similar results (Figure 4.5-B).
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4.3. Components of MyrUSH3 binding to liposomes
The myristoylated N-terminal region of c-Src is known to be essential for binding but
the PB population had not previously been reported. In order to check whether persistent
binding was caused by the presence of additional lipid binding outside the myristoylated
SH4 domain, we measured the binding of a synthetic peptide, containing only residues
2-16 of c-Src with a myristoyl group attached at its N-terminus (MyrSH4), to liposomes.
The presence of a PB MyrSH4 population was clearly observed by injection of antiSH4
antibody (Figure 4.6-A). The affinity of the antibody for the two SH4 containing molecules
may not be directly comparable, impairing comparison of the relative antibody responses
of MyrSH4 or MyrUSH3 PB species. Nevertheless, we can still conclude that formation of
the PB species is a property of the MyrSH4 domain and does not require the presence of
the additional lipid binding regions in the Unique and SH3 domains. The decrease of the
direct SPR response curve during dissociation was slower in MyrSH4 than in MyrUSH3,
thereby suggesting that the presence of the secondary lipid binding domains in USH3
enhances the dissociation rate of the MyrSH4 region from the membrane. This apparently
contradictory result may be explained by the recently reported interaction between the
SH4 and SH3 domains of c-Src (Maffei et al., 2015). Since MyrUSH3 provides a more
native-like environment and gives a stronger SPR response than MyrSH4, we focused our
study on acylated USH3. The effect of myristoylation on the capacity of c-Src to bind
membranes has been extensively discussed. It was concluded that the binding energy
provided by the insertion of a single myristoyl chain was not sufficient to explain the
stable insertion of c-Src in the membrane. However, the electrostatic interaction between
the positively charged SH4 domain and negatively charged lipids, together with myristoyl
chain insertion, was enough to ensure stable binding (Buser et al., 1994) (Murray et al.,
1998) (Sigal et al., 1994). In order to explore the contribution of the hydrophobic and
electrostatic components, we first compared the binding of MyrUSH3 and LaurUSH3 to
liposomes. These two species differ only in the length of the N-terminal acyl chain with
lauric acid having a 12-carbon chain and myristic acid a 14-carbon chain. Figure 4.6-
B compares the binding of MyrUSH3 (1 μM and 20 μM) and LaurUSH3 (20 μM) to
DMPC:DMPG liposomes. When the two proteins were injected at the same concentration
(20 μM), the direct SPR response of LaurUSH3 was circa four times lower than that of
MyrUSH3, and the secondary detection by antiSH4 antibody gave barely any response
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for LaurUSH3. In comparison, the injection of 1 μM MyrUSH3, which provided a direct
SPR response half that of the 20 μM LaurUSH3 injection, still gave a clearly detectable
antibody response. These experiments show that while shortening of the acyl chain clearly
reduced, but did not eliminate, the binding of the fast dissociating form, it abolished the
formation of PB species.
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Figure 4.6: Binding of myristoylated and laurylated peptides to liposomes. (A) Compar-
ison of binding of 50 μM MyrSH4 and 100 μM MyrUSH3 to liposomes. DOPC:DOPG
2:1 liposomes, in 50 mM NaP, 150 mM NaCl.(B) Comparison of the binding of 20 μM
LaurUSH3 with that of 1 μM and 20 μM MyrUSH3. DMPC:DMPG 2:1 liposomes, in
50 mM NaP and 150 mM NaCl. (C) Binding of 10 μM MyrUSH3 to DMPC or DMPC:
DMPG 2:1 liposomes in 50 mM NaP and 150 mM NaCl (D) Binding of 2 μM MyrUSH3
to DMPC:DMPG 2:1 liposomes in the presence or absence of 150 mM NaCl. In (A-D),
the first curve corresponds to direct SPR peptide response, while the second is that of the
secondary antibody detection.
The effect of the electrostatic interactions on the formation of PB MyrUSH3 species
was first tested by comparing MyrUSH3 (10 μM) binding to neutral (DMPC) or charged
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(DMPC:DMPG 2:1) liposomes. For negatively charged liposomes, the direct SPR re-
sponse was higher, the dissociation was slower and the baseline recovered after washing
was also higher. Secondary detection confirmed that the population of the PB forms was
higher for MyrUSH3 bound to negatively charged lipids (Figure 4.6-C). The electrostatic
interaction of MyrUSH3 with charged liposomes increased at lower ionic strengths (Figure
4.6-D). The direct SPR response was doubled when the NaCl concentration was reduced
from 150 mM to 0 mM, in 50 mM NaP. A markedly slower dissociation was observed at
low ionic strength. Consistently, we observed a much stronger response to the antibody,
about four times larger, thereby suggesting that the relative population of the PB forms
with respect to rapidly dissociating ones is increased at low ionic strength. However, the
decrease in the baseline to values lower than before the MyrUSH3 injection suggests that
at low ionic strength, MyrUSH3 binding affects the immobilized liposomes. Consequently,
we quantitatively analyzed the two binding processes presented below in the presence of
150 mM NaCl, a value close to physiological ionic strength.
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4.4. Direct response of MyrUSH3 binding
to liposomes
MyrUSH3 binding was initially measured at protein concentrations ranging from 1 μM
to 100 μM using the direct SPR response. Below 20 μM, the binding curves had the
expected shape, with an association phase leading to a plateau when reaching equilibrium,
followed by protein dissociation after washing with buffer. At concentrations higher than
20μM, the binding curves did not reach a stable plateau after 60 s. Failure to reach a
stable equilibrium, at high concentration may be due to slow binding or a cooperative
binding of peptides over the lipid surface (White et al., 1998) – see Figure 4.7. We chose
to restrict our study to concentrations between 1 μM and 20 μM.
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Figure 4.7: MyrUSH3 direct binding curves to liposomes, ranging from 1 μM to 100 μM.
While saturation appears to be achieved at 10 μM, a change in the binding behavior is
observed at higher concentrations (50 μM and 100 μM), which showed a very high SPR
response and deviation at equilibrium. (red) experimental curves (black) fitted curves
The direct response of MyrUSH3 binding to liposomes was studied in order to ob-
tain kinetics and affinity information on the fast associating and dissociating population.
While the presence of multiple binding modes would in principle prevent the use of a
simple model, the contribution of the PB form to this response was very small. We thus
first analyzed the data with a simple 1:1 Langmuir model. From a formal point of view,
peptides partition to liposomes, and stoichiometry is most often unknown. Nevertheless,
simplification using the Langmuir model gives a satisfactory starting point for analyzing
kinetics data obtained by SPR (Gohlke et al., 2010) (Hong et al., 2002). A reasonable fit
of our experimental curves was obtained, especially for the association phase, although
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deviations were observed at the end of the dissociation phase. (see Figure 4.8 A and B).
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Figure 4.8: SPR responses (red) after 60 s association of MyrUSH3 to (A) (C) DMPC
and (B) (D) DMPC:DMPG liposomes. (A) (B) Best fit curves (black) with the 1:1 model
and (C) (D) with the conformational change model. Each image contains a zoom on the
dissociation phase in the upper right corner.
Data can also be treated with a conformational change model in the Biaevaluation
software, which assumes two separate bound forms. Initial binding generates one of them
(PL). PL may dissociate again or be transformed into a second species (PL*) that does
not dissociate directly but has to be converted back to PL before dissociation. The model
involves two sets of association and dissociation rate constants: ka1 and kd1, ka2 and kd2.
P + L PL (reaction 1)
PL + P→ PL∗ (reaction 2)
The final association and dissociation rates (and their standard deviations) were de-
rived by averaging the results from the global fitting of nine sets of binding curves using
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the two models.
The association constant was derived from the ratio of the rate constants. Data for
charged and neutral liposomes are presented in Tables 4.1 and 4.2.
Table 4.1: Kinetics parameters resulting from the fitting of the direct SPR data of
MyrUSH3 binding to liposomes applying the 1:1 Langmuir model. Association and dissoci-
ation rate constants, as well as association constant, derived from the fitting of MyrUSH3
binding curves to neutral or charged liposomes.
ka(M–1 · s–1) kd(s–1) KD(M–1)
DMPC 4.54 · 103 ± 2.18 · 103 2.81 · 10–1 ± 1.73 · 10–1 1.54 · 104 ± 7.01 · 103
DMPC:DMPG 2:1 2.46 · 104 ± 1.31 · 104 1.29 · 10–1 ± 8.63 · 10–2 1.9 · 105 ± 6.52 · 104
Table 4.2: Kinetics parameters resulting from the fitting of the direct SPR data of
MyrUSH3 binding to liposomes applying the Conformational Change model. Associa-
tion and dissociation rate constants derived from the fitting of MyrUSH3 binding curves
to neutral or charged liposomes.
ka1(M–1 · s–1) ka2(s–1) kd1 · (s–1) kd2(s–1)
DMPC 5.56 · 103 ± 2.44 · 103 6.58 · 10–1 ± 2.62 · 10–1 3.44 · 10–3 ± 3.05 · 10–3 8.16 · 10–3 ± 1.64 · 10–2
DMPC:DMPG 3.21 · 104 ± 1.82 · 104 2.53 · 10–1 ± 1.23 · 10–1 1.92 · 10–3 ± 1.59 · 10–3 4.9 · 10–3 ± 7.2510–3
The association constant for binding of MyrUSH3 to charged liposomes was one order
of magnitude higher than that of binding to neutral liposomes. Independent determination
of this Ka value by fitting the equilibrium responses as a function of protein concentration
was possible for charged liposomes and gave a value (1.35 · 105 M–1 ± 6.4 · 104 M–1) in
good agreement with that obtained from the ratio of rate constants. In the case of DMPC
liposomes, data at concentrations higher than 20 μM would be required because of the
lower affinity of the protein-lipid interaction. The association constant derived from the
1:1 Langmuir model (1.5 · 104M–1) for the binding of MyrUSH3 to DMPC liposomes is in
good agreement with the value (9 ·103 M–1) obtained by Buser et al. for MyrSH4 peptide
using partition methods (Buser et al., 1994). The conformational change model provided
a better fit to the dissociation phase of the SPR response than that of the 1:1 Langmuir
model. Figure 4.8 shows expansions comparing the experimental and best-fit curves for
MyrUSH3 binding to neutral and charged liposomes using the two models. While the
conformational change model improves the fitting of the (fast) processes that dominate
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the direct SPR response (Figure 4.8 C and D) and points to the presence of more than
one second form of bound MyrUSH3, the corresponding dissociation rates are too fast to
explain the PB form observed after more than 60 s of dissociation.
The existence of a persistently bound form of c-Src has strong biological implications
and the characterization of the nature and kinetics properties of MyrUSH3 is thus of great
interest.
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4.5. PB form of MyrUSH3 binding to liposomes
The observation of the PB form after extensive washing, a procedure that removed the
fast dissociating population, offers the possibility to study association and dissociation
kinetics of the two species independently. In addition, secondary detection by antiSH4
antibody capture provided the required sensitivity to study the binding kinetics of the PB
form, which is much less populated and gives a low SPR signal. By varying the MyrUSH3
association time, and applying the antibody at a constant time after the association phase,
we were able to follow the association kinetics of the PB form independently. In a similar
manner, by keeping the association time of MyrUSH3 binding to liposomes constant ,
and applying the antibody at different times of the dissociation phase, we were able to
independently study its dissociation. The experimental design is shown in Figure 4.9.
MyrUSH3 injection
antiSH4 antibody 
injection
 Association Time
antiSH4 
response
Association Time
x
Time
x
x x
MyrUSH3 injection
antiSH4 antibody 
injection
Dissociation Time
antiSH4 
response
Dissociation Time
x
Time
x
x
SPR response SPR response
Figure 4.9: Experimental scheme for the kinetics study of persistent forms of MyrUSH3.
(A) The build-up of antibody detectable MyrUSH3 over liposomes is monitored over time
by varying the association time using a constant dissociation time. (B) Dissociation is
followed by varying the dissociation time after a constant association time.
Figures 4.10-A and -B show the experimental curves obtained by this method for a
given association/dissociation time (60 s/350 s) respectively. The antibody solution was
injected at a constant dilution and therefore, the observed SPR response is assumed to
reflect the population of MyrUSH3 present on the liposome surface. Indeed, the antibody
response was greater with increasing the concentration of MyrUSH3 during the association
phase.
Figures 4.11-A and -B shows the association phase of the PB form of MyrUSH3 bound
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Figure 4.10: Experimental results for the kinetics study of persistent forms of MyrUSH3.
Direct and antibody detected SPR responses of 60 s/350 s association/dissociation of
MyrUSH3 (between 2 μM and 20 μM) on (A) DMPC and (B) DMPC:DMPG liposomes
respectively.
to neutral and charged liposomes. Figures 4.11 C and D show their dissociation phase.
Dissociation from neutral liposomes is negligible in the observed time frame and very
slow from charged liposomes. The population of MyrUSH3 that remains bound to neutral
DMPC liposomes did not decrease between 400 s and 7200 s after the end of the association
phase. In the case of DMPC:DMPG liposomes, the bound population of MyrUSH3 after
400 s was higher than with neutral lipids and slowly decreased between 400 s and 7200 s.
After 2 h, the population of MyrUSH3 bound to neutral and charged liposomes reached a
plateau, suggesting that a fraction of this form became irreversibly bound to both types
of liposomes.
On the light of the above observations, the process leading to the appearance of the
PB form was analyzed using a “conformation change”-like model in which PL gives rise
to PB in an irreversible manner. The rate constant of the transformation of PL to PB is
designated as k′on.
P + L PL (reaction1)
PL + P→ PB (reaction 3)
The model is presented using generic lipid containing species [L]; however the ac-
tual stoichiometry of the interaction is not known. For this reason we write the derived
CHAPTER 4. MYRUSH3 BINDING TO LIPOSOMES 115
●
●
●
●
●
●
●
0 100 200 300 400 500
0
50
0
15
00
25
00
MyrUSH3 Association Time (s)
A
nt
iS
H
4 
R
es
po
ns
e 
(R
U
)
● ●
●
●
●
●
● ● ● ● ● ●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
DMPC:DMPG 2:1 DMPC
●
●
●
●
●
●
●
0 100 200 300 400 500
0
20
0
60
0
10
00
MyrUSH3 Association Time (s)
A
nt
iS
H
4 
R
es
po
ns
e 
(R
U
)
● ● ● ●
●
●
● ●
●
●
●
●
●
● ●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
DMPC
●
● ●
0 2000 4000 6000 8000
0
20
0
40
0
60
0
80
0
 MyrUSH3 Dissociation Time (s)
A
nt
iS
H
4 
R
es
po
ns
e 
(R
U
)
● ●
●
●
●
●
● ●
●
●
● ●
●
●
●
DMPC
● ● ●
0 2000 4000 6000 8000
0
50
0
15
00
25
00
MyrUSH3 Dissociation Time (s)
A
nt
iS
H
4 
R
es
po
ns
e 
(R
U
)
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
DMPC:DMPG 2:1 DMPC
20μM
10μM
4μM
20μM
10μM
4μM
2μM
20μM
10μM
4μM
2μM
1μM
Baseline*
20μM
10μM
4μM
2μM
Baseline*
20μM
10μM
A) B)
C) D)
2μM
1μM
Baseline*
1μM
20μM
10μM
Baseline*
Figure 4.11: Experimental results for the kinetics study of persistent forms of MyrUSH3.
Association to (A) DMPC and (B) DMPC:DMPG, detected by antibody secondary detec-
tion after variable MyrUSH3 association times and constant dissociation times. Dissoci-
ation from (C) DMPC and (D) DMPC:DMPG, detected by antibody secondary detection,
following 60 s MyrUSH3 association time and variable dissociation times.*Baseline cor-
responds to an identical experiment in which the protein was omitted.
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equations in terms of the fraction of lipids bound to protein, θ.
θ = [PL]Lmax
+ [PB]Lmax
(equation 4)
1 – θ = [L]Lmax
(equation 5)
Since the amount of PB formed is small compared to that of PL, we assume that the
kinetics of the formation of PB does not modify the equilibrium of PL:
θ ∼ [PL]Lmax (equation 6)
This hypothesis explains the (experimentally observed) dependence of the binding
levels with protein concentration. Without this hypothesis, the maximum concentration
of [PB] would be the same for all concentrations in our equations, due to the irreversibility
of the second equation.
Assuming (reaction1) is at equilibrium, we can derive an expression of θ.
θ = Ka · [P]1 + Ka · [P] (equation 7)
We want to solve the kinetics equation corresponding to (reaction 3)
∂[PB]/∂t = k′on · [PL] (equation 8)
In terms of occupation
∂θPB/∂t = k′on · θPL (equation 9)
Resolution of equation (equation 9) leads to the following expression:
θPB = θ · (1 – exp(–k′on · t)) (equation 10)
We call R the SPR response of the antiSH4 antibody binding to PB, which is propor-
tional to [PB].
R = C1 · (1 – exp(–k′on · t)) (equation 11)
with C1 proportional to θ · Lmax.
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We fitted (equation 11) locally to the experimental curves obtained at various con-
centrations. The best-fit values are displayed in Figure 4.12 A for DMPC and Figure 4.12
B for DMPC:DMPG. Table 4.3 gives the values of the best-fit parameters.
Table 4.3: Results from the fits (as shown in Figure 4.12-A and B), giving values for
C1 and k′on (and the standard deviations of the fit coefficients) at the different protein
concentrations, for DMPC and DMPC:DMPG 2:1 liposomes
Concentration (M) 10–6 2 · 10–6 4 · 10–6 10–5 2 · 10–5
DMPC
C1(RU) 175.1± 26.9 272.1± 32.5 383.4± 32.8 512.3± 31 520.2± 23.3 697.3± 47
k′on(s–1) 0.01462± 0.004 0.02269± 0, 006 0.06505± 0, 022 0.1688± 0.077 0.1480± 0.046 0.2256± 0.155
DMPC:PG
C1(RU) 512.3± 75.6 889.3± 83.3 1223± 48.2 1484.1± 65 1419.8± 27.7 1678± 36.1
k′on(s–1) 0.00808± 0.002 0.00877± 0.001 0.01829± 0.002 0.04481± 0.009 0.05± 0.005 0.1050± 0.020
We observe that k′on depends linearly on protein concentration (Figure 4.12-C and
-D).
This concentration dependence of the apparent rate constants for the conversion be-
tween the initially (and reversibly) bound form of MyrUSH3 to the PB form indicates
that the conversion between the two forms of is a bimolecular process and suggests that
the PB species of MyrUSH3 are, at least, dimeric forms. Dimerization can be explicitly
included in the binding model, assuming that PL can interact with a second P molecule
to form PB, which we now explicitly label as PB2 to stress its dimeric nature, with an
association rate constant kon:
P + L PL (reaction 1)
PL + P→ PB2 (reaction 4)
In this case, θPB2 can be expressed as:
θPB2 = θ · (1 – exp(–kon · [P] · t)) (equation 12)
Fitting using (equation 11) is equally applicable but in this case
k′on = kon · [P] (equation 13)
The bimolecular kon (unit M–1 · s–1) can be obtained from the slope of the linear fit
between k′on and the protein concentration [P]. For DMPC liposomes, kon = 1.2 ·104M–1 ·
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Figure 4.12: Indirectly detected binding curves of persistent forms of MyrUSH3. Build-
up of persistent MyrUSH3 on (A) DMPC and (B) DMPC:DMPG, detected by antibody
secondary detection, using a constant dissociation time of 350 s. The continuous curves
correspond to the best-fits of the equation shown. Linear concentration dependence of k′on.
for binding to (C) DMPC and (D) DMPC: DMPG liposomes. *Baseline corresponds to
an identical experiment in which the protein was omitted. ** Duplicated results at 10μM
are shown; the error bar is shown in (c) and (d).
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s–1, while for DMPC:DMPG liposomes, kon = 5.1 · 103M–1 · s–1 The kon value obtained
with this model for neutral liposomes is larger than for charged ones. From the fitted
kon values it is possible to estimate and compare the true velocity of the PB species
formation on both types of liposomes and at different protein concentrations. According
to our model, the velocity v is given by:
v = k′on · Req (equation 14)
where Req is the direct SPR response at equilibrium (in Response Units)
The ratio of velocities of PB species formation in DMPC:DMPG versus DMPC alone,
plotted as a function of protein concentration [P], can be found in Figure 4.13. At low
concentration, the formation is faster in charged liposomes, but the ratio reaches a plateau
close to 1 at 10 μM and higher concentrations, suggesting that the inherent rate of dimer
formation is the same in both cases. The difference observed at low concentration may
come from a higher concentration of bound monomers and/or the accumulation of free
protein with their positively charged N-terminal region oriented towards the surface.
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Figure 4.13: Plot of the Ratio (k
′
on·Req)DMPC:DMPG
(k′on·Req)DMPC , as a function of the protein concen-
tration [P]
The model presented is only a first approximation to the binding process, which is
probably more complex. The bound species are assumed to be either fast dissociating
monomers or PB forms. While the second order rate constant needed to fit the experi-
mental rate of formation of the PB species strongly points to the formation of dimers, the
presence of higher oligomers cannot be ruled out. Also the model assumes that the re-
action 4 is irreversible, which would ultimately lead to an infinite concentration of PB2,
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since P is supplied in excess at a constant concentration. This is obviously not the case
and the maximum concentration of PB2 must be limited, possibly by the increase in lat-
eral pressure induced by the inserted proteins (or their mutual electrostatic repulsion),
which reaches a maximum level beyond which no further protein monomer or dimer can
be inserted.
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4.6. Conclusion and Discussion
All the members of the SFK have a myristoyl group attached to their N-terminal
glycine residues. In addition, all of them, with the exception of c-Src, contain additional
palmitoyl group(s) attached to cysteine residues in their SH4 domain. The hydropho-
bic acyl groups are essential for anchoring SFKs to membranes. The rest of the protein
remains soluble and is connected to the membrane-anchored SH4 domain through the in-
trinsically disordered Unique domain. In the case of c-Src, insertion of a single myristoyl
group does not provide enough hydrophobic energy to ensure stable binding. This prob-
lem has been extensively discussed in the literature (Buser et al., 1994) (Murray et al.,
1998) (Sigal et al., 1994) and the consensus view is currently that permanent anchoring of
c-Src is achieved by the combination of hydrophobic insertion of the myristoyl group and
electrostatic interaction of the strongly positively charged SH4 domain with negatively
charged membranes. Here we have used SPR to characterize the kinetics of binding of
Myristoylated USH3, a construct that contains the main lipid binding region of c-Src,
to immobilized liposomes. Surprisingly, two kinetically well-defined binding events were
observed. The first one has fast association and dissociation rate constants and can be
followed directly by the SPR response of MyrUSH3 injections. At low protein concen-
trations, a standard analysis of the binding curves gives an association constant that is
in good agreement with that obtained by partition methods in similar systems. Most
of the bound species can be washed away from the immobilized liposomes with buffer.
However, a small population of a PB form of MyrUSH3 was observed. While the corre-
sponding SPR response was only a small shift from baseline level, the presence of the PB
species was confirmed by capture of an antiSH4 antibody by the proteins remaining on
the liposome surface. The antibody SPR response is proportional to the PB population.
The latter was retained for more than 2 h and could be eliminated only by detachment
of the immobilized liposomes by means of detergents. When liposomes were not exposed
to protein, no antibody was captured.
A PB form was also observed using a synthetic myristoylated peptide containing only
the SH4 domain (MyrSH4). In contrast, USH3 with a C12 lauryl chain instead of the
C14 myristoyl chain showed no PB form, though fast association and dissociation pro-
cesses were observed (with lower affinity than MyrUSH3). Thus from the structural point
of view, MyrSH4 is a necessary and sufficient requirement for the observation of persis-
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tent binding. The electrostatic contribution was tested by comparing MyrUSH3 binding
to neutral and negatively charged liposomes, and by the effect of the ionic strength.
MyrUSH3 affinity and also the rate of formation of the PB form increased in nega-
tively charged lipids. The effect is consistent with an electrostatically driven approach of
MyrSH4 to the liposome surface. The very slow dissociation kinetics and the secondary
detection using antiSH4 antibody allowed an independent analysis of the kinetics of PB
species formation. The association kinetics depends on the population of the labile form
of bound MyrUSH3 and the concentration of free MyrUSH3 during the association phase.
Thus, PB formation follows an effective second order law, thereby suggesting that the PB
form contains more than one MyrUSH3 molecule.
Time
Association Dissociation
SPR Response
Direct Protein Detection Secondary Antibody Detection
SH4
SH3
Unique Domain
Figure 4.14: Illustration of the possible dimer formation during the SPR assay
While membrane-integrated receptor kinases are known to oligomerize, usually in re-
sponse to ligand binding, and this process triggers signaling events, non-receptor kinases,
like c-Src, are commonly believed to be essentially monomeric, even when anchored to
membranes. However, c-Src phosphorylation by a second c-Src molecule is known to
occur, therefore at least transient contacts between c-Src molecules are functionally im-
portant. A super resolution spectroscopy study, in which the first 15 residues of the c-Src
SH4 domain fused to photoswitchable (PS-GFP2) were expressed in HeLa cells, provided
evidence of the formation of clusters of MyrSH4 containing proteins on the membrane
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surface (Owen et al., 2010). Neither non-myristoylated USH3 nor myristoylated USH3
show evidence of dimerization in solution, therefore, we conclude that the dimerization
of MyrUSH3 is directly related to membrane binding. Figure 3.5 shows that replacing
the C14 myristoyl chain by a C12 lauryl also abolished dimerization, although LaurUSH3
retains the capacity to interact with lipids albeit with a lower affinity. These results
suggest that myristoyl insertion is essential for MyrUSH3 dimerization. The strict re-
quirement for a myristoyl group suggests that the insertion of the fatty acid chain in the
lipid bilayer is necessary for dimerization. We speculate that myristoyl insertion induces
a conformation of the SH4 domain that allows the dimerization to occur. In addition,
MyrUSH3 dimerization is observed in the presence of either neutral or negatively charged
lipids and the dimer formed is irreversibly bound in both systems. The slow dissociation
of MyrUSH3 dimers is consistent with the effectively irreversible binding of other SFKs
in which two acyl chains are simultaneously inserted in the membrane. The enhanced
binding and dimer formation observed in negatively charged lipids probably reflects the
additional binding affinity, which results in a larger concentration of bound MyrUSH3
monomer as well as the increased local concentration of soluble MyrUSH3 close to the
membrane. The biological relevance of c-Src dimerization remains to be demonstrated but
we suggest a possible functional role of the coexistence of a fast and a slow dissociation
form of bound c-Src. In its resting state, inactive c-Src is found predominantly in the per-
inuclear region of the cell. However, upon activation c-Src accumulates in specific regions
of the membrane. Switching between monomeric and dimeric forms of c-Src would facili-
tate the fast exploration of the membrane surface until the target site is located, at which
point the binding mode would switch to the persistent form and signaling would start. At
low concentrations, myristoylated c-Src can probably attach and dissociate rapidly from
the membrane surface, allowing fast diffusion on the 2D membrane surface and efficient
exploration of large membrane areas. However, a local increase in c-Src concentration, for
instance by high local concentrations of negatively charged lipids such as phosphoinosi-
tides, may result in the formation of c-Src dimers, which will remain in this particular
membrane site and trans-activation will be facilitated, thus triggering the relevant signal-
ing pathway. A similar strategy is used by transcription factors to explore large regions
of DNA. These systems switch from non-specific low affinity binding mode, to retain the
transcription factor close to the DNA surface and facilitate fast one-dimensional diffusion,
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to specific, high affinity binding at the target site. The observed dual lipid binding mode
of c-Src suggest a similar mechanism in which fast dissociation allow diffusion close to
the 2D surface of the membrane, while dimerization fixes c-Src at the target site to initi-
ate downstream signaling. The problem of c-Src deactivation arises if the binding of the
dimer to membrane is a strong as the one we measure here. Nevertheless, in the previous
chapter, we found a location in the amino acid sequence of the Unique Domain that is
more labile and easily subject to cleavage. It is not clear how this cleavage is triggered.
One hypothesis could be crowding effects, since the degradation may be concentration de-
pendent. Another one would be conformational restriction (a forced conformation might
induce mechanical constraints favoring rupture). Such a degradation mechanism would
enable to stop the signaling process, by detaching the kinase from the membrane.
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4.7. Experimental Methods
Liposome preparation All lipids were from Tebubio. 1,2-Dimyristoyl-sn-glycero-3-
phosphocholine (DMPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine, DOPC, and 1,2- di-
oleoyl -sn-glycero-3-phospho-(1’-rac-glycerol) (sodium salt), DOPG were dissolved in chlo-
roform. 1,2-Dimyristoyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium salt (DMPG) was
dissolved in chloroform:methanol:H2O 65:35:8. Three lipid compositions were used, DMPC
alone, DMPC:DMPG 2:1 or DOPC:DOPG 2:1. The lipid solution were evaporated in a
rotavapor, and lipid films were rehydrated with buffer (50mM NaP, 150 mM NaCl, 0.2 mM
EDTA, pH 7.5) by warming the lipid film at 40 ◦C and vortexing, rendering a final to-
tal lipid concentration of 1 mM. Large unilamellar vesicles were prepared by mechanical
extrusion using a 10-mL Thermobarrel extruder (LipexTM. Northerns Lipids Inc.). The
lipid suspension was extruded repeatedly (10 times) through a 100 nm polycarbonate
filter at 40 ◦C. To verify the appropriate size of the liposomes, the mean diameter was
checked using Dynamic Light Scattering (Zetasizer Nanoseries S, Malvern instruments).
Direct SPR binding assay SPR experiments were carried out in a Biacore 100 in-
strument from GE Healthcare. The SPR chip (a 2D-carboxymethyldextran surface) from
Xantec was modified by covalent attachment of phytosphingosine (TebuBio) to allow the
capture of neutral or negatively charged liposomes containing DMPC or DMPC-DMPG
(2:1), respectively. Experiments were carried out at 25 ◦C where these lipids and lipid
mixtures are in the liquid crystalline phase. Control experiments with the equivalent un-
saturated oleyl lipids DOPC-DOPG (2:1) with a transition temperature of –17 ◦C were
also conducted, by using injections of MyrUSH3 at 10 or 100 μM.The reference channel
was blocked with BSA, with a 1 mg/ml injection at 10 μl/min for 100 s. The immo-
bilization protocol and subsequent liposome coating were performed in the instrument
chamber, at a flow rate of 10 μl/min. To minimize mass transport phenomena, a flow rate
of 50 μl/min was used to monitor the interaction of MyrUSH3 with liposomes. The SPR
response of MyrUSH3 binding to liposomes was followed for 60 s (association phase), while
the subsequent washing lasted 200 s (dissociation phase). Protein concentration ranged
from 1 μM to 20 μM, and all experiments were performed in the running buffer, which
comprised 50 mM NaP, 150 mM NaCl and 0.02 mM EDTA, pH 7.5, unless indicated
otherwise. The surface was regenerated with a 10-mM HCl pulse followed by a 20-mM
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CHAPS pulse, both for 30 s at 10 μl/min. Each experiment was started with freshly
captured liposomes. The liposome coating itself was reproducible, reaching an average
value of 6785 RU (standard deviation 625 RU) for DMPC liposomes, and 8193 RU (stan-
dard deviation 608 RU) for DMPC:DMPG liposomes, guaranteeing reproducible protein
responses as shown in Figure 3.7.
SPR detected antibody capture MyrUSH3 dissociated very quickly from liposomes,
but the presence of a residual population of lipid bound MyrUSH3 was detected by the
SPR response observed after injecting antiSH4 antibody (Abcam) at a 1:10 dilution in
the running buffer. The association and dissociation kinetics of these PB species were
studied separately: dissociation was measured by recording the antibody response at
increasing times after a constant association time of 60 s, while association was monitored
by detecting the antibody response at a fixed time after the end of increasingly long
association times. The flow rate was kept at 50 μl/min during protein association and
dissociation, and decreased to 30 μl/min just before antibody injection.
Model and data analysis Direct SPR responses of MyrUSH3 binding to liposomes
were analyzed using the Biaevaluation software from Biacore using two alternative models:
the 1:1 model and the conformational change model. Data of the PB fraction, obtained by
antiSH4 antibody secondary detection, were analyzed using Igor software, with the models
described in the results section. All data were double referenced (reference channel and
baseline subtraction).
Chapter 5
MyrUGFP binding to
monolayers and SLBs
5.1. The Monolayer Technique
Amphiphilic molecules deposited at low concentration on top of a water surface arrange
in a single layer at the air/water interface. If lipids are used, they are in practice dissolved
in a solvent and deposited on top of an aqueous solution, and they spread and form a
monolayer at the interface, in which the phospholipid head is in contact with the water
and its tail points to the air. In this configuration, at the air/water boundary, there is a
change in interfacial free energy, resulting in the existence of a surface pressure (Maget-
Dan, 1999), or lateral pressure (defined as the first derivative of the monolayer free energy
with respect to the surface area).
In the case of membrane bilayers, the concept of lateral pressure is not relevant since
they are in a tension free state. A lateral pressure manifests only if the membrane is
subject to a lateral stress, and in this case the concept of lateral compressibility can be
applied. In the case of a monolayer, the lateral compressibility is defined as the slope of
the surface pressure against area isotherm. This enables to derive a monolayer pressure
equivalent to a bilayer, which has been found to range from 30 to 35 mN/m (Marsh, 1996)
depending on lipid composition, aqueous buffer composition, temperature, etc.
The surface pressure can be easily measured, for instance using a Wilhelmy plate.
A thin plate is vertically immersed at the interface. The force acting on this plate is
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measured by a tensiometer, or an electrobalance, and is directly proportional to the
surface pressure (Maget-Dan, 1999).
Once the monolayer is formed, it can be used to study how the peptide (or protein)
partitions to the monolayer, and in particular how it inserts into the monolayer, by inject-
ing of the peptide in the subphase. After spreading lipids at a desired constant pressure
Pi, a change in the surface pressure will occur, caused by peptide insertion, and can be
monitored over time. The surface pressure will ultimately reach a stable equilibrium pres-
sure Pe (Calvez et al., 2009). Figure 5.1 shows the experimental set up, as well of typical
pressure changes curves recorded through the Wilhelmy method.
Liquid
Air
Barrier
Monolayer
MyrUGFP
molecules
Agitation
Initial
monolayer
pressure
Maximal pressure
(saturation of 
inserted molecules)
Pressure increase 
from the insertion
of molecules
Pressure
Time
Wilhelmy plate
Tensiometer
A) B)
Figure 5.1: A) Monolayer set up; lipids are organized at the air water interface. Pressure
is measured by a Wilhelmy plate. B) If a molecule inserts into the lipid bilayer, pressure
increases from the initial monolayer pressure Pi until the equilibrium pressure Pe.
One parameter that can be extracted from such a set up is the maximum insertion
pressure (MIP) of a peptide in a monolayer of specific composition. The change in surface
pressure Pe – Pi can be recorded when injecting a constant concentration of peptide at
different initial pressures. At low concentration, this change is linear with initial pressure
Pi (Marsh, 1996). If the experimental data render a linear plot of Pe – Pi versus Pi,
then linear regression permits to interpolate the maximum insertion pressure (or criti-
cal insertion pressure (Rafalski et al., 1990)) of the peptide in the monolayer Pmax. By
knowing the equivalent pressure for a bilayer, this experiment gives insight on the inser-
tion capability of a peptide in a bilayer. If Pmax is higher than the equivalent lateral
pressure of 30-35 mN/m, the peptide is potentially enable to insert into the bilayer. This
technique is very often used to measure the insertion properties of peptides to lipid mono-
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layers (Sánchez-Martín et al., 2011) (Alay et al., 2013). However, several studies have
been conducted which involve myristoylated proteins, for instance Calcineurin or Recov-
erin. The values of MIP obtained with myristoylated and non-myristoylated forms of
Calcineurin were comparable, suggesting that the myristoyl group does not contribute to
monolayer binding in the conditions used (probably due to the recruitment of the myris-
toyl chain in the pocket) (Calvez et al., 2009). On the contrary, binding of recoverin to
monolayers was significantly different in the myristoylated form (Desmeules et al., 2007)
Myristoylated proteins are amphiphile entities, therefore, if they are injected in the
subphase in absence of lipids, they will have a tendency of going at the air/water interface.
Such an experiment enables to determine the activity of the protein; at low concentration,
a small pressure change will be noted at the interface. The pressure change will increase
with protein subphase concentration until a plateau is reached, in which no more proteins
can fit at the surface. Determining the activity of the protein and the concentration at
which saturation occurs permits to choose the concentration at which the protein will be
injected in the MIP experiment. Indeed, this experiment must be conducted at constant
protein concentration in the subphase, which should be high enough to obtain sufficient
signal, but not too high to prevent artifacts. The concentration rendering half of the
pressure change at saturation is usually chosen.
In the case of c-Src, most of the studies have been performed with the N-terminal
MyrSH4 peptide. We measured the MIP obtained for MyrSH4 inserting into a DMPC:
DMPG 2:1 monolayer, but also for a bigger construct, constituted of the myristoylated
Unique Domain followed by a fluorescent reporter (enhanced Green Fluorescent Protein).
We compare the insertion characteristics of both constructs, and showed that both can in-
sert into a bilayer, but the values obtained in case of MyrUGFP were closer to biologically
relevant values.
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5.2. MyrUGFP binding to lipid monolayers
The surface properties of two myristoylated constructs (MyrSH4 and MyrUGFP) were
initially explored, and their minimum insertion pressure (MIP) was subsequently deter-
mined for a monolayer composed of DMPC:DMPG 2:1 monolayer at room temperature.
Surface properties The surface properties of MyrSH4 were explored from 100 nM to
10 μM. At 100 nM, a surface pressure increase of 4 mN/m was observed (Green curve
in Figure 5.2-A). Nevertheless, higher concentrations did not result in higher pressure
changes. At 500 nM and above, a small pressure change of about 1 mN/m was observed,
followed by a pressure decrease indicating peptide desorption from the interface (Red and
blue curves in Figure 5.2-A). This abnormal behavior suggests that at concentrations of
500 nM and higher, MyrSH4 forms micelles in solution. The typical “activity curve”
plotting the pressure increase as a function of concentration could not be determined.
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Figure 5.2: Surface pressure increase due to the adsorption at the air-water interface A)
of MyrSH4 at 100 nM, 500 nM and 1 μM B) of MyrUGFP at 25 nM, 250 nM and 1 μM
On the contrary, MyrUGFP displayed a normal behavior, with surface pressure in-
creasing with concentration, until saturation of the surface with the proteins was reached.
Figure 5.2-B shows examples of pressure increase at the interface due to MyrUGFP ad-
sorption at three different concentrations. Figure 5.3 shows the corresponding surface
activity plot for MyrUGFP (pressure change versus protein concentration).
The pressure changes obtained with the peptide or with MyrUGFP can be compared
at 100 nM concentration, given the hypothesis that MyrSH4 does not form micelles at
this concentration. The 100 nM-MyrSH4 injection induced a pressure change of 4 mN/m,
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while the 100 nM-MyrUGFP injection induced a pressure change of about 13 mN/m.
This difference can be explained by the increased number of exposed hydrophobic amino
acids of the Unique Domain. The GRant AVerage of hYdropathy (GRAVY) of MyrSH4
is -2.553, while that of MyrUGFP is -0.608, indicating that the latter is much more
hydrophobic than the peptide. The disordered Unique Domain possesses indeed several
exposed hydrophobic amino acids.
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Figure 5.3: Activity curve of MyrUGFP
We next studied the insertion of MyrSH4 or MyrUGFP into a DMPC:DMPG 2:1
monolayer. The peptide or the protein were added at a constant concentration but at
different initial pressures. The working concentration for MyrSH4 was chosen arbitrarily
to be 1 μM. In the case of MyrUGFP , the activity curve in Figure 5.3 was used to deter-
mine the working concentration – a concentration rendering about half of the maximal
pressure was chosen, that is to say 100 nM.
Here again, the pressure changes induced by MyrUGFP were higher than for the pep-
tide. After injection of 1 μM MyrSH4, the pressure increased continuously until stabilizing
to a plateau – the abnormal behavior monitored in absence of lipids was not observed.
Figure 5.4-A and -B shows examples of peptide or protein insertion in the monolayer, at
two initial pressures. In both cases, the pressure change is higher when the initial pressure
is lower. The plot of the pressure change versus initial pressure was linear, as illustrated in
Figure 5.4-C and -D. Linear regression of the data enabled to determine the MIP for both
species. A MIP of 50 mN/m was obtained for MyrSH4, way above 35 mN/m, indicating
that MyrSH4 can certainly insert in membranes. The MIP of 34 mN/m for MyrUGFP
was much lower, and also closer to typical values obtained from other proteins (Calvez
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et al., 2009).
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Figure 5.4: Surface pressure increase due to the insertion in the monolayer A) of 1 μM
MyrSH4 at two initial pressures, 6 and 15 mN/m B) of 100 nM of MyrUGFP at two
initial pressures, 8 and 20 mN/m. MIP plots for C) MyrSH4 and D) MyrUGFP
These experiments suggest that MyrUGFP, including the Unique Domain and a folded
domain, is a system much more representative of the biological reality than the peptide
alone. The micelle formation is prevented in this bigger construct, and the MIC is more
realistic.
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5.3. Single Molecule Photobleaching
Fluorescence is a process in which certain photoexcited molecules emit light of a longer
wavelength than that of the light causing excitation, in a fast manner that do not involve
intersystem crossing. This process takes place in three steps, as illustrated in Figure 5.5.
Excitation: A photon of energy hνex is absorbed by a molecule initially in its ground
state. Excited-state lifetime: the molecule remains in the excited state a certain time,
during which the energy is partially dissipated vibrationally to a lower energy excited
state. Emission: a longer wavelength photon is emitted, hνem, and the molecule returns
to its ground state. The process can be cyclical, unless photobleaching occurs, in which
the fluorescence is irreversibly lost in case of prolonged light exposure. Reversible loss
of fluorescence may also occur upon quenching or blinking. Quenching is due to short-
range interactions between the fluorophore and the local molecular environment (including
other fluorophores). Blinking occurs randomly, the fluorophore switching between an ON
(bright) and an OFF (dark) state under continuous excitation.
Energy levels
Internal conversion
Absorbance
Fluorescence
 S0 Ground State
Excited States
 S1
 S2
Figure 5.5: Diagram illustrating the fluorescence phenomenon.
Fluorophores can be excited for instance by laser illumination at the excitation wave-
length, and fluorescent light is collected at the emission wavelength. In biological studies,
fluorescent probes are used as reporters for other molecules. Fluorophores possess an
extinction coefficient, related to their capacity to absorb light at a specific wavelength,
that can be related to the molecule concentration. In our study, we used two fluorescent
probes. One is a GFP mutant, directly attached at the N-terminal of MyrUSrc. The other
one is a lipid functionalized with a fluorophore at the lipid head, namely 1,2-dimyristoyl-
sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) or LissRhode PE.
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eGFP GFP acquires its fluorophore properties upon formation of a chromophore
during protein folding. The chromophore maturation consists in a Cyclization-Oxidation-
Dehydration Mechanism between 3 amino acids (Rosenow et al., 2004a) (Rosenow et al.,
2004b) at positions 64-65-66; this process results in a loss of 21 Da with respect to the
theoretical mass (calculated from the amino acid sequence). During protein expression,
misfolding may occur, in particular if GFP is cloned after a non folded domain. En-
hanced Green Fluorescent Protein has been engineered from GFP. It has faster folding
and brighter fluorescence emission (Goossens et al., 2006) (Yang et al., 1996). Its excita-
tion maximum is in the blue, at 488 nm, and its emission is in the green, with a maximum
at around 507 nm (Tsien, 1998). Figure 5.18 shows the absorption and emission spectrum
of eGFP. The molecule is most efficiently excited at 488 nm but can be excited over a
wide range of wavelength, and fluorescence can be collected between 500 and 600 nm.
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Figure 5.6: Absorption and emission spectrum of eGFP.
eGFP has an extinction coefficient of 56000 M–1 ·cm–1 (Lambert and Thorn) at 488 nm
absorption. The construct in which an Enhanced Green Fluorescent Protein (eGFP) was
appended after the Unique domain of c-Src was used. The amount of correctly folded GFP
can be deduced by comparing the protein concentration calculated with the Beer-Lambert
Law, in which
c = A
ε · l (equation 15)
with A being the measured absorbance, ε the extinction coefficient and l the path
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length of the cuvette. The concentration can be measured either by using the classical
protein absorbance at 280 nM and the related extinction coefficient (27515 M–1 · cm–1 in
case of UGFP), or by using the protein absorbance at 488 nM and the related extinction
coefficient 56000 M–1 · cm–1.
LissRhode PE DMPE is functionalized at the lipid head with LissRhode, as illus-
trated in Figure 5.7 A. Liss Rhode has a maximum absorption at 560 nm and a maximum
emission in the red, at 583 nm. The absorption and emission spectrum is displayed in
Figure 5.7 B. LissRhode is used as a fluorescent reporters to identify the supported lipid
bilayer and characterize its homogeneity.
1,2-dimyristoyl-sn-glycero
-3-phosphoethanolamine
lissamine rhodamine 
B sulfonyl
LissRhode Excitation and Emission spectrumFunctionalized DMPE with LissRhode 
A) B)
Figure 5.7: A) Chemical structure of LissRhode PE B) Absorption and emission spectrum
of LissRhode. Data are from Avanti Polar Inc website.
Single Molecule Fluorescence Microscopy Use of fluorescence microscopy has grown
exponentially in the field of cell biology, in particular since the discovery of fluorescent
proteins such as the Green Fluorescent Protein from jelly fish. Recombinant techniques
have allowed optimization of the fluorescence emission and excitation of such proteins and
expanded the wavelength range available (Cormack et al., 1996). These fluorescence re-
porters can be cloned within the protein sequence and a recombinant protein terminated
by a fluorescent domain can be obtained. The can also be used in cells as a reporter
of gene expression and protein localization (Chalfie et al., 1994) (or colocalization with
another protein derived with a second fluorescent marker). Use of such reporters allows
fluorescent imaging in cells or in model systems with low background and high specificity
Nevertheless, conventional fluorescence microscopy is limited to study such molecules,
because of optical diffraction. Optical systems will introduce distortions in which the
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image of an infinitely small light source is a typical 3D-pattern called the Point Spread
Function (PSF), which can be modeled by a Airy function, and limits the lateral resolution
of an image.
Image resolution is achieved when two points are far enough to be distinguished.
The Rayleygh criterion is used to define resolution. It roughly states that, in order to
distinguish between two points, the minimum distance between them corresponds to the
the full width at half maximum (FWHM) of the PSF. It means that two points can
be resolved if they are separated by at least the distance of a FWHM, which is about
λ
2·NA , where λ is the wavelength of light and NA the numerical aperture. In practice, point
sources need to be about 200 nm apart in the visible wavelength region to be distinguished
with modern high-quality fluorescence microscopes.
There is also a limitation in axial resolution, of about 2λ·nNA2 with n the index of refrac-
tion, corresponding to a depth of field of 500 nm in the visible wavelength region with
modern microscopes (Prasanna Pavani et al., 2009).
Since the size of proteins is below the diffraction limit, they cannot be resolved in
an image by standard microscopy. If a fluorescent signal is imaged, it is not possible
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to know how many molecules are included. Nowadays, several techniques have been
developed to overcome the diffraction limit and obtain fluorescent images of very high
resolution. One general concepts consists in selectively imaging only a few fluorophores
within a sample. The center position of the PSF is considered to be the position of
the excited molecule. Small populations of fluorophores are sequentially excited and
the center positions of their PSF are recorded. By repeating the operation, accurate
position of all fluorophores can be obtained and used to reconstruct a high resolution
image (the protocol of such techniques is illustrated in Figure 5.9. To selectively excite
the fluorophores, two techniques are mainly used. In Stimulated Emission Depletion
(STED), fluorescence is depleted in specific regions of the sample while leaving a center
focal spot active to emit fluorescence (Hell and Wichmann, 1994). In PhotoActivated
Localization Microscopy (Zhong, 2010) (PALM) and STochastic Optical Reconstruction
Microscopy (Rust et al., 2006) (STORM), photoswitchable fluorophores are used: the
fluorophores are driven by light between an active-ON and an inactive-OFF state. In
both cases, the fluorophores have to be specifically chosen in order to be manipulated
according to the needs of the techniques.
Figure 5.9: Schematic representation of the protocol used when recording fluorescence of
only a few chromophores in a sample. Image from Zhong (2010)
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In addition to dramatically improving image resolution, these techniques enable to
image individual objects which size and distance smaller than the diffraction limit. Thus
single protein imaged in a cell can be resolved, and if they are clustered, the number of
protein in a cluster can be evaluated (Owen et al., 2010).
There are simplier ways of indirectly overcoming the diffraction limit and inferring
the stoichiometry in a protein cluster. One of them consists in a single molecule pho-
tobleaching experiment (Garcia-Parajo et al., 2001) (Zijlstra et al., 2012). In this case,
the fluorophore does not need to possess specific properties. The diffraction limit is not
directly overcome either.
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Figure 5.10: Single Molecule Photobleaching protocol
The image is performed with a scanning confocal microscope, rendering very high
resolution. The fluorophore concentration of the sample needs to be adjusted in order to
obtain a very low surface density. If the image size and the number of pixel are correctly
adjusted, the image resolution permits to distinguish separate spots which size is close
to the diffraction limit. In this configuration, single molecules are imaged. Nevertheless,
if these molecules are in complex, many subunits are present in it. To know how many
molecules are in the complex (one or several), each spot is subjected to a high laser power
inducing bleaching of the molecule(s). Fluorescence recorded as a function of time will
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show photobleaching steps, each step corresponding to one subunit. By simply counting
the number of these bleaching steps, one can observe how many fluorophores were imaged
and thus how many subunits are associated in the observed complex. The protocol of
such an experiment is illustrated in Figure 5.10.
Unique 
Domain
SH4
GFP
Figure 5.11: Set up of the sin-
gle molecule photobleaching of
MyrUGFP bound to SLBs.
We applied single molecule photobleaching to test
the formation of membrane-induced formation of c-
Src clusters, by using eGFP as a fluorescent reporter.
eGFP was included in the myristoylated c-Src con-
struct as explained in 8.3, and the resulting molecule
was called MyrUGFP. The fluorescent construct was
bound to a supported lipid bilayer (SLB) formed by
dipalmitoylphosphatidyl choline (DPPC), and dipalmi-
toylphosphatidyl glycerol (DPPG) (supplemented with
LissRhode PE as a fluorescent probe). The associa-
tion state of MyrUGFP bound to supported lipid bilayer
(SLB) was probed using single molecule photobleaching
(Figure 5.11).
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5.4. Single Molecule Photobleaching of
MyrUGFP binding to SLBs
We used the MyrUGFP construct bound to SLBs made of DPPC:DPPG 2:1 in a single
molecule photobleaching experiment. Supported lipid bilayers (SLB) were obtained by
depositing 100 nm-liposomes on glass. After 1-h incubation of the liposomes at 45 ◦C
(DPPC and DPPG are fluid above 41 ◦C), excess lipids were rinsed and MyrUGFP was
incubated over the SLB for 30 min, at 45 ◦C. The excess protein was rinsed with 3 mL of
cold buffers. The sample was mounted in a chamber enabling imaging in buffer solution at
room temperature, in which the lipids are in gel phase, thereby limiting protein diffusion
in the bilayer.
Figure 5.12 shows a two-color image of the fluorescent SLB and bound proteins.
The protein concentration was adjusted for single molecule detection. Individual, well-
separated spots of GFP signal, randomly distributed, were identified, indicating the suc-
cessful incorporation of MyrUGFP in the SLB.
5 µM
Figure 5.12: Merge of the fluorescence
images obtained from the Liss Rhode
embedded in liposomes (red) and from
MyrUGFP (yellow)
Figure 5.13 shows a confocal image of the
fluorescence emitted by MyrUGFP after incu-
bation of 200 pM protein over the SLB. Vi-
sual inspection of the discrete fluorescent spots
in Figure 5.13 indicated a heterogeneous dis-
tribution, ranging from low (gray arrows) to
very high brightness (red arrows), with a ma-
jority of the spots having intermediate inten-
sity values (white arrows). Since brightness
is directly related to the number of molecules,
these results already suggest that incorporation
of MyrUGFP on the SLB was heterogeneous.
We used single molecule photobleaching to
accurately quantify the number of proteins per
spot. Statistics were gathered at three different
incubation concentrations, in which individual
spots could be distinguished, namely 200 pM, 500 pM and 750 pM. MyrUGFP was imaged
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Figure 5.13: Fluorescent image of MyrUGFP proteins bound to deposited liposomes, after
protein incubation at 200pM, ensuring a single molecule regime; 5*5 um area, 256 pixel
resolution. The arrows show different intensities, low (grey), medium (white) and high
(red), possibly corresponding to different numbers of molecules present in each spot.
at low power to avoid bleaching during image recording. Subsequently, a higher power
was applied to each spot to induce photobleaching. Fluorescence recorded as a function of
time showed discrete photobleaching steps, from which the number of monomers present
in a particular spot could be determined. Figure 5.14 shows examples of time traces, in
which one (Figure 5.14-A), two (Figure 5.14-B) or three (Figure 5.14-C) molecules were
bleached.
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Figure 5.14: Time resolved fluorescent traces of MyrUGFP photobleaching when the
bleached fluorescent spot is composed by A) one B) two and C) three molecules.
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Traces were classified according to the number of bleaching steps, corresponding to 1,
2, 3 or more molecules in one spot. Figure 5.15-A shows the histograms corresponding to
the classification obtained for these experimental data at the three distinct concentrations.
The number of monomers (16 % at 200 pM, 24 % at 500 pM and 12 % at 750 pM) was
lower than that of dimers (57 % at 200 pM, 46 % at 500 pM and 48 % at 750 pM) at all
concentrations. Trimers are also found (21 % at 200 pM, 24 % at 500 pM, and 28 % at
750 pM) and their number steadily increased with concentration. Spots containing four
or more molecules represented less than 6 % at 200 and 500 pM, and 12,5 % at 750 pM.
These data show that a majority of MyrUGFP species dimers was found (about 50 %)
when bound to the SLB, at all concentrations used.
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Figure 5.15: Histogram of the number of bleaching steps observed for each discrete spots at
the different concentrations A) experimental data (159 fluorescent trajectories at 200 pM,
220 at 500 pM and 115 at 750 pM) B) simulations (100 spots were simulated) C) control
on PLL (62 fluorescent trajectories).
To exclude that the oligomerized species counted in the experimental data were not
“optical dimers” (due to the probability of counting adjacent monomers as associated
species when crowding occurs at higher concentration), the experimental data were com-
pared with simulations of random distribution of particles. The experimental densities
obtained at the three concentrations and the spatial resolution of the confocal microscope
were taken into account. The experimental densities were derived by counting the density
of fluorescent spots and the experimental distribution of clusters of various stoichiometry.
Spots were convoluted to mimic a diffraction-limited sample and statistics were derived.
A majority of monomers was found, from 83 % at 200 pM to 53 % at 750 pM and a
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much lower number of dimers (from 14 % at 200 pM to 21 % at 750 pM) and trimers
(Figure 5.15-B). Expectedly, the number of higher order oligomers increased with concen-
tration. Thus, a significant deviation between the experimental data and the simulations
was found, which clearly shows that the observed dimers are “biological dimers”. To
rule out that dimers were not due to eGFP dimerization, a control was performed on
a cover slip coated with polylysine, in absence of SLB. MyrUGFP was incubated over
the polylysine surface, at concentration rendering a protein density comparable with that
of a 500 pM-SLB coated sample. A very distinct distribution of the association state of
MyrUGFP was found, as shown in Figure 5.15-C. Monomeric species were the most abun-
dant (68 %), while only 27 % of dimers and 5 % of trimers were found. This distribution
is consistent with a random deposition of monomeric particle.
A statistical test was performed to verify that the difference between the fraction
of monomers of the experimental data and of the control data was significant. The
test was repeated for the fraction of dimers. All tests were performed after adjusting a
linear model with "day" as covariate, since the data acquisitions have been repeated at
different days. Table ?? shows the resulting p-values; p-values below 0.05 indicate that
the difference between two values is statistically significant. All p-values were significant
except when comparing the dimer fractions at 750 pM; crowding effect occurring at this
high concentration probably explains this absence of statistical significance.
Table 5.1: p-value
Concentration Monomers Dimers
200 pM 9.8·10–10 7.1·10–5
500 pM 0.00017 0.036
750 pM 0.00089 0.18
Another control experiment consisted in measuring the fluorescence emission of Myr-
UGFP in solution of different concentrations, and plot a titration curve of intensity emis-
sion as a function of the concentration. Figure 5.16-B shows the corresponding plots.
The measurements were performed between 125 nM and 6 μM, including the concen-
trations used in the single molecule photobleaching experiments. To obtain data over
a larger concentration range, the fluorimeter configuration has to be set, thus the ex-
periment was repeated separately with different instrument settings, at lower and higher
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concentration ranges. Linearity was observed at very low concentrations, from 1 nM to
500 nM (Figure 5.16-A), and also at the experimental range (Figure 5.16-B, from 125 nM
to 6 μM, indicating that at these low concentrations, no association tendencies between
the molecules are observed. At much higher concentrations (Figure 5.16-C), a quenching
of the fluorescence is observed (for concentrations above 20 μM), which possibly come
from association of the molecules (GFP has a known tendency for dimerization). These
controls excluded in principle eGFP dimerization as the cause for the high percentage
of dimers formed on the SLB. MyrUGFP self-association results from its binding to the
SLB.
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Figure 5.16: Plot of MyrUGFP fluorescence emission at 210 nM as a function of the
concentration, A) from 25 nM to 6 μM, B) from 10 nM to 400 nM C) from 2 μM to
60 μM
Altogether, these data demonstrate that a dominant population of MyrUGFP proteins
persistently bound to lipid bilayers are in a dimer state, and that dimerization does not
take place in solution but is an assisted-diffusion process occurring upon lipid binding. To
further infer on the association mechanism of MyrUGFP proteins, a competition exper-
iment was designed, in which 200 pM of MyrUSH3 was added to 200 pM of MyrUGFP.
The experimental scheme is shown in Figure 5.17-A. In this experiment, both proteins
were mixed before incubation over the SLB. By adding to MyrUGFP a non fluorescent
protein, the probability of detecting monomers or dimers is expected to increase if mixed
complexes can be created between MyrUGFP and MyrUSH3. The statistics of the fluo-
rescent trajectories obtained for 200 pM MyrUGFP in presence of 200 pM MyrUSH3 was
compared with that of 200 pM of MyrUGFP alone, as shown in Figure 5.17-B. They were
significantly displaced when compared with the ones obtained in absence of MyrUSH3. A
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higher amount of monomers was found (52 % instead of 16 %), a lower amount of dimers
(42 % instead of 57 %) and a lower amount of trimers (6 % instead of 21 %). This result
first confirmed that eGFP did not promote MyrUGFP dimerization in solution. More im-
portantly, it demonstrates that the oligomers can be formed by a MyrUGFP/MyrUSH3
complex. Figure 5.17-C illustrates the different complexes that the two proteins may
form.
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Figure 5.17: A) Scheme of the two-proteins assay, in which MyrUGFP and/or MyrUSH3
are anchored to the lipid bilayer B) Histogram of the number of bleaching steps observed
for each discrete spots. The histogram compares the statistics when a protein mixture
MyrUGFP/MyrUSH3 is used or when MyrUGFP is use alone (64 trajectories) C) Scheme
of the different configurations when a protein mixture is used, in which MyrUGFP and
MyrUSH3 can form a complex of higher order species. Histograms from the simulations
in which heterogeneous population of monomers, dimers or trimers are assumed as the
starting point. Statistics of the number of D) monomers E) dimers F) oligomers.
To infer whether the observed trimers were “biological trimers”, and not optical trimers
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appearing because of the probability of having a monomer close to a trimer, simulations
were performed with the same densities as previously, but this time, a heterogeneous
population was assumed (monomers, dimers and/or trimers). Different situations were
modeled. The simulation that approached the experimental data most closely was for an
population of 25 % monomers, 70 % dimers and 5 % trimers, as shown by Figure 5.17-
D, -E and -F. Thus, the experimental trimers observed may be real trimers. Though
dimerization is found in most of the cases, complexes of 3 or more molecules are probably
also formed by MyrUGFP when bound to SLBs.
CHAPTER 5. MYRUGFP BINDING TO MONOLAYERS AND SLBS 147
5.5. Conclusion and Discussion
By using these single molecule photobleaching experiments, we found for MyrUGFP
bound to SLBs a stoichiometry deviating from the monomeric one, with a specific ca-
pacity to form dimers. In Surface Plasmon Resonance (SPR) experiments, we showed
in the previous chapter that two distinct kinetics modes of MyrUSH3 proteins binding
to liposomes exist. A dominant form has a very fast dissociation kinetics, while another
population of persistently bound species was detected, with a very long residence time.
This population is certainly the one studied in this work. The SPR data also showed that
MyrSH4 was sufficient to induce persistently bound species, and in addition, MyrSH4
was found to cluster in vivo, upon binding in the cell membrane (Owen et al., 2010).
The monolayer experiments showed that MyrSH4 is capable of forming micelles at low
concentrations, already at 500 nM. This could explain why clusters of MyrSH4, and not
dimers, are found in the above mentioned in-cell experiments. Micelle formation is not
observed in MyrUGFP, but we postulate that MyrSH4 is the promoter of the autoas-
sociation observed in MyrUGFP and that it is responsible for the stabilization of these
specific dimers. As a side comment, the fact that the MIP of MyrUGFP is in the range of
30-35 mN/m indicates that the insertion features of c-Src are probably tuned in a subtle
way.
SH4
GFP GFP
Unique Domain
Figure 5.18: Scheme of MyrUGFP
dimerized over the bilayer.
All other members of the c-Src family possess
one or two palmitoylated chains, in addition to the
myristoyl, which provides strong anchoring to mem-
brane (Leo et al., 1971). c-Src does not, and cur-
rently, the consensus view is that c-Src anchoring to
membranes is achieved by cooperative hydrophobic
and electrostatic interactions (in which the strongly
positively charged SH4 domain strongly interacts
with the negatively charged liposomes enhancing
binding). This mechanism would be compatible
with the fast dissociating species found by SPR,
for which there is no evidence of clustering phe-
nomenon. Here we find a population of dimerized
proteins with a very stable binding to the bilayer, probably via cooperative binding of two
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myristoylated chains; as for dually myristoylated and palmytoylated proteins, two fatty
acids are better than one and considerably increase the residence time of the acylated
protein over the membrane (Martin et al., 2011) (Resh, 1999). Myristoyl chain has the
minimum length to induce micelle formation, but only at high concentration (Pool and
Thompson, 1998), thereby a local concentration increase upon lipid binding could favor
this phenomenon and induce dimerization. Other myristoylated proteins are known to
form trimers upon myristoyl exposure and membrane binding (Resh, 2004).
c-Src family members are targeted to the plasma membrane, but Src is distributed
in both rafts and non rafts regions (Seong et al., 2009), while the other members of the
c-Src family, are targeted to lipid rafts because of their dual acylation (especially and
the presence of the saturated palmitoyl chain) (Martin et al., 2011). Dimer forms of c-
Src would conserve non specific targeting to membrane, providing a stably bound kinase
with a broadened distribution over the plasma membrane, possibly fine tuned by other
factors (such as lipid composition, phosphorylation events in the SH4 domain, etc). Or,
on the contrary, c-Src could be displaced to raft through dimerization, as occurs for other
species (Simons and Sampaio, 2011), and be specifically targeted to rafts in a more active
state. Transient contacts between two c-Src molecules are functionally important since
full activation of the kinase is achieved by autophosphorylation (Sun et al., 2002) (Ingley,
2008). Thereby, dimerization of two c-Src molecules, by increasing contacts, could favor
the autophosphorylation step and directly influence triggering of the signaling cascade.
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5.6. Experimental Methods
Monolayers
Monolayer Set up
The surface properties of MyrSH4 were analyzed in a NIMA (Conventry, UK)
film balance equipped with a Wilhelmy platinum plate and a round Teflon dish (surface
area 19.6 cm2, 27.2 cm3 of capacity)
The surface properties of MyrUGFP were analyzed in a rectangular teflon cu-
vette (surface area 31 cm2, 14 cm3 of capacity) equipped with a Wilhelmy filter paper
plate attached to a Kibron DeltaPi 4x balance (Kibron Inc.), controlled by the software
DeltaGraph4X 1.13 (Kibron Inc.).
MyrSH4 and MyrUGFP activity determination The Teflon trough and the plate
were thoroughly cleaned before each run with chloroform and boiling water to avoid
carryover of lipid. The cuvette was filled with the buffer (50 mM NaP, pH 7 in case of
MyrSH4, 50 mM NaP, 150 mM NaCl, pH 7.5 in case of MyrUGFP). Pressure baseline was
established and set to 0 before peptide or protein injection in the subphase. Increasing
volumes of a concentrated solution of the peptide or the protein were injected beneath the
surface through a lateral hole. During the experiments, the subphase was continuously
stirred. MyrSH4 was injected from 0.5 to 8 μM, MyrUGFP from 25 nM to 1.5 μM.
Surface pressure with time was monitored until a steady-state value was obtained, and
the equilibrium pressure Pe was recorded.
MyrSH4 and MyrUGFP MIP experiments The kinetics of peptide or protein
binding to the lipid monolayer was monitored using the same conditions as above (Teflon
through and buffer conditions). A few microliters of DMPC:DMPG 2:1 solution dissolved
in chloroform:methanol were deposited on the top of the subphase with a microsyringe;
the deposited volume was varied in order to form monolayers at the required initial pres-
sures. After 10 min of solvent evaporation, a stock solution of the peptide or protein
(in the same buffer as in the subphase) were injected in the subphase, rendering final
concentrations of 1 μM of MyrSH4 and 100 nM of MyrUGFP. The subphase was stirred
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continuously to ensure a homogeneous distribution and a good interaction of the peptide
with the monolayer. Pressure increases ΔP were recorded with time until no further
changes occurred indicating that equilibrium was reached; the equilibrium pressure Pe
was recorded. The experiment was repeated at different initial pressures Pi, which ranged
from 6 to 26 mN/m in case of MyrSH4 and from 7.5 to 30 mN/m incase of MyrUGFP.
Single molecule photobleaching
Fluorescence titration measurements MyrUGFP samples at different concentra-
tions were prepared, from 25 nM to 60 μM. Fluorescence emission was measured in a
customized fluorimeter from PTI and analyzed with the software Felix 32. Excitation
was set to 488 nm, and emission was scanned from 505 to 600 nM. Plots of fluorescence
intensity versus concentration were established by taken the fluorescence emission value at
510 nM. Titration was performed in the total concentration range by varying the aperture
of the slit (adjusting it for the different concentration ranges).
Liposome preparation Lipids were from TebuBio. 1,2-dipalmitoyl-sn-glycero-3- phos-
phocholine (DPPC) and Liss Rhode PE were dissolved in chloroform, 1,2-dipalmitoyl-
sn-glycero-3- phospho-(1’-rac-glycerol) sodium salt (DPPG) in chloroform:methanol:H2O
65:35:8. Lipids were mixed in a DPPC:DPPG 2:1 ratio, with addition of 0.015 % Liss
Rhode PE, and the solvent was evaporated in a rotavapor. Lipid film was rehydrated
with phosphate buffer by warming the lipid film at 55 ◦C and vortexing, at a final total
lipid concentration of 2 mM. Large unilamellar liposomes were prepared by mechanical
extrusion using a 10-mL Thermobarrel extruder (LipexTM. Northerns Lipids Inc.). The
lipid suspension was extruded repeatedly (10 times) through a 100 nm polycarbonate
filter at 55 ◦C. To verify the appropriate size of the liposomes, the mean diameter was
checked using Dynamic Light Scattering (Zetasizer Nanoseries S, Malvern instruments).
Liposome deposition over microscope coverslips Glass cover slips (circle cover
slip 30 mm, thickness 1, Menzel Gl´’aser) were sonicated for 15 min in 50 % ethanol, and
further cleaned for 10 min in a ozone plasma cleaner and used immediately. 200 μL of
liposomes (pre-warmed at 45 ◦C) were deposited on the cover slip and incubated for 1 h
at 45 ◦C. Liposomes were manually rinsed with 2 mL MilliQ water and 1 mL phosphate
buffer. 200 μL of MyrUGFP protein were deposited over the supported lipid bilayer (SLB)
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formed on the cover slip and incubated for 30 min at 45 ◦C. Three protein concentrations
were used (200 pM, 500 pM, 750 pM). Final wash was performed with 3 mL cold phosphate
buffer before mounting the cover slip in the chamber and covering it with 1.5 mL cold
phosphate buffer. Imaging was performed at room temperature, after 10 min incubation
at 4 ◦C (DPPC and DPPG are in the gel phase at room temperature, slowing down protein
diffusion in the bilayer). SLB homogeneity was verified by imaging the Liss Rhode PE
fluorescence.
Fluorescence microscopy Set Up All measurements were acquired using the Micro-
time200 from PicoQuant, consisting of an inverted IX73 microscope from Olympus. Exci-
tation was achieved by a picosecond pulsed diode laser LDH-P-C-470 (470 nm, 40 MHz)
for eGFP and Rhodamine-PE. Linear excitation light from the diode passed through a
λ/4 plate to obtain circular polarized light, which was focused onto the sample by a 60x
water (UPlanSApo, 1.2 NA) or oil (ApoN, 1.49 NA) immersion objective from Olympus.
Emission light from the sample was collected through the same objective and spectrally
separated from the excitation light by a dichroic (Di01-R405/488/561/635, Semrock),
passing through a 50 nm pinhole and detected by single photon counting APD (PDM
series from MPD). Emission light from eGFP and Rhodamine-PE was spectrally sepa-
rated using a dichroic (600DCRX, Semrock) and further filtered using bandpass filters
(520/35 for eGFP and 692/40 for Rhodamine-PE).Images were acquired by scanning the
sample over the objective, using a computer controlled 2-dimensional XY piezo stage
from Physics Instruments (P-733) with sub-nanometer resolution. A PIFOC system from
Physics Instrument ensured that the changes in focus (z) were minimal.
Image acquisition For single molecule photobleaching measurements, a 256 x 256 pix-
els image corresponding to a 5 x 5 μm area of the sample was acquired at a 300 W/cm2
excitation power density (after the objective) and 1 ms integration time. Regions that
show signal were then selected for acquisition of photobleaching traces. Intensity trajec-
tories over time were then recorded on these spots using 1 Kw/cm2 of excitation power
density.
Statistical analysis Data was fitted with a generalized linear model using the date of
experiment as covariable. In order to fit a model to the proportion of monomers (dimers)
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of controls and the various concentrations we used the function "glm" from the R statistical
language (Team, 2015) with the binomial family and logit link function. P-value for the
effect of the concentration variable was calculated with a Χ-square test using the “drop1"
function in R. Individual p-values for the comparison of concentrations vs the two controls
were computed through a wald-test (function “wald.test" in the “aod" package (M and
R., 2012) in R).
Simulation parameters The protein density used in the simulations was derived from
ten images recorded at 200 pM. The number of spots was manually counted and an aver-
age of the total number from the different images was used. This number was corrected
with the experimental statistics of the multimeric species, and the final density was de-
duced. Linear concentration dependence was assumed to calculate the density at the
higher concentrations (this assumption is justified by surface plasmon resonance experi-
ments in which binding of MyrUSH3 at different concentrations was recorded and specific
detection of the bound proteins followed a linear trend in the low concentration range).
Table 5.2: Densities
concentration (pM) 200 500 750
average (/μm2) 3.12 7.8 11.7
Chapter 6
NMR study
6.1. NMR for biomolecules
Very few techniques allow for protein structure determination with atomic resolution.
X-ray crystallography is the most widely used, but is limited to the study of proteins that
have been crystallized, which does not occur with IDPs. Nuclear Magnetic Resonance is
the other technique; it has the potential to study the structure, but also the dynamics,
of proteins of limited size, when they can be sufficiently concentrated. It is thus perfectly
suitable for the study of small and partially disordered myristoyl constructs of c-Src.
NMR is based on the existence of a nuclear spin angular momentum, giving rise to
a nuclear spin quantum number I. I can be equal to 0, 1/2, 1, 2, etc. If I is different
from zero, the nucleus possesses a nuclear magnetic moment μ. Spins 1/2 nuclei are
especially convenient for NMR, and the most used are 1H, 13C, 15N, 19F and 51P. Their
nuclei in a magnetic field (B0) present only two states with different energy, corresponding
to magnetic moments of opposite orientation. The energy difference results in different
populations of the two states and a in small bulk magnetization. B0 is usually very intense
and its direction represent the longitudinal (z) direction (Cavanagh et al., 2007).
The existence of this bulk magnetization, M = Mo · z, parallel to B0, is exploited in
NMR spectroscopy. M can be perturbed by applying a radio frequency (rf) pulse at a
suitable frequency, corresponding to the energy level difference between the two spin states
of the nucleus (thus it is different for different nucleus types), which induces magnetic
resonance of the nuclei; in the simplest examples, M is moved to a plane perpendicular to
B0. After the pulse, M will relax back to the Boltzman equilibrium by precessing around
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B0 at the Larmor frequency ω0. This time dependent magnetization induces an electric
current, which is measured as a Free Induction Decay (FID). Nevertheless, each nuclei,
even of the same type is surrounded by different electronic environments. The electronic
cloud has a shielding effect in which it slightly modifies the resonance frequency of each
specific nucleus, by creating a specific local magnetic field different for each of them. This
so-called chemical shift enables to distinguish between each nucleus within a molecule,
since each nucleus will resonate at a specific frequency. The time domain FID of a nucleus
is Fourier transformed to obtain its specific resonance frequency peak which will have with
a certain linewidth.
Relaxation is described by two processes. First, the spin-lattice relaxation R1 comes
from the interactions of the spin with the environment; it is also called longitudinal re-
laxation time T1 =1/R1, since it measures how fast the magnetization relaxes back along
the z-axis. Second, the spin-spin relaxation R2 comes from the interactions between the
adjacent spins; it is also called transverse relaxation time T2=1/R2, since it measured
how fast the spins loose coherence in the transverse plane (Cavanagh et al., 2007) (James,
1998). Relaxation occurs though various processes. All of them require fluctuating in-
teractions at specific frequencies related to the existing energy between spin levels. The
most important interactions are dipole dipole and chemical shift anisotropy. Longitudinal
relaxation influences the rate at which experiments can be repeated. Repeated excitation
may result in decreased population differences between spin states (or even equalize them
at saturation), and therefore lower sensibility. Transverse relaxation is directly related to
the line width. Fast R2 results in broad lines. Since the peak integral is constant, broad
lines have lower intensities and can even disappear in the noise level. Dynamic properties
have a strong influence in relaxation. In the case of transverse relaxation, slowly rotat-
ing molecules relax slowly and give broad lines, while small, fast reorienting molecules
give sharp lines. Longitudinal relaxation rate also increase when the molecules tumble
slower but a minimum is reached after which relaxation rates decrease. Thus very large
molecules suffer from broad lines and easy saturation setting a limit to the size of proteins
that can be studies in solution. Temperature is an important parameters since tempera-
ture increase will enhance molecular dynamics. Some of the barriers can be overcome by
solid state NMR methods.
Some nuclei may be submitted to more than one chemical environment, for instance if
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intramolecular interactions occur within a molecule, or if an interacting parter is present
in solution. Two different chemical environments will result in two resonance frequencies.
If a nucleus is in exchange between two environments, the shape of the spectrum will
depend on the exchange rate. If the exchange is slow, two peaks will be observed. If the
exchange is fast, a chemical shift corresponding to a weighted average of both frequencies
will be observed. In intermediate situations, broadening and eventual coalescence of the
peaks is observed (James, 1998). Figure 6.1 illustrates the effect of chemical exchange on
the spectral shape.
Fast exchange
Slow exchange
Intermediate
Figure 6.1: Chemical Exchange affects the
chemical shift of a nuclei according to the ex-
change rate, as explained in the text. Figure
from Bain (2003)
In order to obtain information from
NMR spectroscopy, sequences of rf pulses
are used, in order to measure the de-
sired parameters. For protein NMR, one-
dimensional spectra, in which only the res-
onance frequencies of the protons are mea-
sured, are not sufficient to characterize and
differentiate all the nuclei in a molecule.
Multidimensional NMR was developed and
enabled to enlarge NMR spectroscopy to
molecules above 10 kDa. There are sev-
eral NMR experiments that enable to con-
nect the resonance frequencies of directly
bonded atoms. The main experiments use
1H-13C and 1H-15N coupling. In order to
perform such experiments, the protein ex-
pression medium needs to be enriched in either 15N or 13C isotopes because of their low
natural abundance. Several pulse sequences exist, the most common ones being HSQC
(Heteronuclear Single Quantum Correlation) and HMQC (Heteronuclear Multiple Quan-
tum Correlation). The pulse sequence of 2D experiments includes four steps. A “prepa-
ration phase”, in which the proton is allowed to relax – in HSQC or HMQC experiments,
the polarization of the proton is transfered to the other nuclei (15N or 13C). The labeling,
in which the evolution of the magnetization is followed during a time a time t1. Then
comes the mixing, in which another group of pulses results in transfer of the magnetiza-
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tion – in HSQC or HMQC, magnetization is transfered to the adjacent bonded atom (15N
or 13C) via J coupling. The FID of the proton is subsequently measured during a time
t2. The experiment needs to be repeated by varying t1, which means that many scans
are needed to perform this experiment. Only the chemical shifts of the bonded atoms
give a cross peak in the 2D spectra, which contains 1H frequencies on one axis and the
other atom frequencies (15N or 13C) on the other axis (Vasavi et al., 2011). In case of
15N-1H correlation spectra, one peak is obtained for each backbone amide proton, so one
peak corresponds to one residue (except for proline). The 15N-1H spectrum constitutes
a fingerprint of a protein at the atomic level. The disordered state of a protein can be
assessed in such a spectrum. If all amino acids are exposed to a similar environment, it
will result in a poor signal dispersion in the spectrum, which is the “signature” spectrum
of an IDP. If alpha helix or beta sheets are present, the local environment of the different
residues will vary more and give rise to a more dispersed spectrum (Kwan et al., 2011),
typical of folded molecules.
These techniques are intrinsically time consuming since they require a large num-
ber of scans. New pulse sequences have been developed and optimized to decrease the
experimental time. In this study, we used 15N-1H SOFAST-HMQC ( (band-Selective
Optimized-Flip-Angle Short Transient-HMQC) (Schandaa et al., 2005).
Individual crosspeaks can be traced to a specific protein residue. Changing the envi-
ronment of the protein will result in changes in chemical shift positions and/or broadening
of the resonance peak (also noticed in the change of the peak intensity). By comparing
a reference spectrum of the protein with a spectrum of interest (for instance when an
interacting partner is added), intra or intermolecular interactions can be followed, as
illustrated in Figure 6.2 B.
Here, USrc and SH3 assignments have been previously reported (Pérez et al., 2013)
(Maffei et al., 2015). Therefore, the intramolecular interactions induced by the presence of
the myristoyl tail can be studied by comparing the spectra of the myristoylated and non-
myristoylated form. 15N-1H spectra of MyrUSrc and MyrUSH3 constructs were acquired
with 15N-1H SOFAST-HMQC pulse sequences. Since c-Src resides at the membrane
interface, the spectra were also acquired in presence of lipids. Lipid interactions of non-
myristoylated constructs had been previously studied by adding high concentrations of
DHPC:DMPG bicelles, thus for consistency reasons, we kept this lipid system in the non-
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myristoylated forms. In case of myristoylated proteins we used liposomes composed of
DOPC or DOPC:DOPG, for which the transition temperature is very low, ensuring that
even at 4 ◦C , they remain in a fluid state to allow diffusion of the anchored protein in
the bilayer. Figure 6.2 gives a scheme of the different measurements performed. Effect of
the myristoylation was studied by comparing the spectra of of the protein in absence or
in presence of myristoyl. Effect of lipid binding was studied by comparing the spectra of
the myristoylated protein in absence or in presence of liposomes.
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Figure 6.2: A) Main samples measured in this study: USH3, MyrUSH3,
MyrUSH3+liposomes B) Possible effect on the chemical shifts of the protein residues in-
volved in intra or intermolecular interactions: changes in chemical shift and/or increase
or decrease in the instensity
Changes in the chemical shifts position or intensity could be observed in presence of
the myristoyl tail, and upon liposome addition. These experiments shed light on the weak
interactions features, either intramolecular or intermolecular, in presence of the myristoyl
tail.
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6.2. NMR study of MyrUSrc
6.2.1. MyrUSrc in solution
15N labeled MyrUSrc was obtained by the in-vitro purification method. Figure 6.3
shows the SOFAST-HMQC spectra of MyrUSrc, compared with that of USrc. The 1H-
15N 2D spectrum of MyrUSrc was measured at two concentrations, 150 μM and 400 μM.
The spectrum could be compared with that of USrc. 1H-15N USrc spectrum had been
previously assigned, however the signals from the first three residues were not visible.
Glycine 2 is in its free amino acid form. The other two residues may be absent due to
solvent exchange or because they are involved in some conformational exchange processes.
In case of MyrUSrc, the three missing signals were visible. There were few chemical shifts
changes between the non-myristoylated and the myristoylated form of USrc, however, the
changes in intensity were more significant. Intensity changes in SOFAST-HMQC spectra
can originate from two effects. A decrease in intensity, as in other NMR experiments, may
reflect signal broadening caused by a shorter T2 (related to an increase in correlation time
or chemical exchange in an intermediate time-scale). An increase in intensity may be the
result of shortening of T1, which can only originate from an increase in the local correlation
time. SOFAST-HMQC experiments are recorded under steady state conditions due to the
fast pulse rate. The intensity of the signal depends on the balance between saturation
(caused by fast pulsing) and relaxation. Under identical experimental conditions, faster
relaxation (T1) will lead to stronger steady state signals.
Quantifying the changes in intensity of different samples implies that the spectra have
to be normalized. The choice of the normalization signal is somewhat arbitrary. We chose
residue A79, near the C-terminal extreme, opposite to the myristoylation site.
Figure 6.4 displays the differences in intensity between MyrUSrc (150μM) and USrc.
The increase in intensity of the signals in all residues up to the ULBR suggested a confor-
mational restriction induced by the presence of the myristoyl tail. The restriction seemed
to affect all the N-terminal amino acids until the ULBR, pointing out that the myristoyl
tail may be interacting with this region; since the ULBR has a lipid binding propensity
and possesses hydrophobic amino acids, its interaction with the myristoyl tail could be
favored and minimize the contacts of the tail with water.
Figure 6.4 plots the differences in intensity between MyrUSrc measured at the two con-
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Figure 6.3: A) 1H 15N spectra of MyrUSrc (red), compared with that of USrc (grey)
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Figure 6.4: Normalized Intensity values of MyrUSrc, 150μM, subtracted from Normalized
Intensity values of USrc.
centrations. Increasing the concentration provoked a general effect on the protein, since
the subtracted intensities were all negative, indicating that some intermolecular interac-
tions are occurring. The SH4 region was most affected, suggesting that the global effect
on the whole protein was mediated by intermolecular interactions in the SH4 domain.
6.2.2. MyrUSrc bound to liposomes
DOPC liposomes Liposomes were added to MyrUSrc in a 67 fold excess (75 μM of
MyrUSrc, 5 mM of lipids). Binding of MyrUSrc to liposomes was first recorded in the
case of zwitterionic liposomes composed of DOPC. The spectrum obtained in presence of
neutral liposomes was compared with that of MyrUSrc in solution. Here again, changes
in the intensity were more important than chemical shifts. Figure 6.6 represents the
difference in intensity of MyrUSrc bound to DOPC liposomes and MyrUSrc in solution.
Expectedly, two main regions were perturbed by the presence of neutral lipids: the SH4
region and the ULBR region. The SH4 is most probably perturbed because of the myris-
toyl insertion (in the non myristoylated form, the SH4 region was hardly perturbed by
CHAPTER 6. NMR STUDY 161
In
te
ns
ity
 ch
an
ge
 (a
u)
−0
.8
−0
.6
−0
.4
−0
.2
0.
0
0.
2
SH4 ULBR
MyrUSrc 400uM - MyrUSrc 150uM
In
te
ns
ity
 c
ha
ng
e 
(a
u)
 -0
.8
   
   
   
   
 -0
.6
   
   
   
   
  -
0.
4 
   
   
   
   
-0
.2
   
   
   
   
   
0.
0 
   
   
   
   
   
0.
2 
   
   
 
Figure 6.5: Normalized Intensity values of MyrUSrc, 400μM, subtracted from Normalized
Intensity values of MyrUSrc, 150μM.
addition of DMPC:DHPC bicelles (Pérez et al., 2013)). As in the non-myristoylated form,
the ULBR was also perturbed, confirming its affinity for lipids. Hydrophobic amino acids
were mainly affected, such as L62, F63, F67. In this experiment, the concentration of
lipids used was much lower than the one used in the USrc-bicelles experiments (Pérez
et al., 2013), highlighting the fact that ULBR interaction was facilitated in presence of
the primary myristoyl anchor point. A third region was found to be slightly influenced
by the presence of liposomes, especially K40.
DOPC:DOPG liposomes The experiment was then repeated in presence of nega-
tively charged liposomes composed of DOPC:DOPG 3:1, in the same lipid:protein ratio.
Figure 6.7 compares MyrUSrc bound to DOPC:DOPG liposomes with MyrUSrc.
The same regions as for neutral liposomes were interacting, but as expected, the
strengths of the binding of both the SH4 and the ULBR increased with the presence of
negative charges in the liposomes. Chemical shift perturbation were higher in the SH4
domain in case of charged liposomes; the 6 charged residues, 3 lysines and 3 arginines
interact electrostatically with the negatively charged lipids. In the case of the ULBR, the
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Figure 6.6: (Normalized Intensity values of MyrUSrc, bound to DOPC liposomes sub-
tracted from Normalized Intensity values of MyrUSrc in solution.
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chemical shift perturbations are also stronger than in absence of charges. The additional
electrostatic effect was also visible since positively charged or polar amino acids (K63 and
S68 were more affected than F64 and F67).
The third region, from amino acids 34 to 40, is composed of mainly polar and positively
charged amino acids, and also interacted stronger in case of DOPC:DOPG (in particular
A34 and S35 appeared to be affected). The importance of this binding still needs to be
investigated; it is interesting to note that two serine are present in this region, S35 and
S39, just at the side of a lysine (K40).
Interestingly, while the residues perturbed by neutral lipids were in good agreement
with the boundaries of the SH4 domain, in the case of charged liposomes the interaction
extended up to at least residues 25. The streptag region also displays some interactions
with lipids in MyrUSrc bound to neutral or charged liposomes.
DOPC:PI(3,4,5)P3 liposomes Experiments were also conducted with another lipo-
some type, namely by supplementing short chains C8-PI(3,4,5)P3 to the DOPC liposomes
and conserving the same protein lipid proportions, 75 μM MyrUSrc, 5 mM lipids. Since
C8-PI(3,4,5)P3 are soluble, they were incubated at room temperature to the DOPC lipo-
somes, assuming that they would insert into their outer layer. Spectra of MyrUSrc bound
to DOPC:PI(3,4,5)P3 liposomes were recorded, and a titration was performed in which
the liposomes were doped with increasing concentrations of PI(3,4,5)P3 (40, 80, 160, and
330μM). It is not obvious to evaluate the net charge of PI(3,4,5)P3; Zheng Li et al. (2000)
have estimated it to 6 positive charges at pH 7.
Figure 6.8: A) C8-PI(3,4,5)P3
Figure 6.9 shows the difference in intensity
of NMR signals between MyrUSrc bound to
DOPC:PI(3,4,5)P3 liposomes and MyrUSrc in
solution. The plot shows the comparison when
using DOPC liposomes supplemented with 80
μM PI(3,4,5)P3. It gives a total amount of neg-
ative charges in the same order of magnitude of
that used in DOPC:DOPG 3:1 liposomes (DOPG has only one negative charge), how-
ever the local charge distribution will be very different in case of DOPG or PI(3,4,5)P3
liposomes. Figure 6.8 gives the chemical structure of PI(3,4,5)P3.
In a similar way as with DOPC:DOPG liposomes, the SH4 region was affected by
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myristoyl insertion and electrostatic attraction between the positively charged residues
and the negatively charged lipids. The third region, from amino acids 34 to 40, also in-
teracted in a very similar way that in case of DOPC:DOPG. However, the ULBR region
displayed only a moderate interaction with liposomes, in which charged amino acids are
not involved so much in the binding (A58 and 59, F64 and S69 were mostly affected). Sur-
prisingly, the effect resembled more the one observed with DOPC than with DOPC:DOPG
liposomes. The higher charge density in PI(3,4,5)P3 may favor the interaction with the
highly charged SH4 domain. In addition, adequate separation of the charged amino acids
within a polybasic peptide may facilitate binding of densely negatively charged lipids Li
et al. (2014) Hansen et al. (2011) such as PI(3,4,5)P3. This may result in PIP(3,4,5)PI
recruitment around this domain in a synergistic effect. PI(3,4,5)P3 clustering at the SH4
domain would deplete the rest of the bilayer from charged groups. This results point
our the differential effect of the charge density in the bilayer; though both DMPG and
PI(3,4,5)P3 are negatively charged, the binding of the ULBR to bilayers containing one
or the other was different.
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Figure 6.9: Normalized intensity values of MyrUSrc bound to DOPC-PI(3,4,5)P3 lipo-
somes subtracted from normalized intensity values of MyrUSrc in solution.
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Figure 6.10 shows the effect of MyrUSrc binding to DOPC liposomes when increasing
concentrations of PI(3,4,5)P3 were used. The figure focuses in the two affected regions,
the SH4 and ULBR domains, and shows (as in the previous plot) the differences in NMR
signal intensities between the protein bound to liposomes and the protein in solution.
In the SH4 region, an increase in the PI(3,4,5)P3 concentration resulted in increasingly
perturbed amino acids, though the extent of perturbation was already very high at the
lowest concentration used (40μM). Interestingly, as observed with the DOPC:DOPG li-
posomes, the perturbations extended up to residue 25 (A22 and E23); these residues were
mostly sensing the increase in PIP(3,4,5)P3 concentration, probably indicating increasing
electrostatic repulsion between E23 and the negatively charged PI(3,4,5)P3. In the ULBR
region, the effect of increasing the PIP(3,4,5)P3 was very subtle; increasing concentrations
of PI(3,4,5)P3 did not result systematically in increased perturbations of the residues in
the ULBR.
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Figure 6.10: Normalized intensity values of MyrUSrc bound to DOPC:PI(3,4,5)P3 lipo-
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These results point out the complexity of the modulation of ULBR binding to lipid
bilayers of different types and concentrations.
Our USrc and MyrUSrc constructs possess a N-terminal Streptag for purification pur-
poses, and these spectra also revealed that the Streptag had some affinity for lipids. This
might favor the binding of USrc to lipids; but since the natural form contains the SH3
domain just after USrc (SH3 also has some affinity for lipids), it could also “represent”
an additional lipid binding region present in the natural form. Nevertheless, optimization
of the expression conditions of MyrUSH3 in minimum medium enabled to further study
the MyrUSH3 construct by NMR.
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6.3. NMR study of MyrUSH3
15N-labeled MyrUSH3 and MyrUSH3A3 were obtained by the coexpression methods.
The MyrUSH3 construct contained a HisTag situated after the folded SH3 domain. In
this construct, the influence of the tag is expected to be much smaller than the StrepTag
in the case of USrc. The non-myristoylated forms of USH3 did not contain the histidine
tail, since they came from expression and purification of a construct with a N-terminal
GST-HisTag. The two tags were enzymatically removed. This construct was not adequate
to obtain proteins myristoylated at the N-terminal glycine. Thus, all reference spectra
were measured again in order to serve as a reference. Spectra of the mutant forms in the
ULBR region (USH3A3) and in the RT loop of the SH3 domain (USH3IHH) were also
recorded, in order to study the effect of removing one of this region. USH3IHH could
not be obtained in its myristoylated form due to fast sample degradation. Table 6.1
lists the proteins from which 2D-spectra were recorded. In the case of myristoylated
constructs, spectra were recorded in absence or presence of DOPC:DOPCG 3:1 liposomes
(at 5 mM lipid concentration). In the case of non-myristoylated constructs, the spectra
were recorded in absence or presence of DMPC:DHPC 0.8:1 bicelles.
Table 6.1: List of USH3 related constructs measured by NMR
Protein Bilayer Model
USH3 A2G
MyrUSH3 WT DOPC:DOPG 3:1 liposomes
USH3A3 A2G
MyrUSH3A3 DOPC:DOPG 3:1 liposomes
USH3IHH A2G DMPC:DHPC 0.8:1 bicelles
SH3
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6.3.1. MyrUSH3 in solution
Figure 6.11 displays the combined 1H-15N chemical shift differences between MyrUSH3
and USH3. Chemical shift perturbations (CSPs) were observed in the N-terminal region,
mainly affecting serine 6 and lysine 7. Similar perturbations were also observed when
comparing MyrUSrc versus USrc (Figure 6.12). Thus, they were most probably due to
the local effect of myristoylation. Moreover, in USH3, additional changes were observed
in the entire SH4 domain and also in the SH3 domain. The changes in K5 and S6 could
not be monitored, since they were already affected by myristoylation. In the nSrc loop,
no important chemical shift changes were observed, except for V114. The chemical shifts
corresponding to V114 in MyrUSH3 are represented in Figure 6.15 and compared with
the position of V114 in SH3 (a non interacting situation). In all constructs, V114 was
interacting, since its chemical shift was displaced from its non-interacting position in SH3.
In addition, in MyrUSH3, V114 showed two signals indicating a slow exchange between
two conformations. The “closed” conformation of USH3 coming from the interactions
between the SH4 and SH3 domains (Maffei et al., 2015) was thus probably retained in the
myristoylated form, nevertheless, the splitting of V114 may indicate that the nSrc loop is
affected by the presence of the myristoyl group bound to the SH4 domain.
The ULBR itself was not affected by the presence of the myristoyl chain, in contrast
with what was observed for MyrUSrc in solution. The interaction of the SH4 domain and
myristoyl group with the SH3 domain probably prevents or competes with the interaction
of the myristoyl group with the ULBR.
The region most affected by the presence of the myristoyl was situated in the RT loop
of the SH3 domain, as shown in Figure 6.11. Five amino acids in this region showed
split signals (R98, T99, T101, D102 and L103), meaning that they were in slow exchange
between two different states. At least one of them involved the myristoyl group. The most
affected residues were R98, T99 and T101. This region was also found to be responsible
for Unique/SH3 domains interactions (amino acids A55, E60 and K62 were affected in the
ULBR, and R98 and D102 in the RT loop). The absence of perturbation in the ULBR
suggested that the interaction was partially retained in the myristoylated form.
A similar comparison was conducted with MyrUSH3A3. Figure 6.13 A displays the
CSP between MyrUSH3A3 and USH3A3 (the amino acids corresponding to the ULBR
are absent of the plot). Here again, the entire SH4 domain was perturbed by the presence
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Figure 6.11: Chemical shifts changes between MyrUSH3 and USH3 A2G, both in solution.
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of the myristoyl tail, with S6 and K7 most affected by the acyl chain addition. The other
perturbed region was situated in the RT loop, as for the wild type, at residues R98, T99,
T101 and D102. However, only one peak per residue was observed in this case, which
means that the species having the RT loop interacting with the myristoyl group dominate
in absence of the ULBR.
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Figure 6.13: Chemical shifts changes between MyrUSH3A3 and USH3A3 A2G, both in
solution.
6.3.2. MyrUSH3 bound to liposomes
Figure 6.14 shows the chemical shift changes between MyrUSH3 bound to liposomes
and MyrUSH3 in solution.
As expected, the most affected region was the SH4 regions. Interestingly, arginines
(R14, R15 and R16) were more affected that lysines (K5, K7 and K9). Surprisingly, the
ULBR was only very slightly affected, indicating a very low interaction with liposomes
in the conditions used. Since S6 and K5 were not substantially affected by the addition
of liposomes, we can conclude that the SH3/SH4 interactions were retained in this case
as well. The splitting observed in V114 almost disappeared (See Figure 6.15), probably
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Figure 6.14: Chemical shifts changes between MyrUSH3 bound to liposomes and MyrUSH3
in solution.
indicating that the nSrc loop was affected in a much less extent by the myristoyl group,
since the latter is inserted in the bilayer. Still, the position of V114 did not come back to
the non-interacting position, therefore indicating that the “closed” USH3 configuration,
involving the interaction of the SH4 domain with the nSrc loop of SH3 was also probably
retained in the liposome bound form.
The residues in the RT loop are affected as well by the addition of liposomes. However,
this is interpreted as a loss of the intramolecular interactions with the myristoyl group,
rather than a new intermolecular interaction of the RT loop with the added lipids. The
position of the RT loop signals in the presence of liposomes is identical to that observed
in USH3 in absence of lipids. A detailed analysis of the CSPs in the RT loop is conducted
in part 6.3.3
6.3.3. Study of the RT loop
IHH mutant A mutant in the RT loop was designed; amino acids RTE were replaced
by IHH, a naturally occurring sequence in the SH3 domain of Hck – the RT loop in Hck
has a higher flexibility than in c-Src (Arold et al., 1998). USH3IHH was compared with
the wild type form. Changes in the SH3 region involved only the mutated residues. No
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Figure 6.15: Detail of the chemical shift corresponding to residue V114 in the different
constructs; red: USH3 construct of interest, grey: SH3.
chemical shift changes were observed in the Unique Domain, however changes in intensity
in the Unique Domain were observed in certain residues, as shown in Figure 6.16.
In wild type USH3, residues A55, E60 and K62 were involved in the Unique/RT
loop interaction (Maffei et al., 2015). Here we observed changes in intensity in related
amino acids, A53, E60 and K62. Additional residues were affected, before (F32, S43) and
after (F64). This results confirmed that upon mutations in the RT loop, amino acids in
the ULBR were affected, as already observed indirectly in the wild type forms (Maffei
et al., 2015). The myristoylated mutant would provide valuable additional information
on the interplay between the myristoyl tail, the ULBR and the RT loop, but could not
be produced due to fast degradation following myristoylation.
USH3IHH was subsequently measured in presence of DMPG:DHPC 0.8:1 bicelles.
Here again, we observed interactions between the SH4 or the ULBR domain and lipids
(as in others non-myristoylated forms in similar conditions). No significant binding by
the SH3 domain was found, consistent with the location of the SH3 lipid binding site of
c-Src in the RT loop.
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Figure 6.17: Chemical shifts changes between USH3IHH+bicelles and USH3IHH)
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RT loop interactions As described earlier, the signals from the residues in the RT
loop of the SH3 domain were split, only in the case of MyrUSH3 in solution. This
phenomenon did not occur when the MyrUSH3A3 mutant was in solution, neither when
liposomes were added to the wild type or the mutant forms. A study of the chemical
shifts of these residues showed how their environment changes under various conditions.
To understand whether the observed CSPs were explained by interactions of the RT
loop with other partners, the positions needed to be compared to a situation in which
there were no interactions. The SH3 domain was actually the reference in which the RT
loop is not interacting with anyone. Figure 6.18 to 6.22 gives the detailed position of the
chemical shifts corresponding to the different amino acids in the RT loop of the different
constructs. In all figures, the reference position of the SH3 spectrum is displayed in grey,
and the chemical shifts of the other species are in red. We label as position 1 the location
of the chemical shifts observed in the isolated SH3 domain, corresponding to a lack of
interaction.
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Figure 6.18: Detail of the chemical shift corresponding to residue R98 in the different
constructs; red: USH3 construct of interest, grey: SH3.
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Figure 6.19: Detail of the chemical shift corresponding to residue T99 in the different
constructs; red: USH3 construct of interest, grey: SH3.
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Figure 6.20: Detail of the chemical shift corresponding to residue T101 in the different
constructs; red: USH3 construct of interest, grey: SH3.
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Figure 6.21: Detail of the chemical shift corresponding to residue D102 in the different
constructs; red: USH3 construct of interest, grey: SH3.
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Figure 6.22: Detail of the chemical shift corresponding to residue L103 in the different
constructs; red: USH3 construct of interest, grey: SH3.
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The first observation was that in myristoylated forms bound to liposomes, signals from
residues in the RT loop were always in position 1, thus they were not interacting. The
capacity if the RT loop to interact with lipids observed in the non-myristoylated form
(CSP of T99 and D102) was “lost” when the myristoyl group at the N-terminus of the
molecule was inserted in the lipid bilayer. This is probably caused by the SH3 domain
being forced in an orientation with respect to the lipid membrane that prevents the RT
domain to interact with it.
Secondly, when MyrUSH3 was in solution, all amino acids of the RT loop were in
slow exchange between position 1 and a second position (2). Position 2 was also found
when the ULBR was removed, in the MyrUSH3A3 construct. This result suggests that
the RT loop is interacting with both the myristoyl group and the Unique domain in the
wild-type constructs, but that in the absence of the ULBR only the interaction with the
myristoyl tail is retained. Indeed, in USH3, signals from residues D102 and L103 were
found in a position close to position 2, corresponding to a situation in which the RT loop
was exclusively interacting with the ULBR since the acyl chain was absent.
In order to provide an overview of the different positions of the residues in the RT
loop, Table 6.23 summarizes the positions in the different USH3. The table contains the
positions in absence or presence of the myristoyl group, of the ULBR or of lipids. V114
from the nSrc loop is also included.
Hoja1
Página 1
R98 T99 T101 D102 L103 V114
USH3 H6 WT - - + 2' 1 1''' 2' 2' 2 – 3
USH3 H6 A3 - - - 2' 1 1''' 2' 2' 2 – 3
MyrUSH3 H6 WT - + + 1+2 1'+2 1'+2 (1+) 2 1'+2 2+3
MyrUSH3 H6 A3 - + - 2 1 – 2 2(1') 2 1 – 2 2 – 3
+ - + 1'' 2 1' 2' 1' 2 – 3
+ - - 1'' 2 1'' 2'' 1'' 2 – 3
+ + + 1 – 2 1 1 1+2 1 2(+3)
+ + - 1 – 2 1 1 1(+2) 1 2
SH3 1 1 1 1 1 1
Construct Lipid Myr ULBR
Position
USH3 WT H6 + bicelles
USH3 A3 + bicelles 
MyrUSH3 H6 WT + 
liposomes
MyrUSH3 H6 A3 + 
liposomes
Figure 6.23: Summary of the positions of the different amino acids in the RT loop in the
different constructs, and in V114 in the nSrc loop.
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The interaction between the RT loop and the Unique domain is not directly abol-
ished by the MyrUSH3AAA mutation in the ULBR. The interaction was observed in the
non-myristoylated USH3AAA mutant. However, the differences observed between the
wild type and mutant in the myristoylated USH3 constructs suggests that the interaction
between the Unique and the SH3 domains is perturbed in the AAA mutant. As a conse-
quence, the chemical shifts observed in the AAA mutant reflect simply the interaction of
the RT loop with the myristoyl group.
This simple two-state switching model between alternative positions associated to the
positions labeled 1 and 2 is clearly an oversimplification and the real situation is more
complex. Additional chemical shift positions were observed (some residues adopt positions
that significantly differed from positions 1 or 2). Often, the positions were close but not
identical to positions 1 or 2; the positions slightly differing from the actual reference
positions 1 or 2 are indicated by a “prime” or a “double prime” mark in the table. Also,
not all residues within the RT loop are directly sensing the interaction as changes in
chemical shift: T99 and T101 were in position 1 in the non-myristoylated forms of USH3.
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6.4. Conclusion and Discussion
1H-15N-2D spectra of MyrUSrc, MyrUSH3 and MyrUSH3A3 were recorded in solution
and compared to those of the non myristoylated proteins. The presence of the myristoyl
tail permitted to visualize the first three residues of the N-terminal; since they are not
visible in the non- myristoylated construct, the effect of myristoylation on these residues
can not be assessed. The N-terminal residues S6 and K7 were mostly affected by myris-
toylation. In absence and presence of the SH3, the changes observed in the myristoylated
forms revealed that the myristoylated proteins remained soluble but adopted a different
conformation in presence of the acyl chain. In MyrUSrc, the myristoyl group may interact
with the slightly hydrophobic ULBR region. In case of MyrUSH3, it may interact with
the RT loop. Many myristoylated proteins possess a hydrophobic pocket, and presence
of a myristoyl binding pocket has been suggested for c-Src by Cowan-Jacob et al. (2005)
– though the binding site was not found until now (Patwardhan and Resh, 2010). Our
results indicate that the N-terminal myristoyl group interacts with the RT loop.
c-Src is mostly anchored to membranes in cells, however, the behavior of its soluble
form gives insight on the propensities of the different regions of the USH3 to undergo intra
or intermolecular interactions and on how the presence of the myristoyl tail influences
them. In addition, as pointed out in the introduction, soluble pools of c-Src have been
observed in cells, so the observed conformations may be biologically relevant. In summary:
• MyrUSrc has been measured at two concentrations and most of the differences were
visible in the SH4 domain, indicating possibly intermolecular interactions through
this domain. This result is compatible with the observed dimerization of several
myristoyl constructs upon binding to lipid bilayers, as studied in the previous parts.
MyrSH4 may be the promoter for intermolecular interactions.
• The “closed” conformation through the SH3/SH4 interaction is retained in pres-
ence of the myristoyl since no changes have been found between the myristoylated
or non-myristoylated forms in the regions that are known to be reporting on this
particular interaction. This result is also compatible with the experiments in which
MyrUSH3 was separated from its degraded form using SEC at low pH which indi-
cate that MyrUSH3 has probably an even more restricted conformation in presence
of myristoyl.
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• In the MyrUSH3 construct, the RT loop was found to interact with the myristoyl
tail, as well as with the Unique domain; in the myristoylated form, the RT/Unique
domain interaction is at least partially retained. In case of the MyrUSH3A3 mutant,
the RT loop appears to interact almost only with the myristoyl group.
• The ULBR constituted the cleavage point observed when myristoylation-dependent
degradation occurs. The forced conformation induced by the intramolecular inter-
actions of the myristoyl tail with the ULBR (observed mainly in the absence of
the SH3 domain), or with the RT loop when the SH3 domain is present, probably
plays a role in the cleavage propensity. Interestingly, the USH3IHH mutant showed
more extensive degradation than the wild type when it was myristoylated. Since in
this mutant, the modified RT loop has lost its capacity to interact with the Unique
domain, the interaction between the myristoyl group and the RT loop in wild-type
c-Src may in fact decrease the degradation process. This raises the intriguing hy-
pothesis that modulation of the interaction between the SH3 and Unique domains
may affect the protein life-time under physiological conditions, and therefore, con-
stitute a further Unique domain-related regulatory process in c-Src signaling.
Since these experiments gave data at the residue level, the weak intra or intermolecular
interactions, mainly in the ULBR and the RT loop, could be studied also when N-terminal
myristoylated proteins were anchored to lipid bilayers. In the experimental conditions
used, enhanced binding of the secondary lipid binding region ULBR and RT loop was
expected, because of the entropic gain of belonging to the same peptide; in fact, it only
occurred in absence of the SH3 domain in our measurements.
• When MyrUSrc was bound to neutral liposomes, the SH4 was found to interact
strongly with the liposomes upon myristoyl insertion and hydrophobic interactions
of the ULBR to lipids were also observed. Anchoring of the myristoyl group to
the lipid bilayer facilitated the secondary ULBR binding, since the amount of lipids
needed to observe the interaction between ULBR and liposomes was much smaller
than in case of the non myristoylated form (a molar excess of 67 was used in
the experiments with the myristoylated form, while it was of 800 in case of the
non-myristoylated form). When negative charges were introduced in the bilayer,
electrostatic enhancement of SH4 binding to lipids was noticed at the two charge
CHAPTER 6. NMR STUDY 181
density studied. ULBR binding to lipids was also reinforced with DOPC:DOPG
liposomes. However, with an otherwise comparable charge content, a higher charge
density did not favor electrostatic interactions in this region (as measured in case of
DOPC:PI(3,4,5)P3). These lipids might be depleted from the membrane through
MyrSH4 recruitment, as happens in other myristoylated protein: this phenomena
has been described in MARCKS (Roskoski, 2004). Thus the charge density or the
nature of the charged lipid may modulate the strength of the ULBR interaction to
membranes. This finding can be related to one of our working hypothesis, in which
the binding of ULBR to membranes could modulate the position of the catalytic
domain of c-Src (Maffei, 2014), and thereby the enzyme’s accessible substrates.
• In presence of USH3, the cooperative effect enhancing ULBR binding to lipids was
not observed. When MyrUSH3 was bound to DOPC:DOPG liposomes, neither the
ULBR nor the RT loop were found to interact with the lipids. The intramolecular
interactions between the Unique and the SH3 domains probably directed the lipid
binding domains away from the lipid bilayer. Nevertheless, it might be possible
to recover these interactions in the presence of competing reactions. For instance,
adding a polyproline peptide – which binds to the SH3 domain – might hamper the
interaction between the RT loop and the ULBR, and permit interaction of the lat-
ter with lipids. The previous hypothesis of further regulation by lipid composition
would hold. The SH3 domain or the ULBR might also display stronger affinities
to other lipid types (this parameter was only very partially screened in this study).
If it would be the case, new interactions between the SH3 or the ULBR domains
might be forced and trigger protein spatial reorganization, and subsequently enzy-
matic activity. Dimerization concerns a minor protein population and is probably
not observed in these data. Nevertheless, if dimerization would occur via the SH4
domain, it may compete with the SH4/SH3 interaction and induce conformational
changes with respect to the monomeric form.
The results described in this chapter confirm some previous findings about long-range
intramolecular interactions within the SH4-Unique-SH3 region of c-Src studied in the ab-
sence of the naturally occurring myristoyl group. Thus we confirm that these interactions,
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and in particular the key interaction between SH4 and SH3 restraining the intrinsically
disordered Unique domain in a loop, are preserved in the myristoylated forms.
In contrast, the additional lipid-binding sites present in the Unique and SH3 domains
are clearly affected by the insertion of the myristoyl group.
SH4 Unique Domain SH3
Primary Lipid Binding Region
Secondary Lipid Binding region
Intramolecular interactions
SH4 Unique Domain SH3
SH4 Unique Domain SH3 SH4 Unique Domain SH3
Figure 6.24: Scheme of the effect of the myristoyl on the intra- and intermolecular inter-
actions in the USH3 domain
However, the presence of the myristoyl group enables additional interactions, beyond
the known effect of lipid anchoring: the SH3 domain presents a binding site that is
occupied by the myristoyl group when it is not inserted in the membrane. This finding
suggests that c-Src may possess a myristoyl-switch, as found in other signaling membrane-
associated proteins such as Abl. This putative myristoyl-switch could be relevant for c-Src
trafficking processes.
Therefore, this work has demonstrated new potentially relevant interactions for c-
Src function and, possibly, some general processes that are important to understand the
functions of membrane-anchored intrinsically disordered proteins. As a consequence, a
whole new field has just been opened.
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6.5. Experimental Methods
Liposome preparation 1,2-dioleoyl-sn-glycero-3-phosphocholine, DOPC, and 1,2- di-
oleoyl - sn-glycero-3-phospho-(1’-rac-glycerol) (sodium salt), DOPG (both from TebuBio)
were dissolved in chloroform, in a proportion of DOPC:DOPG 3:1. The solvent was evap-
orated in a rotavapor, and the lipid film was rehydrated with buffer (50mM NaP, pH 7)
by vortexing the lipid film at ambient temperature, rendering a final total lipid concen-
tration of 10 mM. Large unilamellar vesicles were prepared by mechanical extrusion using
a 10-mL Thermobarrel extruder (LipexTM. Northerns Lipids Inc.). The lipid suspension
was extruded repeatedly (10 times) through a 100 nm polycarbonate filter at room tem-
perature. To verify the appropriate size of the liposomes, the mean diameter was checked
using Dynamic Light Scattering (Zetasizer Nanoseries S, Malvern instruments).
A third liposome type was prepared, in which Phosphatidylinositol 3,4,5-trisphosphate
diC8, PI(3,4,5)P3, was supplemented to DOPC liposomes. The short chain C8-PI(3,4,5)P3
are soluble in water; they were resuspended in water and incubated half an hour with
DOPC liposomes at ambient temperature, before using them immediately for the NMR
experiments. The concentration of DOPC was kept at 5 mM and small volumes of con-
centrated PI(3,4,5)P3 solutions were added. Four liposome compositions were used by
supplemented the DOPC liposomes with 40, 80, 160 and 330 μM of PI(3,4,5)P3.
Bicelle preparation 1,2-dihexanoyl-sn-glycero-3-phosphocholine, DHPC (Avanti Po-
lar Lipids) was dissolved in chloroform and 1,2-Dimyristoyl-sn-glycero-3-phospho-rac-(1-
glycerol) sodium salt (DMPG) (TebuBio) in chloroform:methanol:H2O 65:35:8. The lipids
were dissolved in a DHPC:DMPG 1:0.8 proportion and the solvent was evaporated in a
rotavapor; lipid film was rehydrated with warm buffer (50mM NaP, pH 7, 40 ◦C) and
vortexing, which rendered a solution containing of 12.5% w/w of lipids. Bicelles were ho-
mogenized by repeating 10 freeze-thaw cycles (the solution was frozen in liquid nitrogen
and warmed at 65 ◦C).
NMR sample preparation All samples were dyalised in the “NMR buffer” used
throughout all NMR experiments, namely 50 mM NaP at pH 7.
15N MyrUSrc was obtained by the in-vitro myristoylation method and measured at
two different concentrations, 150 and 400 μM. 1H 15N 2SOFAST-HMQC spectra were
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recorded 50 mM NaP at pH 7, at 278 K. In the experiments with liposomes, the latter
were added to a concentrated protein solution, rendering a final concentration of 75 μM
protein and 5 mM lipids.
15N MyrUSH3 and 15N MyrUSH3A3 were obtained by the coexpression method.
Degradation free MyrUSH3 sample were obtained by the combination of Histrap chro-
matography with an imidazole gradient, and lyophilization/dyalisis cycles. Both proteins
were measured at 150 μM, at two temperatures, 278 K and 298 K. Residues in the dis-
ordered Unique domain are best seen at 278 K, but were also still sufficiently resolved at
298 K. Thus all spectra of the USH3 constructs presented in this part were acquired at
298 K. In the experiments with liposomes, the latter were added to a concentrated protein
solution, rendering a final concentration of 150 μM protein and 5 mM lipids.
A2G mutation in the USH3 or USH3A3 pETDuet1 plasmid enabled to express non
acylated proteins. USH3 A2G and USH3A3 A2G were expressed and purified by stan-
dard expression and purification methods (Pérez et al., 2013) (Maffei et al., 2015). In
the experiments with bicelles, the latter were added to a concentrated protein solution,
rendering a final concentration of 150 μM protein and 8 % w/v bicelles.
NMR spectra acquisition All experiments were performed in a Bruker 600 MHz
Advance III spectrometer equipped with a TCI CryoProbe. All measurements were 1H
15N SOFAST-HMQC experiments.
NMR data treatment NMR spectra were processed using Bruker TopSpin 3.0 and
NMRPipe (Delaglio et al., 1995) and analysed using the free-software Sparky (Goddard
and Kneller).
Combined chemical shift differences were calculated using the following equation:
Δδ =
√
ΔδH
2 + ΔδN5
2
(Equation 16)
Relative intensity differences were calculated using the following equation:
ΔI =
Is,n
Is,0
– Ir,nIr,0
Ir,n
Ir,0
(Equation 17)
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where I is the peak height, n are the different residues along the sequence and 0 is
the normalizer residue. s corresponds to the amino acids from the sample spectra and r
to that of the reference spectra. The normalizing residue was chosen as a non affected
residue (not affected by changes from the environment). The sample can be for instance
the myristoylated construct, or the myristoylated construct in presence of liposomes.
The reference can be for instance the non myristoylated construct, or the myristoylated
construct in absence of liposomes.

Chapter 7
Conclusion
7.1. Concluding Remarks
Although the association of c-Src with membranes through the myristoylated SH4
domain was well known, the details of the interactions of other regions of c-Src with lipids
remained obscure. Previous work had demonstrated that at least the Unique and SH3
domains contained lipid binding regions. However, no attempt had been made to place
these interactions in the context of the myristoylated protein.
We have studied myristoylated constructs containing the SH4, unique and SH3 do-
mains of c-Src. In this process, a general problem in the preparation of recombinant
myristoylated protein associated with shorter acyl chains addition was solved, together
with additional problems specific to the SH4-Unique domain of c-Src.
Biophysical studies have uncovered intermolecular protein-protein interactions of myris-
toylated constructs of c-Src causing clustering when they were binding to supported lipid
bilayers. A myristoyl binding site has been identified in the SH3 domain of c-Src. Signif-
icant effects of myristoylation on intramolecular and lipid interactions within the Unique
and SH3 domains have been demonstrated.
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7.2. Conclusions
(i) Protocols for the efficient production of myristoylated proteins have been developed.
In particular:
• The incorporation of shorter acyl chains has been characterized as a general
problem in the preparation of myristoylated proteins, and conditions minimiz-
ing their formation have been found.
• A well-defined myristoylation-induced cleavage site has been identified and
characterized in the Unique Lipid Binding Region of the Unique Domain of c-
Src. Conditions to obtain degradation-free samples for structural studies have
been established.
(ii) Formation of self-associated complexes of limited size was observed upon MyrUSH3
or MyrUGFP binding to supported lipid bilayers, by two independent methods. A
short MyrSH4 peptide was also found to autoassociate in the lipid bilayer.
(iii) A myristoyl binding site has been found in the SH3 domain in soluble MyrUSH3
constructs. Interaction of the myristoyl chain with lipids results in the loss of other
lipid binding interactions in the Unique and SH3 domains, that were observed in
the non myristoylated form.
(iv) The interaction between the SH4 and the SH3 domains that restricts the conforma-
tional space of the Unique domain is preserved in the myristoylated forms and in
the presence of lipids.
Capítulo 8
Resumen de la tesis
8.1. Introducción
Membranas y proteínas periféricas La organización espontanea de lípidos en mem-
branas, generando espacios cerrados, contribuyó a la aparición de la vida, principalmente
porque permitió la segregación de reacciones químicas específicas. Las membranas de las
células eucariotas y de sus orgánulos están compuestas de glicerofosfolípidos, esfingolípi-
dos y colesterol, pero contienen también carbohidratos y proteínas en abundancia. Las
membranas no son únicamente bidimensionales y tampoco son estáticas: pueden adoptar
una variedad de formas y están en un estado fluídico, dejando que las moléculas que las
constituyen se difundan en su bicapa. Sus dos capas son asimétricas. Lateralmente, se
pueden encontrar nanodominios llamados balsas lipídicas, que se forman y se deshacen
dinámicamente, y enriquecidos tanto en lípidos específicos (esfingolípidos, colesterol, fos-
foinositoles) como en ciertas proteínas. Estos dominios permiten a su vez una segregación
en dos dimensiones de reacciones químicas, por su capacidad de incluir o excluir molécu-
las (Sonnino and Prinetti, 2013). Son entidades cruciales en los fenomenos de señalización
celular. Nuevas teorías completan la descripción de las membranas; una de ellas describe
las existencia de proteínas rodeadas de lípidos específicos fuera de las balsas lipídicas. El
inicio de la señalización podría ocurrir cuando pequeñas balsas o proteínas rodeadas de
lípidos se unen, causando la activación de moléculas inactivas (Simons and Toomre, 2000)
(Ken~Jacobson et~al., 2007). Las proteínas que residen en las membranas son de varios
tipos, principalmente proteínas transmembranales o periféricas (Makoto~Asashima et~al.,
2010). Dentro de las proteínas periféricas, nos enfocaremos en las protéinas que poseen
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un grupo lipídico que contribuye a su interacción con la superficie de la membrana, y en
particular en las proteínas miristoiladas (Martin et~al., 2011), en las que el lípido unido
es un grupo miristoilo.
La miristoilación es una modificación que tiene lugar en la glicina 2 de algunas proteí-
nas, generalmente durante la síntesis proteínica, catalizada por la enzima N-miristoiltransferasa
(NMT). El grupo mirístico resulta atado de manera covalente y la reacción es irreversible.
El mirístico es la cadena acilada más corta que permite la unión de proteínas a membranas
de manera estable, pero no irreversible (Taniguchia, 1999). Ciertas proteínas miristoiladas
tienen en su cadena peptídica una zona hidrófoba en la que el grupo mirístico se puede
“esconder” del agua, lo cual les confiere una solubilidad completa cuando no están unidas
a membranas (Resh, 1999). Por su afinidad limitada para las membranas, la unión de
proteínas miristoiladas a membranas esta en general reforzada por otros elementos de
unión a lípidos (Buss and Sefton, 1985).
                
Figura 8.1: Unión de proteinas miristoiladas a
membranas, reforzadas por otros señales
Dichos elementos pueden ser otras
cadenas aciladas: un grupo palmitoi-
lado está reversiblemente añadido en
una cisteína y con su cadena más lar-
ga, asegura una unión fuerte de la pro-
teína a la membrana. Una alternativa
es que la proteína posea un motivo po-
libásico en su secuencia: los aminoáci-
dos cargados positivamente interacio-
nan electrostáticamente con los lípidos
cargados negativamente en la mem-
brana, aumentando la afinidad de la
proteína por la membrana en un efecto cooperativo. Llamaremos esta secuencia un domi-
nio positivamente cargado, PCD1 (Tournaviti et~al., 2009). La interacción electrostática
puede ser modulada por la fosforilación en serinas o treoninas presentes en el PCD, que
disminuye la carga total de la proteína, por lo tanto su afinidad para lípidos (Arbuzova
et~al., 1998). El papel del grupo mirístico, en conjunción con otros motivos de unión a lí-
pidos, es principalemente de anclar la proteína a la membrana, pero también influye sobre
1Positively Charged Domain
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su localización. En particular, una proteína que posee las dos cadenas aciladas de mirístico
y de palmítico se hallará generalmente dentro de las balsas lipídicas (Resh, 1999).
Proteínas desordenadas miristoiladas El paradigma que vincula la estructura tridi-
mensional de las proteínas y sus funciones ha estado evolucionando en los años recientes.
Muchas proteínas no tienen estructura tridimensional, pero sí son funcionales. Estas pro-
teínas llamadas intrínsicamente desordenadas lo pueden ser enteramente, o pueden con-
tener regiones plegadas y regiones desordenadas (Dunker and Obradovic, 2014). Las pro-
teínas desordenadas tienen características específicas: tienen generalmente una carga neta
alta, son poco hidrófobas, y su secuencia de aminoácidos es de baja complejidad (Uversky
et~al., 2000). Estas características permiten predecir por métodos estadísticos el carácter
desordenado de una secuencia de aminoácidos, cálculos que han demostrado la abun-
dancia significativa de tales proteínas (Radivojac, 2007). Con su carácter desordenado,
estas proteínas presentan propiedades únicas: pueden adoptar de manera dinámica una
multitud de conformaciones (desde completamente desordenadas hasta parcialmente y a
veces completamente plegadas). En consecuencia, pueden interaccionar con una multitud
de substratos; estas interaciones son generalmente altamente específicas pero fáciles de
romper. Las interacciones pueden ser moduladas simplemente porque la proteína inter-
cambia espacialmente entre muchas conformaciones, o porque un factor exterior ocasiona
un cambio de conformación. La formación de una hélice α tras la unión a membrana de
un péptido desordenado es un ejemplo de tal efecto. Por las propiedades que le confiere
su plasticidad, las proteínas desordenadas tienen un papel muy importante en las cade-
nas de señalización celular (Dunker and Obradovic, 2001), y son generalmente altamente
reguladas (Uversky et~al., 2014). Estas proteínas son también fácilmente degradables y
altamente susceptibles a modificaciones postraduccionales (Jakob et~al., 2014). Una de
ellas es la miristoilación.
La presencia del grupo miristoilo confiere la capacidad de unión a lípidos. El hecho
que la región adyacente esté desordenado tiene un efecto sinérgico:
• La presencia de un dominio desordenado puede disminuir el impedimento estérico
que ocasionaría la presencia de un dominio plegado muy cerca a la membrana (enton-
ces el dominio desordenado facilita la unión a la membrana) (Pool and Thompson,
1998).
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• Puede favorecer modificaciones postraduccionales adicionales en el dominio desor-
denado, más accesible; la palmitoilación (Resh, 1999) o la fosforilación (Tournaviti
et~al., 2009) son probablemente facilitadas en estos casos, y ayudan a la regulación
de la proteína con estas modificaciones reversibles.
• La posible formación de helices α tras el encuentro del dominio desordenado con
la membrana permite crear un dominio adicional de unión a lípidos y aumentar el
anclaje de la proteína a la membrana (Tholey et~al., 2001).
• La interacción del grupo miristoilo con la propia proteína puede representar una
alternativa a su inetracción con lípidos. Los sitios de unión de grupos miristoilo
conocidos se encuentran en dominios globulares. La interacci’ón del grupo miristoilo
puee afectar alostericamente la actividad de la enzima (Hantschel et~al., 2003).
Tanto las proteínas miristoiladas (Traverso et~al., 2013) como las desordenadas (Ra-
divojac, 2007) son abundantes y la asociación entre miristoilación y desorden es proba-
blemente un aspecto que merece considerable atención. Ambas características juegan un
papel importante en la regulación de las proteínas que las poseen, proteínas a menudo
implicadas en la señalización celular. Las proteínas que son a la vez desordenadas y mi-
ristoiladas podrían jugar un papel no despreciable en las cascadas de transducción de
señal.
c-Src
c-Src y la familia tirosina quinasa c-Src es el miembro que da nombre a una
importante familia de tirosina quinasas, las enzimas que transfieren un grupo fosfato a un
residuo de tirosina de otras proteínas (Parsons and Parsons, 2004). Este proceso consti-
tuye una etapa muy importante dentro de la transdución de señales en las células, y de
la regulación de la actividad enzimática. Las tirosinas quinasas de la familia Src están
implicadas en varias rutas de señalización, y la desregulación de c-Src afecta a la migra-
ción, la proliferación y la supervivencia de las células (Ingley, 2008). La actividad de c-Src
está finamente controlada y su desregulación promueve cánceres (Irby, 2000). c-Src es
una proteína miristoilada (Buss et~al., 1994), lo cual confina su actividad catalítica a la
interfase de la membrana, lo cual es esencial para su buen funcionamiento (Patwardhan
and Resh, 2010). Los otros miembros de la familia Src poseen casi todos una cadena de
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ácido palmítico adicional unida a la cisteína 3 (Buss and Sefton, 1985), pero c-Src se
distingue por tener un dominio polibásico justo después de su sitio de miristoilación Si-
gal et~al. (1994). La región N-terminal de c-Src y de los otros miembros de la familia
está desordenada y poco conservada dentro de la familia, lo cual le ha dado su nombre,
el Dominio Único. Debido a su carácter desordenado, este dominio está ausente de las
estructuras de c-Src obtenidas por difracción de rayos X de cristales – que han permitido
conocer la estructura e interacciones de los otros dominios que forman la parte globular
de la proteína. La estructura de c-Src fue resuelta en 1997 (Xu et~al., 1997). A continua-
ción del dominio Único vienen los dominios plegados SH3, SH2 (dominios de interación
con ligandos) y SH1 (el dominio catalítico). Los dominios SH2 y SH1 están conectados
por otro dominio semidesordenado que contiene un motivo de poliprolina. En la región
C-terminal se encuentra una cola flexible que participa en la regulación negativa de la
actividad de c-Src. El mecanismo de autoinhibición esta controlado por dos tirosinas, una
en la cola C-terminal, Y537, y otra en un bucle del dominio SH1, Y416. Cuando Y537
está fosforilada, se une al SH2 mientras el SH3 interaciona con el motivo de poliprolina
del conector SH2-SH1, manteniendo c-Src en una conformación cerrada. Si Y537 es defos-
forilada, la proteína se abre y vuelve a ser enzimáticamente activa. La autofosforilación
de Y416 permite la actividad enzimática máxima. Los miembros miristoilados y palmitoi-
lados de la familia están situados en las balsas lipídicas, pero c-Src se encuentra dentro o
fuera de ellas. Cuando no está activada, c-Src se halla en la zona perinuclear Kim et~al.
(2009), y viaja hasta la membrana plasmática (Courtneidge, 1980) donde llega a su estado
de activación máxima (Yeatman, 2004). c-Src ha sido visualizada también en endosomas,
que participan en la entrega de c-Src a la membrana plasmática. Además, c-Src ha sido
observada en estado soluble en varios estudios (Buss et~al., 1994) (David-Pfeuty et~al.,
1993) (Donepudi and Resh, 2008).
Los Dominios Únicos y SH3 (USH3) La figura 8.2-A y -B ilustra las considera-
ciones en este párrafo. La unión a membranas de c-Src tiene lugar principalmente por la
inserción de la cola de miristoilo en la bicapa y por la interacción electrostática con lípidos
negativos del dominio polibásico al extremo N-terminal de c-Src, el dominio SH4 (Buser
et~al., 1994). El dominio Único posee también una zona de unión a lípidos (denominada
ULBR, “Unique Lipid Binding Region”) (Pérez et~al., 2013). Varios residuos de serina
o tirosina del SH4 y del Dominio Único pueden ser fosforilados en condiciones fisiológi-
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cas (Amata et~al., 2013), posiblemente modulando la carga y la fuerza de unión a lípidos
de las zonas de interacción cercanas. El papel de la ULBR se entiende hasta ahora como
un segundo nivel de regulación de la enzima y no participa en la unión fuerte de c-Src a
membranas. Las mutaciones en la ULBR de c-Src entero en células de ranas y humanas
resultaron en fenotipos muy perturbados y distintos de la forma no mutada, lo cual apunta
a la importancia funcional del ULBR. El dominio SH3 viene después del Dominio Único
y posee también sitios de unión a lípidos en dos zonas, el bucle RT y el bucle n-Src. La
unión al dominio SH3 de un ligando con un motivo de poliprolina compite alostéricamente
con la unión a lípidos del bucle RT (Pérez et~al., 2013).
SH4 Dominio Unico SH3 SH2 SH1
Unión fuerte a lípidos
Unión moderada a lípidos
Interaciones intramoleculares
SH3
Dominio 
Unico
SH4
+++-     -     -     -     -     -     -     -     -     -     -     -     
-     -     -     -     -     -     -     -     -     -     -     -     
ULBR
A) B)
Figura 8.2: A) Estructura de la MyrUSH3; las interacciones intramoléculares o con lípidos
están indicadas. B) Esquema de MyrUSH3 unido a una bicapa de lípidos.
Estudios in-vitro de la forma no miristoilada del USH3 revelaron interacciones intra-
moleculares entre la ULBR y el bucle RT, y entre el SH4 y el bucle nSrc. Estos resultados
muestran que las interacciones intramoleculares limitan el espacio conformacional explo-
rable por el Dominio Único, a pesar de ser desordenado, y que el USH3 mantiene, en las
condiciones observadas, una conformación relativamente cerrada (Maffei et~al., 2015).
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8.2. Objetivos
Establecer protocolos experimentales para la producción de proteínas miris-
toiladas en cantidad adecuadas para su carácterización con técnicas biofísicas
i Optimizar métodos de expresión y purificación de proteínas miristoiladas usando es-
trategias de coexpresión con NMT y eliminar posibles fuentes de contaminación.
ii Escalar métodos de miristoilación in-vitro
Carácterizar la unión de construcciones miristoiladas conteniendo el Dominio
Único de c-Src con bicapas lipídicas.
i Estudiar su cinética de unión a bicapas lipídicas
ii Estudiar su posible asociación cuando se une a bicapas lipídicas
iii Estudiar las interacciones de la ULBR y del bucle RT con lípidos en presencia de la
cola miristoilada insertada en la bicapa.
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8.3. Miristoilación
En la reación de miristoilación intervienen tres especies: la enzima NMT, el substrato
y la especie donadora de ácido mirístico (myristoil-Coenzima A, MyrCoA) (Towler and
Glaser, 1986). El substrato es una proteína que, tras la eliminación de la metionina 1,
posee una glicina en posición 2, y otros aminos específicos en las posiciones siguientes,
que permiten el reconocimiento por la enzima. MyrCoA se une primero a la NMT, quién
después de un cambio conformacional puede acomodar la proteína en un segundo sitio,
y catalizar la transferencia de la cadena acilada desde el CoA hasta la proteína (Farazi
et~al., 2001). La reacción está resumida en la Figura 8.3.
Unión de MyrCoA 
Cambio conformacional
Unión del peptido
Transformación química
Liberación de CoALiberación del peptido
miristoilado
Figura 8.3: Esquema de la reacción de miristoilación
Se han utilizado dos métodos para obtener proteínas recombinantes miristoiladas:
• La expresión simultanea de la NMT y de la proteína en bacterias de E.coli Gluck
et~al. (2010) (las bacterias no producen normalmente la NMT) - llamaremos este
procedimiento coexpressión.
• Producir los tres productos por separado (la NMT, la proteína y MyrCoA) y mez-
clarlos para realizar la reacción de miristoilación Padovani et~al. (2013).
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Myristoilación de la USH3 La estrategia de coexpressión se utilizó para producir la
USH3 miristoilada (la MyrUSH3). En el protocolo clásico, después de la expresión de la
proteína en E.coli, las células se sonicarons y centrifugaron, y la proteína se recuperó del
sobrenadante. En el caso de la USH3, la presencia de una cola de histidinas en el extremo
C-terminal permitió la purificación de la USH3 con una resina de niquel. Las proteínas
fueron finalmente separadas por cromatografía de exclusión molécular (SEC2). Con este
método, la proteína miristoilada se obtuvo pura juntamente con otras especies visibles
por SEC (Figura 8.4 A, curva negra y B): una forma laurilada de USH3, la LaurUSH3, en
la que la cadena acilada tenía dos atomos de carbono menos que la forma miristoilada y
una forma degradada. La proteína MyrUSH3 deseada apareció formando un complejo con
la NMT. Este complejo podría utilizarse para obtener la proteína MyrUSH3, separándola
de la enzima, pero los métodos que lo permitirían funcionaron sólo parcialmente, y con
poco rendimiento.
Se desarrolló otro método de purificación: en lugar de usar el producto soluble de la
sonicación de las bacterias, se recuperó el sedimento celular, del que se extrajo la proteína
MyrUSH3 con un detergente (Triton X) y después de una nueva centrifugación, el producto
solubilizado se purificó como fue descrito anteriormente. Este método permitió deshacerse
de la NMT ( (Figura 8.4-A, curva roja y -C), pero no eliminó totalmente la proteína
laurilada y las formas degradadas.
• Las proteínas lauriladas se originan por la falta de especificidad de la enzima NMT
que puede reconocer la LaurCoA (Towler and Glaser, 1986) (Yizhou~Liu et~al.,
2009). La degradación en LaurCoA es la primera especie formada en el proceso de β-
oxidación de la MyrCoA (una ruta celular de producción de energía). Para minimizar
su producción, se añadió ácido palmítico, que aumenta la cantidad de la MyrCoA por
la degradación de la PalmCoA mientras que el propio PalmCoA no es incorporado
por la enzima NMT. Además, se usó un tiempo de expresión corto para evitar que las
células recurrieran a la β-oxidación. En caso de crecimiento en medio mínimo, se usó
adicionalmente el método llamado método de Marley Marley et~al. (2001), en el que
las bacterias se hacen crecen en medio rico, y a continuación se transfieren a un medio
mínimo para la inducción. En estas condiciones, se minimizó la formación de formas
lauriladas, pero no se consiguió evitar la presencia de productos de degradación.
2Size exclusion chromatography
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Cromatografía líquida de alta resolución y F) Espectrometría de masas de las fracciones
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• La forma degradada obtenida es un producto de degradación de MyrUSH3, que
tiene la cola de histidinas pero no el grupo miristoilo. El sitio de corte se encontró
mediante un estudio de análisis de masa: la ruptura tiene lugar en la zona del ULBR,
después de la L63. Se expresó y purificó un mutante en el que los aminoácidos
64LFG66 se remplazaron por tres alaninas 64AAA66. Este mutante no se degradó.
Desafortunadamente, el uso de este mutante no es apropiado en el estudio de las
propiedades de la ULBR.
• La separación del producto de degradación se logró optimizando las condiciones de
purificación por afinidad mediante una columna HisTrap. Después de unir el produc-
to solubilizado a la columna Histrap, la elución se inició con una concentración baja
de imidazol. El producto de degradación se eluyó muy fácilmente en estas condicio-
nes, mientras la MyrUSH3 tenía una afinidad más grande con la resina de niquel y
permaneció mayoritariamente unida a la columna. Una vez se haya eluido todo el
producto de degradación, MyrUSH3 se eluyó en forma pura subiendo la concentra-
ción de imidazol. Con este método, la MyrUSH3 se pudo obtener puro, sin producto
degradado (Figura 8.4-D y -E).
Myristoilación del Dominio Único de c-Src El método de coexpresión del Dominio
Único de c-Src (USrc3) con la NMT en las bacterias no permitió obtener USrc miristoilado
(MyrUSrc). Los tres productos, la NMT, la MyrCoA y la USrc se obtuvieron por separado.
El ácido mirístico se activó químicamente con carbonildiimidazol y se hizó reaccionar con
CoA según el método de Gaffarogullari et~al. (2011). USrc se expresó y se purificó en
E.coli con el método clásico (Pérez et~al., 2013). La NMT se recuperó del complejo con
MyrUSH3 obtenido como fue descrito en parte 8.3: se unió el complejo a la resina de
niquel, y se eluyó específicamente la NMT con una solución conteniendo MyrCoA. El
protocolo de miristoilación consistió en mezclar la NMT con una solución conteniendo un
exceso de MyrCoA, y añadir USrc después de 20 min, como fue ilustrado en el esquema de
la Figura 8.5-A. La reacción se dejó 2 h a 37 ◦C, y a continuación a 4 ◦C durante la noche.
El éxito de la reacción se comprobó con un ensayo de sedimentación de vesículas: después
de mezclar el producto de la reacción con vesículas y de centrifugarlo, se separaron el
sobrenatante y la fase lipídica. Una electrofóresis en gel de las dos fases permitió identificar
3Unique Domain of Src
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si la proteína se encontraba unida a liposomas, lo cual fue el caso del producto de la
reacción de miristoilación, pero no del control con USrc (Figura 8.5 B). Este producto de
reacción se purificó mediante el uso de cromatografía líquida de alta resolución (HPLC),
en la que se separaron los productos – la MyrCoA, la USrc, la MyrUSrc y la NMT
(Figure 8.5-C). Las fraccione que contenían MyrUSrc se colectaron, se liofilizarono y
MyrUSrc se resuspendió en una solución tampón.
+ +
NMT NMT NMT
USrc
USrcMyrCoA
MyrCoA MyrCoA
USrc
36 kDa
21 kDa
14 kDa
  6 kDa
USrc
55 kDa
MyrUSrc/USrc
Super   Pellet   Super   Pellet
natant               natant
NMT
USrc MyrUSrc NMT
A)
B) C)
Figura 8.5: A) Esquema de la reacción in-vitro B) Electroforesis en gel de las especies de
las USrc y MyrUSrc antes y después de la reacción de miristoilación, tras haber realizado
un LSA con ellas. C) HPLC del producto de miristoilación de USrc.
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8.4. Unión de la MyrUSH3 a los lípidos
La unión de MyrUSH3 a liposomas se estudió por resonancia de plasmones superficiales
(SPR4). Esta técnica permite obtener la cinética de la unión entre el ligando inmoviliza-
do en la superficie de la cámara y un analito (Bakhtiar, 2013). El ligando imnovilizado
está constituido por liposomas en nuestro experimento, y el analito es una solución de
MyrUSH3 a una concentración definida. Los liposomas se inmovilizaron en la superficie,
retenidos por un lípido (fitoesfingosina) covalentemente unido a esta (Besenicar et~al.,
2006). La inyección de la proteína sobre los liposomas dió lugar a unas curvas de unión
que mostraban una asociación relativamente rápida, y una disociación muy rápida, que
indican uan constante de asociación relativamente baja. Esta unión reversible se estudió
de una manera clásica, como fue descrito en la primera parte de este párrafo. Sin embargo,
la disociación de MyrUSH3 no era completa y se observó una señal residual que podría
corresponder a la presencia de proteínas no disociadas. Para confirmar esta observación,
se inyectó un anticuerpo secundario que reconoce al dominio SH4, el antiSH4. La res-
puesta positiva de SPR confirmó la presencia de una población de proteina que se disoció
muy lentamente de los liposomas, que llamaremos “especie persistemente unida” (PB5).
Esta especie se caracterizó en un protocolo específico, recurriendo al antiSH4, como fue
descrito en la segunda parte de este párrafo. Un comportamiento similar se observó tras
la inyección del péptido MyrSH4, sugiriendo que los determinantes de la formación de
las especies PB se localizan en el dominio SH4 miristoilado; aún así, la caracterización
cinética se realizó con la proteína MyrUSH3, que contiene los dominios adicionales de
unión a lípidos (la ULBR y el bucle RT).
Análisis cinético de la unión reversible de la MyrUSH3 a los liposomas La
proteína se inyectó a varias concentraciones (los ciclos de inmovilización de liposomas e
inyección de proteínas se pueden repetir gracias a la regeneración completa obtenida con
la aplicación de un detergente, CHAPS6), y su asociación y disociación a liposomas se
monitorizó. Las curvas de asociación y disociación pudieron ser ajustadas mediante un
modelo simple de interacción 1:1, en el que la proteína P interacciona con los lípidos L
para formar el complejo PL, con unas constantes de reación ka y kd, equivalente a una
4surface plasmon resonance
5persistently bound
63-((3-cholamidopropyl)dimethylammonio)-1-propanesulfonate
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constante de equilibrio K = kakd :
P + L PL (reaction1)
Estas constantes se midieron en dos casos: con lípidos neutros o lípidos conteniendo
cargas negativas. La constante de equilibrio calculada se acerca a la descrita en la literatura
para el péptido SH4 miristoilado (MyrSH4) (Buser et~al., 1994), mostrando que este
péptido es el responsable principal de la unión de c-Src a lípidos. La afinidad calculada
es más fuerte en el caso de liposomas cargados negativemente, lo cual se esparaba debido
a la interacción electrostática adicional que aparece con el SH4. La tabla 8.1 resume los
resultados de los ajustes.
Cuadro 8.1: Parametros de cinética resultantes del ajuste de los datos de unión directa de
MyrUSH3 a liposomas neutrales o cargados negativamente, usando un modelo 1:1.
ka(M–1 · s–1) kd(s–1) KD(M–1)
DMPC 4.54 · 103 ± 2.18 · 103 2.81 · 10–1 ± 1.73 · 10–1 1.54 · 104 ± 7.01 · 103
DMPC:DMPG 2:1 2.46 · 104 ± 1.31 · 104 1.29 · 10–1 ± 8.63 · 10–2 1.9 · 105 ± 6.52 · 104
Análisis cinético de la unión irreversible de la MyrUSH3 a los liposomas El
antiSH4 se usó como método de detección de las especies PB para estudiar por separado
su cinética de unión a lípidos, dado que la respuesta del anticuerpo refleja la cantidad
de especies PB presentes en la superficie. La proteína MyrUSH3 se inyectó con distintos
tiempos de asociación, y después de un tiempo de disociación constante se realizó la
detección secundaria de las especies PB con anticuerpo antiSH4. Este protocolo permitió
estudiar la cinética de unión de las especies PB a liposomas. Por otra parte, MyrUSH3
se inyectó con tiempos contantes de asociación, pero la detección con antiSH4 se realizó
a tiempos variables de disociación (Figura 8.6 A y B dan un ejemplo de tal protocolo con
60 s de asociación de MyrUSH3 y con una inyección del anticuerpo después de 350 s) .
Este protocolo permitió estudiar la cinética de desunión de las especies PB a liposomas.
La curvas de respuestas a un tiempo dado del anticuerpo en función de los tiempos de
asociación o disociación se trazaron, como está ilustrado en la figura 8.6-C a -F, mostrando
primeramente que la disociación de las especies PB era despreciable, tanto en liposomas
neutros como en los cargados negativamente. Incluyendo esta observación, se propuso un
modelo cinético que permitió ajustar estas curvas para obtener la constante de asociación
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k′on. El modelo que explica los datos experimentales contiene una ecuación de segundo
orden que sugiere que las especies PB son, como mínimo, dimeros, llamados PB2. La
disociación muy lenta se explicaría por la presencia de especies unidas por dos cadenas de
miristoiles en lugar de una, permitiendo una unión mucho más estable a lípidos, incluso
en el caso de lípidos sin cargas negativas. El modelo se desarrolló a partir de las reacciones
cinéticas (con kon la constante de asociación de la formación de PB2):
P + L PL (reacción 1s)
PL + P→ PB2 (reacción 4s)
La ecuación que describe la unión de las especies PB2 a lípidos obtenida a partir de
estas reacciones es de la forma:
R = C1 · (1 – exp(–k′on · t)) (ecuación 11s)
donde R representa la respuesta de SPR del antiSH4 y C1 depende de la concentración
de la proteína [P]. Las curvas de la figura 8.6-C y -D se ajustaron con esta ecuación y
permitieron obtener los valores de kon (resumidas en 8.2).
Cuadro 8.2: Ajustes de las curvas de las Figuras 8.6 C y D con (equation 11)
Concentration (M) 10–6 2 · 10–6 4 · 10–6 10–5 2 · 10–5
DMPC
C1(RU) 175.1± 26.9 272.1± 32.5 383.4± 32.8 512.3± 31 520.2± 23.3 697.3± 47
k′on(s
–1) 0.01462± 0.004 0.02269± 0, 006 0.06505± 0, 022 0.1688± 0.077 0.1480± 0.046 0.2256± 0.155
DMPC:DMPG 2:1
C1(RU) 512.3± 75.6 889.3± 83.3 1223± 48.2 1484.1± 65 1419.8± 27.7 1678± 36.1
k′on(s
–1) 0.00808± 0.002 0.00877± 0.001 0.01829± 0.002 0.04481± 0.009 0.05± 0.005 0.1050± 0.020
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Figura 8.6: Asociación y disociación de MyrUSH3 a liposomas y detección secundaria con
antiSH4 A) sobre liposomas neutros B) sobre liposomas cargados. Gráficas de la respuesta
del anticuerpo en función del tiempo de asociación de MyrUSH3 C) en liposomas neutros
y D) en liposomas cargados negativamente. Gráficas de la respuesta del anticuerpo en fun-
ción del tiempo de disociación de MyrUSH3 E) en liposomas neutrales y F) en liposomas
cargados negativamente.
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8.5. Unión de la MyrUGFP a lípidos
Con el fin de obtener una variante de MyrUSrc susceptible de ser observada por fluo-
rescencia, se diseño la proteína MyrUGFP, que contiene una proteína verde fluorescente
(GFP7) en lugar del dominio SH3. Para verificar su capacidad de interacción con lípidos,
se comparó la inserción de MyrUGFP y de MyrSH4 en monocapas lipídicas cargadas
negativamente. A continuación, se realizó un estudio de microscopía de fluorescencia de
las especies PB de MyrUGFP unidas a liposomas, al nivel de las moléculas individuales
(“single molecule experiments”).
Estudio de inserción en monocapas de MyrUGFP y MyrSH4 En un experimen-
to de monocapas, se depositan lípidos en una interfase agua-aire. Se forma una monocapa,
con las colas lipídicas apuntando al aire, y la cabezas polares tocando el agua. La presión
generada por la presencia de lípidos en la interfase se puede medir con una balanza de
Wilhemy Maget-Dan (1999). Una pequeña placa de papel o de metal se inmersa parcial-
mente en el agua y esta conectada a un tensiómetro, que mide la presión superficial. Si una
proteína se inyecta en la subfase acuosa y se une a los lípidos de la monocapa, se detectará
un cambio de presión. A medida que aumenta la presión inicial de los lípidos, disminuye
la capacidad de inserción de las proteínas y el cambio de presión será menor. El MyrSH4 y
la MyrUGFP se inyectaron a una concentración de proteína constante, pero con distintos
valores de presión lipídica iniciales. Se derivó en ambos casos el cambio de presión debido
a la inserción de la proteína en función de la presión inicial, y por regresión lineal se dedujo
el valor de la presión de exclusión (Calvez et~al., 2009) – la presión máxima a la que se
pueden insertar MyrSH4 o MyrUGFP. En este experimento, la presión de exclusión de
MyrSH4 era 50 mN/m, mientras la de la MyrUGFP era de 34 mN/m, valor mucho más
representativo de valores obtenidos con otras proteínas. La presión de una monocapa con
la misma capacidad de exclusión de las membranas celulares en equilibrio se ha estimado
que es entre 30 y 35 mN/m. Este resultado confirma que MyrUGFP se puede insertar
en membranas. El valor de exclusión de MyrUGFP, y posiblemente otras construcciones
que contienen el dominio Único además del extremo SH4 miristoilado, sugiere que estas
formas pueden unirse y disociarse de las membranas causando una mínima perturbación
en el sistema lipídico. La extrema capacidad de penetración del péptido SH4 miristoilado
7Green Fluorescent Protein
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parece ser modulada por la regiones vecinas de la proteína natural. Es importante, por
tanto, estudiar las construcciones más largas, más cercanas a la realidad biológica.
Estudio de microscopía de fluorescencia de la MyrUGFP unido a los liposomas
al nivel “single molecule” Para aclarar la naturaleza de las especies PB encontradas
en el experimento de SPR, se estudió la unión de MyrUGFP a liposomas, mediante su
observación con microscopía confocal, usando la técnica de fotoblanqueo de moléculas
individuales (SMP8) (Garcia-Parajo et~al., 2001).
Se usaron liposomas cargados negativamente que están en fase gel a temperatura
ambiente, con el fin de limitar la difusión de proteínas una vez insertadas. Los liposomas
se depositaron sobre unos cubreobjetos de vidrio hidrófilos. El exceso de liposomas se
limpió con una solución tampón y una solución conteniendo la MyrUGFP se depositó
sobre los liposomas adsorbidos en fase fluida (45 ◦C). El exceso de proteínas se limpió y el
cubreobjetos se montó en una cámara permitiendo dejar la solución tampón encima de la
preparación y observar la muestra con un microscopio confocal. La figura 8.7-A muestra
tal imagen, en la que los puntos amarillos correspondían a la proteína de MyrUGFP. Los
liposomas contenían una sonda fluorescente permitiendo visualizarlos también, en rojo en
la imagen. La concentración de la proteína se ajustó para obtener imágenes separadas
de moléculas individuales o pequeños grupos de moléculas, es decir puntos luminosos
discretos, como está ilustrado en la figura 8.7-B . Sin embargo, estos puntos luminosos
podrían corresponder a una o más proteínas asociadas, debido al limite de difracción
intrínseco a la técnica. Para contar el numero de moléculas presentes en cada punto
luminoso, se fotoblanquearon cada uno de los puntos luminosos (apuntando precisamente
un laser con alta intensidad sobre cada uno de ellos) y se gravó la señal de fluorescencia con
el tiempo. Después de un cierto tiempo de exposición, las moléculas se fotoblanquearon: la
perdida de fluoescencia de cada molécula individual aparece como un escalón en la gráfica
de fluorescencia versus tiempo. Si hay solo un escalón en esta gráfica, significa que el punto
luminoso estaba constituido de una sola molécula. Si hay varios escalones, entonces habían
varias moléculas en el punto, y el numero de moléculas presentes corresponde al numero
de escalones. La figura 8.7 representa ejemplos de datos experimentales que corresponden
a tales casos, con puntos luminosos conteniendo figura 8.7-C 1 molécula -D 2 moléculas o
8Single Molecule Photobleaching
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-E tres moléculas.
Se prepararon muestras de MyrUGFP unida a lípidos a varias concentraciones, y se
realizó el experimento de SMP. Se generaron estadísticas contando el número de moléculas
en todos los puntos discretos estudiados. A todas las concentraciones usadas (250 pM hasta
750 pM), las estadísticas revelaron un número importante de dímeros, como se puede
observar en la figura 8.7-F. Los datos experimentales se compararon con un control en
ausencia de lípidos, en el se observó un número más grande de monomeros (figura 8.7-G).
Para descartar que los dímeros observados eran reales y no simplemente el resultado de una
distribución estadística de monómeros a distancias menores de la capacidad de resolución
óptica del sistema, se realizaron simulaciones utilizando las densidades experimentales. La
distribución de especies predichas para un modelo sin interacciones especifícas coincidió
con las observaciones realizadas en controles sin lípidos (figura 8.7-H). Por consiguiente,
el predominio de especies diméricas en presencia de lípidos es un resultado significativo
que indica que MyrUGFP se autoasocia en presencia de lípidos.
En otro experimento, se mezcló una proteína no fluorescente, MyrUSH3, con My-
rUGFP, antes de la incubación, a concentración 1:1 (200 pM). Las estadísticas obtenidas
revelaron una disminución del numero de dímeros y un aumento de la de monómeros fluo-
rescentes (respecto a los datos experimentales de la MyrUGFP unido a los liposomas),
pero con una cantidad de monómeros todavía menor que la del control en ausencia de
lípidos. Este experimento demuestra que la presencia de MyrUSH3 afecta la formación de
dímeros de MyrUGFP. Dado que ambas proteínas comparten el grupo SH4 miristoilado
y el dominio Único, el efecto de MyrUSH3 puede interpretarse como una evidencia adi-
cional de la participación de esta región en la autoasociación de MyrUGFP o MyrUSH3
(anteriormente observada en los experimentos de SPR). La disminución de dímeros de
MyrUGFP en presencia de MyrUSH3 sugiere un efecto de competición dando lugar a he-
terodímeros formados por MyrUGFP y MyrUSH3 que en el experimento de SMP darían
lugar a un único evento de blanqueo y serían, por tanto, contabilizados como monómeros.
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Figura 8.7: A) Imagen con doble color de MyrUGFP (amarillo) unida a liposomas (rojo).
B) Imagen en tres dimensiones de MyrUGFP unido a liposomas al nivel de moléculas
individuales. Fluorescencia en tiempo real de un punto discreto, limitado por la difracción,
conteniendo C) una molécula D) dos moléculas E) tres moléculas. Estadísticas del numero
de eventos de blanqueo en experimentos de SMP de MyrUGFP F) unido a liposomas G)
sobre vidrio sin liposomas. H) Simulaciones.
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8.6. Estudio de Resonancia Magnética Nuclear
de MyrUSrc y MyrUSH3
Las proteínas MyrUSrc y MyrUSH3 se obtuvieron con los métodos detallados en los
párrafos 8.3 y 8.3 con marcado 1H 15N para el estudio de Resonancia Magnética Nuclear
(RMN). Se adquirieron espectros 1H 15N SOFAST-HMQC (Schandaa et~al., 2005) de
MyrUSrc y de MyrUSH3 en ausencia o presencia de lípidos. El espectro de MyrUSrc
se midió a 280 K, mientras el de MyrUSH3 se observó a 298 K. Los distintos espectros
adquiridos están resumidos en la tabla 8.3.
Cuadro 8.3: Lista de constucciones con USH3 medidas por RMN
Protein Bilayer Model
USH3 A2G
MyrUSH3 WT DOPC:DOPG 3:1 liposomes
USH3A3 A2G
MyrUSH3A3 DOPC:DOPG 3:1 liposomes
USH3IHH A2G DMPC:DHPC 0.8:1 bicelles
SH3
MyrUSrc El espectro de MyrUSrc en solución se comparó con el espectro de USrc no
miristoilado. Los desplazamientos químicos de ambas especies eran similares, sin embargo
se observaron cambios de intensidad significativos entre las dos especies. Se observó un
aumento de la intensidad de las señales de MyrUSrc respecto a la de USrc en toda la zona
N-terminal hasta la ULBR, lo cual sugiere una zona de restricción conformacional en esta
parte. La coincidencia del extremo de la zona inmovilizada por la presencia de una cadena
lipídica con la región de unión a lípidos del dominio Único sugiere que el grupo miristoilo
pueda interaccionar, al menos de forma transitoria, con la ULBR. A continuación, se
añadieron liposomas a la MyrUSrc y se comparó este nuevo espectro con el de la MyrUSrc
en solución. De nuevo se observaron cambios de intensidad. En este caso se afectaton dos
zonas, el dominio SH4 y la ULBR. El SH4 está probablemente perturbado por la inserción
del grupo myristoilo en la bicapa, y la región correspondiente a la ULBR por su interacción
con los liposomas via sus aminoácidos hidrófobos. Las mismas interacciones se observaron,
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pero aumentadas, cuando los liposomas contenían cargas negativas. Esto indica que las
interacciones de ambas regiones incluyen un componente de interacción electrostática
adicional entre los aminoácidos cargados positivamente (las argininas en el dominio SH4 y
las lisinas en la ULBR) y las cargas negativas de los liposomas. Estos resultados confirman
las observaciones previamente obtenidas en ausencia del grupo miristoilo.
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Figura 8.8: Cambios de intensidad entre el espectro de la MyrUSrc con liposomas cargados
negativamente y el de la MyrUSrc en solución.
MyrUSH3 El espectro 1H 15N de MyrUSH3 en solución se comparó con el espectro
de USH3 no miristoilado. En este caso, se observaron importantes cambios de desplaza-
mientos químicos en varias zonas. La presencia del grupo myristoilo afectó a los despla-
zamientos químicos en el SH4 (S6 y K7), pero no se notaron otros cambios en la zona del
SH4, tampoco en el bucle n-Src. Esto indica que la interacción entre los dominios SH4 y
SH3 se mantiene en presencia del grupo miristoilo; la especie USH3 miristoilada conserva
una conformación bastante cerrada debido a estas interacciones intramoleculares. Sin em-
bargo, se observaron perturbaciones substanciales en los residuos del bucle RT, en el que
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se observó un desdoblamiento en los picos de varios residuos. Este desdoblamiento indi-
ca que esta zona, el bucle RT, esta intercambiando lentamente entre dos conformaciones
distintas; las dos posiciones de los residuos desdoblados se llamaron posiciones 1 y 2. El
mutante en la ULBR, MyrUSH3A3, se midió igualmente en solución, y se comparó con
el espectro de USH3A3. Como en el caso de la forma no mutada, se observaron cambios
en los desplazamientos químicos en el bucle RT, pero sin desdoblamiento, y casi todos los
residuos de esta zona se hallaron en la posición 2 previamente observada. Sabiendo que en
la forma no miristoilada se observaron interacciones entre la ULBR y el bucle RT, estos
resultados podrían indicar que la presencia de la cola de miristoil perturba esta interac-
ción ULBR/bucle RT. Es probable que el bucle RT interaccione con la ULBR o con el
miristoil. En ausencia de la ULBR en el mutante MyrUSH3A3, el bucle RT interacciona
únicamente con la cola acilada.
Se midió el espectro 1H 15N de la proteína MyrUSH3 en presencia de liposomas car-
gados negativamente, y el espectro se comparó con el de MyrUSH3.
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Figura 8.9: Cambios de desplazamientos químicos entre los espectros de MyrUSH3 y de
USH3
Como en el caso de la MyrUSrc, aparecieron cambios significativos en la zona del
dominio SH4, debido a la inserción del grupo miristoilo en la bicapa, y a la interacción
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electrostática. En el bucle RT, se observaron desplazamientos químicos respecto a My-
rUSH3, pero los desdoblamientos en los picos desaparecieron. El espectro del dominio
SH3 en MyrUSH3 en presencia de liposomas se comparó con el del dominio SH3 aislado.
Los desplazamientos químicos de los residuos del bucle RT eran muy parecidos en ambas
moléculas sugiriendo que en presencia de liposomas, el bucle RT no interaciona con nadie
(ni con ULBR, ni con liposomas). Este resultado apunta a que cuando MyrUSH3 está
unido a liposomas, la interacción de MyrSH4 con lípidos y, simultaneamente SH4 con el
bucle nSrc del dominio SH3, da lugar a una orientación del dominio SH3 respecto a la
superficie de la membrana, que impide la interacción del bucle RT con lípidos. De la mis-
ma manera, se observaron muy pocos cambios en la zona de la ULBR entre los espectros
de MyrUSH3 y MyrUSH3 en presencia de liposomas, al contrario de lo que se observó
en ausencia del dominio SH3. Esto indica que el dominio SH3 en las formas miristoiladas
impide el acercamiento de la ULBR a la superficie de la membrana. La persistencia de la
interacción SH4/SH3 y la restricción en la orientación del dominio SH3 en la superficie
de la membtrana posiblemente también sean responsables de las restricciones observadas
para el acercamiento de la ULBR a lípidos en la forma miristoilada MyrUSH3. No se
observaron cambios en el bucle n-Src, sugiriendo que la conformación cerradade USH3 se
conserva en MyrUSH3 unida a liposomas
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8.7. Conclusiones
(i) Se han desallorado protocolos que permiten la producción de proteínas miristoiladas.
Dichos protocolos se han optimizado para evitar los problemas identificados en estos
procesos:
– La incorporación de cadenas aciladas más cortas ha sido identificado como un
problema general en la preparación de proteínas miristoiladas y se optimizaron
las condiciones, permitiendo minimizar la formación de tales cadenas.
– La degradación inducida únicamente en presencia del grupo miristoil ha sido
caracterizada y el sitio de corte exacto ha sido identificado. Se han desarrollado
condiciones para obtener muestras sin degradación.
(ii) Se ha demostrado la autoasociación de las proteínas MyrUSH3 y MyrUGFP pa-
ra formar complejos de pequeño tamaño tras su unión a bicapas lipídicas. Esta
asociación se observó por dos métodos independientes. El péptido MyrSH4 forma
complejos similares cuando se une a bicapas lipídicas.
(iii) Se ha identificado un sitio de unión del grupo miristoilo en el bucle RT del dominio
SH3 de la construcción MyrUSH3. La inserción del grupo miristoilo en la bicapa
lipídica compite con la interacción con el grupo SH3 y afecta la unión a lípidos de la
región ULBR y del bucle RT que había sido observada en ausencia de myristoil. La
interacción entre los dominios SH4 y SH3 que restringe el espacio conformacional
del dominio Único se mantiene en las formas miristoiladas y en presencia de lípidos.

Chapter 9
Appendix
9.1. List of constructs
The different constructs used in this thesis is listed in this appendix. The complete
sequence of the construct is indicated, including the C-terminal Tag sequence (SAWSH-
PQFEK in the case of the StrepTag, HHHHHH in the case of the HisTag) and mutations
differing from the wild type sequence are indicated in bold. The vector in which they
are cloned is mentioned; the petDuet always contains the sequence of the protein and the
sequence of the NMT; the pEt14b only contains the sequence of the protein). The molec-
ular weight is indicated, with or without the processes methionine (MS analysis mostly
encounter masses corresponding to proteins in which the methioninie has been processed).
Myristoylation occurs only if a gGlycine is present in position 2; the masses of the myris-
toylated constructs are indicated in this case. For each construct, the isoelectric point
(pI) and the extinction coefficient at 280 nm, ε, are indicated.
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#
1 USrc WT pet14b* 9612 9481 N/A 9,99 5500
2 USrc A3 pET14b 9508 9377 9587 9,99 5500
3 9612 9481 9691 9,99 5500
4 9508 9377 9587 9,99 5500
5 9626 9495 N/A 9,99 5500
6 9568 9437 9647 10,27 5500
7 9572 9441 9651 9,99 5500
8 9528 9397 9607 10,27 5500
9 9598 9467 9677 9,99 5500
10 10492 10361 10571 9,99 5500
Name Sequence Tag Vector Restriction enzymes
MW 
(Da)
MW sin 
M1 (Da)
MW 
Myristoyl
ated (DA)
pI
 
(280n
m)
MGSNKSKPKDASQRRRSLEPAENVHG
AGGGAFPASQTPSKPASADGHRGPSA
AFAPAAAEPKLFGGFNSSDTVTSPQRA
GPLAGGSAWSHPQFEK
StrepTag NdEI,NcOI
MGSNKSKPKDASQRRRSLEPAENVHG
AGGGAFPASQTPSKPASADGHRGPSA
AFAPAAAEPKAAAGFNSSDTVTSPQRA
GPLAGGSAWSHPQFEK
StrepTag NdEI,NcOI
USrc
(NMT)
MGSNKSKPKDASQRRRSLEPAENVHG
AGGGAFPASQTPSKPASADGHRGPSA
AFAPAAAEPKLFGGFNSSDTVTSPQRA
GPLAGGSAWSHPQFEK
StrepTag petDuet* NdEI, XhoI
USrc A3 
(NMT)
MGSNKSKPKDASQRRRSLEPAENVHG
AGGGAFPASQTPSKPASADGHRGPSA
AFAPAAAEPKAAAGFNSSDTVTSPQRA
GPLAGGSAWSHPQFEK
StrepTag petDuet NdEI, XhoI
USrc A2G 
(NMT)
MASNKSKPKDASQRRRSLEPAENVHG
AGGGAFPASQTPSKPASADGHRGPSA
AFAPAAAEPKLFGGFNSSDTVTSPQRA
GPLAGGSAWSHPQFEK
StrepTag petDuet NdEI, XhoI
Usrc D10A 
(NMT)
MGSNKSKPKAASQRRRSLEPAENVHG
AGGGAFPASQTPSKPASADGHRGPSA
AFAPAAAEPKLFGGFNSSDTVTSPQRA
GPLAGGSAWSHPQFEK
StrepTag petDuet NdEI, XhoI
USrc P8G 
(NMT)
MGSNKSKGKDASQRRRSLEPAENVHG
AGGGAFPASQTPSKPASADGHRGPSA
AFAPAAAEPKLFGGFNSSDTVTSPQRA
GPLAGGSAWSHPQFEK
StrepTag petDuet NdEI, XhoI
USrc D10A 
P8G (NMT) 
MGSNKSKGKAASQRRRSLEPAENVHG
AGGGAFPASQTPSKPASADGHRGPSA
AFAPAAAEPKLFGGFNSSDTVTSPQRA
GPLAGGSAWSHPQFEK
StrepTag petDuet NdEI, XhoI
USrc E19D 
(NMT)
MGSNKSKPKDASQRRRSLDPAENVHG
AGGGAFPASQTPSKPASADGHRGPSA
AFAPAAAEPKLFGGFNSSDTVTSPQRA
GPLAGGSAWSHPQFEK
StrepTag petDuet NdEI, XhoI
USrc 6His 
(NMT)
MGSNKSKPKDASQRRRSLEPAENVHG
AGGGAFPASQTPSKPASADGHRGPSA
AFAPAAAEPKLFGGFNSSDTVTSPQRA
GPLAGGSAWSHPQFEKGHHHHHH
StrepTag
and HisTag petDuet NdEI, XhoI
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11 16550 16418 16628 6,52 16960
12 16445 16314 16524 6,49 16960
13 16460 16327 N/A 6,53 16960
14 16564 16432 N/A 6,53 16960
15 16506 16375 16585 6,82 16960
16 16507 16376 16586 6,49 16960
17 16506 16375 16585 6,82 16960
USH3
(NMT)
MGSNKSKPKDASQRRRSLEPAENVHG
AGGGAFPASQTPSKPASADGHRGPSA
AFAPAAAEPKLFGGFNSSDTVTSPQRA
GPLAGGVTTFVALYDYESRTETDLSFK
KGERLQIVNNTEGDWWLAHSLSTGQT
GYIPSNYVAPSDSIQAEEHHHHHH
HisTag petDuet NdEI, XhoI
USH3 A3 
(NMT)
MGSNKSKPKDASQRRRSLEPAENVHG
AGGGAFPASQTPSKPASADGHRGPSA
AFAPAAAEPKAAAGFNSSDTVTSPQRA
GPLAGGVTTFVALYDYESRTETDLSFK
KGERLQIVNNTEGDWWLAHSLSTGQT
GYIPSNYVAPSDSIQAEEHHHHHH
HisTag petDuet NdEI, XhoI
USH3 A2G 
A3 (NMT) 
MASNKSKPKDASQRRRSLEPAENVHG
AGGGAFPASQTPSKPASADGHRGPSA
AFAPAAAEPKAAAGFNSSDTVTSPQRA
GPLAGGVTTFVALYDYESRTETDLSFK
KGERLQIVNNTEGDWWLAHSLSTGQT
GYIPSNYVAPSDSIQAEEHHHHHH
HisTag petDuet NdEI,NcOI
USH3 A2G 
(NMT)
MASNKSKPKDASQRRRSLEPAENVHG
AGGGAFPASQTPSKPASADGHRGPSA
AFAPAAAEPKLFGGFNSSDTVTSPQRA
GPLAGGVTTFVALYDYESRTETDLSFK
KGERLQIVNNTEGDWWLAHSLSTGQT
GYIPSNYVAPSDSIQAEEHHHHHH
HisTag petDuet NdEI, XhoI
USH3
D10A
(NMT)
MGSNKSKPKAASQRRRSLEPAENVHG
AGGGAFPASQTPSKPASADGHRGPSA
AFAPAAAEPKLFGGFNSSDTVTSPQRA
GPLAGGVTTFVALYDYESRTETDLSFK
KGERLQIVNNTEGDWWLAHSLSTGQT
GYIPSNYVAPSDSIQAEEHHHHHH
HisTag petDuet NdEI, XhoI
USH3
N68A
(NMT)
MGSNKSKPKDASQRRRSLEPAENVHG
AGGGAFPASQTPSKPASADGHRGPSA
AFAPAAAEPKLFGGFASSDTVTSPQRA
GPLAGGVTTFVALYDYESRTETDLSFK
KGERLQIVNNTEGDWWLAHSLSTGQT
GYIPSNYVAPSDSIQAEEHHHHHH
HisTag petDuet NdEI, XhoI
USH3
D71A
(NMT)
MGSNKSKPKDASQRRRSLEPAENVHG
AGGGAFPASQTPSKPASADGHRGPSA
AFAPAAAEPKLFGGFNSSATVTSPQRA
GPLAGGVTTFVALYDYESRTETDLSFK
KGERLQIVNNTEGDWWLAHSLSTGQT
GYIPSNYVAPSDSIQAEEHHHHHH
HisTag petDuet NdEI, XhoI
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18 16463 16332 16542 6,82 16960
19 16518 16387 16597 6,52 16960
20 16551 16420 16630 6,62 16960
21 16565 16434 N/A 6,63 16960
22 16578 16447 16657 6,31 16960
23 37828 37697 37718 6,52
USH3
N68A
D71A
(NMT)
MGSNKSKPKDASQRRRSLEPAENVHG
AGGGAFPASQTPSKPASADGHRGPSA
AFAPAAAEPKLFGGFASSATVTSPQRA
GPLAGGVTTFVALYDYESRTETDLSFK
KGERLQIVNNTEGDWWLAHSLSTGQT
GYIPSNYVAPSDSIQAEEHHHHHH
HisTag petDuet NdEI, XhoI
USH3
SS69AA
(NMT)
MGSNKSKPKDASQRRRSLEPAENVHG
AGGGAFPASQTPSKPASADGHRGPSA
AFAPAAAEPKLFGGFNAADTVTSPQR
AGPLAGGVTTFVALYDYESRTETDLSF
KKGERLQIVNNTEGDWWLAHSLSTGQ
TGYIPSNYVAPSDSIQAEEHHHHHH
HisTag petDuet NdEI, XhoI
USH3 IHH 
(NMT)
MGSNKSKPKDASQRRRSLEPAENVHG
AGGGAFPASQTPSKPASADGHRGPSA
AFAPAAAEPKLFGGFNSSDTVTSPQRA
GPLAGGVTTFVALYDYESIHHTDLSFK
KGERLQIVNNTEGDWWLAHSLSTGQT
GYIPSNYVAPSDSIQAEEHHHHHH
HisTag petDuet NdEI, XhoI
USH3 A2G 
IHH (NMT)
MASNKSKPKDASQRRRSLEPAENVHG
AGGGAFPASQTPSKPASADGHRGPSA
AFAPAAAEPKLFGGFNSSDTVTSPQRA
GPLAGGVTTFVALYDYESIHHTDLSFK
KGERLQIVNNTEGDWWLAHSLSTGQT
GYIPSNYVAPSDSIQAEEHHHHHH
HisTag petDuet NdEI, XhoI
USH3 T37E 
(NMT)
MGSNKSKPKDASQRRRSLEPAENVH
GAGGGAFPASQEPSKPASADGHRGP
SAAFAPAAAEPKLFGGFNSSDTVTSP
QRAGPLAGGVTTFVALYDYESRTETD
LSFKKGERLQIVNNTEGDWWLAHSLS
TGQTGYIPSNYVAPSDSIQAEEHHHH
HH
HisTag petDuet NdEI, XhoI
UGFP 
(NMT)
MGSNKSKPKDASQRRRSLEPAENVHG
AGGGAFPASQTPSKPASADGHRGPSA
AFAPAAAEPKLFGGFNSSDTVTSPQRA
GPLAGGSAWSHPQFEKGLEGGMVSKG
EELFTGVVPILVELDGDVNGHKFSVSG
EGEGDATYGKLTLKFICTTGKLPVPWP
TLVTTLTYGVQCFSRYPDHMKQHDFF
KSAMPEGYVQERTIFFKDDGNYKTRA
EVKFEGDTLVNRIELKGIDFKEDGNILG
HKLEYNYNSHNVYIMADKQKNGIKVN
FKIRHNIEDGSVQLADHYQQNTPIGDG
PVLLPNNHYLSTQSALSKDPNEKRDH
MVLLEFVTAAGITLGMDELYKGHHHH
HH
StrepTag
and HisTag petDuet NdEI, PacI
27515 
at 280 
55000 
at 488
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24 37724 37593 37803 6,54
25 37842 37711 N/A 6,54
26 USH3 6His pET14b 16550 16418 N/A 6,52 16960
27 N/A N/A 48141 48009 N/A 8,2
UGFP A3 
(NMT)
MGSNKSKPKDASQRRRSLEPAENVHG
AGGGAFPASQTPSKPASADGHRGPSA
AFAPAAAEPKAAAGFNSSDTVTSPQRA
GPLAGGSAWSHPQFEKGLEGGMVSKG
EELFTGVVPILVELDGDVNGHKFSVSG
EGEGDATYGKLTLKFICTTGKLPVPWP
TLVTTLTYGVQCFSRYPDHMKQHDFF
KSAMPEGYVQERTIFFKDDGNYKTRA
EVKFEGDTLVNRIELKGIDFKEDGNILG
HKLEYNYNSHNVYIMADKQKNGIKVN
FKIRHNIEDGSVQLADHYQQNTPIGDG
PVLLPNNHYLSTQSALSKDPNEKRDH
MVLLEFVTAAGITLGMDELYKGHHHH
HH
StrepTag
and HisTag petDuet NdEI, PacI
27515 
at 280 
55000 
at 488
UGFP A2G 
(NMT)
MASNKSKPKDASQRRRSLEPAENVHG
AGGGAFPASQTPSKPASADGHRGPSA
AFAPAAAEPKLFGGFNSSDTVTSPQRA
GPLAGGSAWSHPQFEKGLEGGMVSKG
EELFTGVVPILVELDGDVNGHKFSVSG
EGEGDATYGKLTLKFICTTGKLPVPWP
TLVTTLTYGVQCFSRYPDHMKQHDFF
KSAMPEGYVQERTIFFKDDGNYKTRA
EVKFEGDTLVNRIELKGIDFKEDGNILG
HKLEYNYNSHNVYIMADKQKNGIKVN
FKIRHNIEDGSVQLADHYQQNTPIGDG
PVLLPNNHYLSTQSALSKDANEKRDH
MVLLESYKSAGITLGMDELYKGHHHH
HH
StrepTag
and HisTag petDuet NdEI, PacI
27515 
at 280 
55000 
at 488
MGSNKSKPKDASQRRRSLEPAENVHG
AGGGAFPASQTPSKPASADGHRGPSA
AFAPAAAEPKLFGGFNSSDTVTSPQRA
GPLAGGVTTFVALYDYESRTETDLSFK
KGERLQIVNNTEGDWWLAHSLSTGQT
GYIPSNYVAPSDSIQAEEHHHHHH
HisTag NdEI, NcoI
NMT (Nef)
MNSLPAERIQEIQKAIELFSVGQGPAKT
MEEASKRSYQFWDTQPVPKLGEVVNT
HGPVEPDKDNIRQEPYTLPQGFTWDAL
DLGDRGVLKELYTLLNENYVEDDDN
MFRFDYSPEFLLWALRPPGWLPQWHC
GVRVVSSRKLVGFISAIPANIHIYDTEK
KMVEINFLCVHKKLRSKRVAPVLIREI
TRRVHLEGIFQAVYTAGVVLPKPVGTC
RYWHRSLNPRKLIEVKFSHLSRNMTM
QRTMKLYRLPETPKTAGLRPMETKDIP
VVHQLLTRYLKQFHLTPVMSQEEVEH
WFYPQENIIDTFVVENANGEVTDFLSF
YTLPSTIMNHPTHKSLKAAYSFYNVHT
QTPLLDLMSDALVLAKMKGFDVFNAL
DLMENKTFLEKLKFGIGDGNLQYYLY
NWKCPSMGAEKVGLVLQ
petDuet 69380 / 69330
*petDuet and pet14b both contain the ampicillin resistance
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